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Epithelial Ovarian Cancer (EOC) kills more women annually in the United Kingdom than 
any other gynaecological cancer.  Survival rates for women diagnosed with EOC have not 
improved over the past 30 years, due to the often advanced stage at presentation, where 
widespread intra-peritoneal dissemination has occurred.  The natural history of the disease 
remains uncertain but the ovarian surface epithelium (OSE) is a strong candidate for the 
tissue of origin.  The OSE undergoes cyclical damage and repair in women of reproductive 
age following ovulation, which can be considered an acute inflammatory event.  Factors that 
prevent ovulation (pregnancy, breastfeeding and contraceptive pill use) also protect against 
the development of EOC.  Previously published data show that the OSE is able to up-
regulate the enzyme 11-beta hydroxysteroid dehydrogenase type 1 (11βHSD1) in response to 
inflammation, the enzyme responsible for converting inactive cortisone to anti-inflammatory 
cortisol.  This thesis hypothesises that 11βHSD isozymes are deregulated in ovarian cancer; 
that the peritoneal surface epithelium (PSE) is indistinguishable from the OSE in its response 
to inflammation and should be considered a potential source of some “ovarian cancers”; and 
finally that the expression of the tumour suppressor gene OPCML (OPioid binding Cell 
adhesion Molecule-Like) is altered by inflammation.  These hypotheses were examined at 
three levels.  Firstly, primary cultures of EOC were established, and glucocorticoid 
metabolism and the response to inflammation was compared to normal OSE.  Results from 
these investigations reveal that the11βHSD1 response to IL-1α stimulation is impaired in 
EOC compared to normal OSE at the mRNA level but there is no significant difference when 
11βHSD1 enzyme activity is measured in these tissues. When basal levels of 11βHSD1, 
11βHSD2 and COX2 are compared amongst untreated samples of EOC and OSE, there was 
a significant correlation between 11βHSD1 and COX2 mRNA expression (P<0.001).  
11βHSD2 mRNA expression was significantly higher in the EOC specimens compared to 
OSE (P<0.05).  Secondly the response to inflammation was compared in primary cultures of 
human peritoneal surface epithelial (PSE) cells and OSE.  The data suggest that the mRNA 
response to inflammation was similar in OSE and PSE, but that the 11βHSD1 enzyme 
activity was reduced in PSE (P<0.05), which may result in differences in tissue healing.  
Finally, the effect of inflammation on the expression of the ovarian cancer associated tumour 
suppressor gene (TSG), OPCML (OPioid binding Cell adhesion Molecule-Like) and the 
other members of the IgLON family, was examined in OSE. These results suggest that 
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1 General Introduction 
1.1 Clinical Aspects of Epithelial Ovarian Cancer  
 
 
More women die each year from epithelial ovarian cancer than any other 
gynaecological malignancy.  Compared with many other cancers, improvements in 
ovarian cancer survival have been modest and overall survival remains poor with 
only 32% alive at 5 years (figure 1.1).   
 
Figure 1.1 Trends in ovarian cancer survival in Scotland from 1980-2004 
Ages 15-99. (ISD, 2010) 
 
 
The poor survival associated with EOC is explained by the fact that most women 
who develop the disease present at an advanced stage and therefore the disease is less 
amenable to treatment and cure. Thus survival figures are inversely related to the 
FIGO stage of the malignancy (see table 1.1).   
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Table 1.1 FIGO staging of ovarian cancer with associated 5 Year 
survival rates.  Modified from (Benedet, J.L. et al. 2000; Heintz, A.P. et 
al. 2003). 
Stage Definition 
5 Year Survival 
Rate 
(%) 
I Growth confined to ovaries  
Ia 
Growth limited to one ovary; no ascites present 
containing malignant cells; No tumour on external 
surface; capsule intact 
91.7 
Ib 
Growth limited to both ovaries; no ascites present 
containing malignant cells; No tumour on external 
surfaces; capsules intact 
76.0 
Ic 
Tumour either Stage Ia or Ib but with tumour on surface 
on one or both ovaries or with capsule ruptured or with 
ascites present containing malignant cells, or with 
positive peritoneal washings  
81.2 
II Growth involving one or both ovaries with pelvic extension  
IIa Extension and/or metastases to uterus and/or tubes 78.8 
IIb Extension to other pelvic tissues 64.0 
IIc 
Tumour either Stage IIa or IIb but with tumour on 
surface on one or both ovaries or with capsule ruptured 
or with ascites present containing malignant cells, or 
with positive peritoneal washings  
69.5 
III 
Tumour involving one or both ovaries with histologically confirmed 
peritoneal implants outside the pelvis and/or positive retroperitoneal or 
inguinal nodes. Superficial liver metastases. Tumour is limited to the 
true pelvis, but with histologically proven malignant extension to small 
bowel or omentum. 
IIIa 
Tumour grossly limited to the true pelvis with negative 
nodes but with histologically confirmed microscopic 
seeding of peritoneal surfaces, or histologically proven 
extension to small bowel or mesentery. 
57.0 
IIIb 
Tumour of one or both ovaries with histologically 
confirmed implants, peritoneal metastases of abdominal 
peritoneal surfaces, none exceeding 2cm in diameter; 
nodes are negative 
43.8 
IIIc 
Peritoneal metastases beyond the pelvis >2cm in 




Growth involving one or both ovaries with distant 
metastases. If pleural effusion is present, there 
must be positive cytology to allot to stage IV. 





The growth of the tumour within the peritoneal cavity is often asymptomatic thus the 
term “silent killer” is used to describe the disease.  There is considerable lack of 
understanding of the natural history of EOC particularly its mode of onset and 
mechanisms of dissemination.  Once suspected, management of EOC involves 
excision of the tumour, most often by laparotomy, total abdominal hysterectomy and 
bilateral salpingo-oophorectomy (TAH and BSO), peritoneal lavage and 
omentectomy.  The purpose of surgery is not only to remove the tumour and be able 
to make a histological diagnosis but also to assess degree of spread of the tumour 
within the peritoneal cavity, allowing the FIGO stage to be determined (Table 1.1).  
The advantage of this international system of staging is that trials can be compared 
and correlated at a global level, adding value to research.  The disadvantages are that 
the staging is arbitrary, based on anatomical extent of the disease and not its 
histology, and it does not reflect the fact that the majority of cases are stage IIIc or 
IV at presentation.  In addition the staging presumes a step-wise progression of the 
disease which may not reflect the natural history of the disease.  The uncertainty over 
EOC’s natural history makes it a difficult disease to screen for and there is no test 
currently available that fulfils the necessary screening criteria set down by the World 
Health Organization (Wilson J et al. 1968).     
 
Some studies have shown that the more tumour that is removed the better the 
outcome, such that patients with residual tumour measuring less than 1cm have 
improved survival rates (Bristow, R.E. et al. 2002; Bristow, R.E. et al. 2002).  
However another explanation for these results could be that the biological nature of 
the tumours is different and the more aggressive tumours (with poorer prognoses) are 
more difficult to surgically debulk to less than 1cm.  Evidence for this is supplied by 
Berchuck et al who have discovered that there are genetic differences between 
tumours that are optimally and sub-optimally cytoreducable on microarray analysis 
(Berchuck, A. et al. 2004). Following histological diagnosis, intravenous 
chemotherapy with a platinum based agent (carboplatin or cisplatin) is standard 
practice in the United Kingdom with or without paclitaxel.  Recent clinical studies 
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have suggested that survival can be extended by using intra-peritoneal chemotherapy 
in combination with intravenous chemotherapy (Armstrong, D.K. et al. 2006) albeit 
with an increase in abdominal complications.  A major criticism of this study 
however is the adjuvant use of intravenous chemotherapy – to truly assess the 
efficacy of intra-peritoneal chemotherapy then a randomized control trial of 
intravenous versus intraperitoneal chemotherapy alone is required.  Furthermore the 
dosing schedule meant that the patients in the intra-peritoneal arm were receiving 
paclitaxel in two out of every three weeks as opposed to once every three weeks in 
the intravenous arm.   
 
Preventing the intra-peritoneal spread of EOC is a highly desirable therapeutic target, 
particularly because it is unusual for the disease to disseminate beyond the coelom.  
Unlike many cancers e.g. breast cancer which commonly spreads haematogenously, 
EOC is largely confined to the peritoneal cavity, forming widespread nodules on the 
surface of the peritoneum or replacing the adipose tissue of the omentum.  This is 
often associated with a rise in serum levels of CA125 (MUC16), a glycoprotein 
tumour marker which is raised in 80% of EOC cases (Bast, R.C. et al. 1983).  
Although CA125 is a useful marker of disease progression and response to treatment 
its source is likely to be the peritoneum (Epiney, M. et al. 2000) and subsequently it 
is often raised in non-malignant disease making it a poor screening tool for early 
detection of EOC.  When EOC does spread beyond the peritoneum it is usually to 
abdominal lymph nodes or the pleural cavity: another mesothelium.  However it is 
the effect of intra-abdominal tumour that in many cases ultimately leads to death.  
Multiple chemoresistant tumour nodules develop on the serosal surface of the bowel 
and peritoneum which impairs normal motility and function (figure 1.2).  The stasis 
of luminal contents then causes distension of the bowel, leading to pain and vomiting 
and predisposes to bacterial infection whereby the vomitus can become faeculant.   
Nutrient, electrolyte and fluid absorption across the bowel is unable to occur 
normally.  Further deterioration of bowel function occurs in the now critically 
undernourished patient, with localised disruption of vascular perfusion and ischaemia 
and finally the patient succumbs after a distressing and often prolonged course of 
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bowel obstruction.  If extension of EOC to the bowel could be prevented then 
prolongation of life for patients with ovarian cancer would follow.  
 
Figure 1.2 Laparoscopic view of liver and peritoneal surface in patient 
with FIGO Stage IV serous ovarian carcinoma. Picture courtesy of Dr G 
Walker. 
Figure 1.2 shows the extent of tumour burden commonly discovered at initial 
laparotomy.  The omental involvement alone may consist of billions of malignant 
cells.  Given this scenario, the complete removal of the entire malignant component 
by surgery alone is not possible and even after subsequent chemotherapy it is 
unlikely that all malignant cells would be entirely destroyed.  In the author’s opinion 
the overall goal of ovarian cancer research should be to prevent EOC ever reaching 
such an advanced stage. 
 
The development of a preventative strategy requires a thorough understanding of the 
natural history of ovarian cancer.  This includes; identifying the cell type of origin 
and the necessary oncogenic transforming factors, determining what controls 
propagation of the transformed cell locally and subsequently how malignant cells are 
dispersed from the initial locus. From here; identifying what processes are involved 
in the adhesion of disseminated cells at distant sites within the peritoneum, and how 





1.2 Origins of Epithelial Ovarian Cancer 
 
The source of EOC is widely held in the literature as being the ovarian surface 
epithelium (OSE)(Auersperg, N. et al. 2001; Murdoch, W.J. et al. 2002).  The term 
epithelium is a misnomer as the OSE is not a true epithelium, arising as it does from 
mesodermal tissue.  This led to the generation of the term mesothelium by Minot in 
1890.  The evidence for EOC arising from OSE is somewhat circumstantial and 
indirect: the risk of developing EOC increases with number of lifetime ovulations 
and ovulation causes repetitive and cyclical injury to the OSE (Espey, L.L. 1994; 
Fleming, J.S. et al. 2006; Ness, R.B. et al. 2000).  Many authors then hypothesise 
that the regeneration of the OSE following ovulation renders the OSE progenitor cell 
population vulnerable to genetic mutation and therefore oncogenic transformation.   
 
Figure 1.3.  Photomicrograph of section of ovarian cortex 
demonstrating the presence of an inclusion cyst (ic) and proximity to 
the ovarian surface epithelium (ose).   Inset shows tubal metaplasia 




Leading on from “the OSE as cancer source” hypothesis is the suggestion that the 
OSE is subjected to an oncogenic environment within small cysts in the ovarian 
cortex referred to as “inclusion cysts” (Auersperg, N. et al. 2001).  The name arises 
from the assumption that they form following injury to the ovary by ovulation and its 
subsequent repair, resulting in entrapment and inclusion of OSE cells within the 
ovarian cortex.  Interestingly, occasional ciliated cells can often be identified within 
these cysts (Okamura, H. et al. 2001) suggesting either that metaplasia occurs or that 
cells shed by the Fallopian tube can also accumulate within them.  Although there is 
some evidence linking their presence to cancer development, again this is mostly 
circumstantial, as inclusion cysts are more numerous in patients with family histories 
of ovarian cancer and in normal ovaries contralateral to ovaries affected by ovarian 
cancer (Mittal, K.R. et al. 1993; Werness, B.A. et al. 1999).  Brewer et al have 
presented evidence that nuclear abnormalities can be detected in women with a 
higher risk of developing EOC or in the ovaries of women with ovarian cancer 
(Brewer, M.A. et al. 2004).  However, nuclear abnormalities alone do not equate 
with malignancy and there have been no studies showing that patients with nuclear 
abnormalities go on to develop EOC.  So, unlike other epithelial tumours e.g. 
cervical or colonic cancer, in EOC there is no clear stepwise progression from a pre-
neoplastic lesion to an in-situ tumour to widespread malignancy.  There are case 
reports in the literature of malignant change appearing within inclusion cysts but 
these are rare and anecdotal (Aoki, Y. et al. 2000).  Some authors believe, 
controversially, that the lack of a defined pre-cursor lesion is simply due to not 
looking hard enough (Scully, R.E. 1995). Another possibility is not that pre-cursor 
lesions in the OSE are being missed but that the precursor lesions exist in a different 
tissue altogether: the Fallopian tube or peritoneum for example.  To explain the 
absence of a precursor lesion, it is possible that once the disease develops it rapidly 
progresses beyond the inclusion cyst.  Alternatively some cases of EOC may not 
arise within an inclusion cyst.  However, one of the attractions of the inclusion cyst 
hypothesis is that it explains how tumours can appear at FIGO Stage IA, without 
breaching the capsular surface of the ovary.  If EOC developed from OSE from the 
exterior surface of the ovary in every case then early stage cancer would not be seen, 
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as malignant cells would be more likely to shed and disseminate within the pelvis 
than invade into the ovarian stroma.   
 
The literature regarding the genesis of inclusion cysts is controversial. Evidence that 
their formation is linked with ovulation was presented by Radisavljevic, however this 
is a histological study of thousands of ovaries and a purely descriptive study 
(Radisavljevic, S.V. 1977).  The author does describe the presence of the inversion of 
the ovarian surface that occurs at sites where ovulation has recently occurred (as 
shown by the presence of an underlying corpus albicans).  In addition there is a 
description of inclusion cysts that form following the enclosure of the fimbrial end of 
the fallopian tube, which the author suggests is evidence of “auto-transplantation”.  
A more dynamic study of inclusion cyst generation was undertaken using a mouse 
model, where ovaries from incessantly ovulating mice were compared with those 
from breeding mice and fetal ovaries.  It appeared that inclusion cyst development 
was more closely related to age than number of lifetime ovulations (Clow, O.L. et al. 
2002).  A similar study  from Australia, which also used a murine model discovered 
that inclusion cyst number was greater in the incessantly ovulating group (Tan, O.L. 
et al. 2005).  In the human, a study examining incidence of inclusion cysts in women 
undergoing oophorectomy for benign gynaecological conditions demonstrated that 
the association between number of ovulations and presence of inclusion cysts was 
weak and the use of the combined oral contraceptive pill (COCP) and pregnancy was 
not associated with a statistically significant reduction in number of inclusion cysts 
(Heller, D.S. et al. 2005). From several epidemiological studies it is apparent that the 
risk of developing EOC is proportional to the number of lifetime ovulations 
(Fathalla, M.F. 1971; Ness, R.B. et al. 2000; Ness, R.B. et al. 2001; Purdie, D.M. et 
al. 1999; Purdie, D.M. et al. 2003).  Therefore if inclusion cyst formation was 
necessary for ovarian cancer development, it would be expected that inhibition of 
ovulation by the oral contraceptive would also reduce the incidence of ovarian 
inclusion cysts.  In summary the evidence for inclusion cysts being a pre-cursor for 





1.3 Alternative Tissue Origins of EOC 
 
Returning to the origins of ovarian cancer some authors have challenged the dogma 
that EOC arises from the OSE (Dubeau, L. 1999; Piek, J.M. et al. 2004).  The 
authors point out deficiencies in the OSE theory but they fail to provide substantive 
evidence for any other theory of origin of EOC, although one candidate tissue they 
discuss is the secondary Mullerian system.  This tissue includes the rete ovarii and 
paratubal cysts but the author acknowledges that little is known about their origin or 
indeed how they could be the source of ovarian cancer.  However one point that is 
raised is that tumours that are designated primary peritoneal carcinomas are 
indistinguishable from serous epithelial ovarian cancers.  Dubeau cites this as 
evidence that the OSE cannot be the cell of origin of EOC whereas what this finding 
contributes is the possibility that the same factors which cause the development of 
EOC are equally able to cause oncogenic change in other cell types including 
Fallopian tube epithelium and the mesothelial surface or peritoneal surface 
epithelium (which will be abbreviated to PSE to acknowledge the close relationship 
between the peritoneal mesothelial cell and the OSE).   
 
A further explanation is that in ovarian tumours not arising in inclusion cysts the 
transformed OSE cell is shed from the surface of the ovary at an early stage and the 
fertile milieu of the peritoneum allows attachment and further proliferation.  That 
cells from ectopic tissue can attach to the peritoneum has been demonstrated in 
models of endometriosis where endometrial epithelium and shed menstrual epithelial 
cells are able to attach in vitro to human peritoneal tissue (Witz, C.A. et al. 2002; 
Witz, C.A. et al. 2001).  It is therefore conceivable that transformed EOC cells could 
attach to the peritoneum once they have disaggregated from the initial tumour 
growth. 
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In many epithelial cell types when epithelial cells are removed from their home 
environment they undergo apoptosis; a process known as anoikis (Liotta, L.A. et al. 
2004).  Moreover this phenomenon appears to be absent in epithelial ovarian cancer 
cells which, once freed from their origin, appear to be able to survive not only in the 
distant peritoneum but also anchorage-free, suspended in ascitic fluid.  Another area 
of potential targeted therapy therefore is the possible reconstitution of anoikis 
induced apoptosis in disseminated EOC cells.  It is presumptive however to assume 
that peritoneal metastases arise from disseminated cells from a precursor. In a similar 
hypothesis to the metaplastic theory of endometriosis, it might be the case that it is 
not the transformed OSE cells themselves that disseminate to cause widespread 
disease but that there are oncogenic proliferative factors released into the coelomic 
cavity which stimulate metaplasia, and ultimately dysplasia, in the peritoneum. 
 
 
1.3.1 Peritoneal Biology and Pathophysiology 
 
The peritoneum plays an important role in the progression of EOC and indeed EOC 
could be considered to be a peritoneal disease rather than a disease of the ovary.  
However it is remarkable how little work has been undertaken to look at the role of 
the tumour/peritoneal interface in EOC.  The importance of such research is clear as 
the peritoneum is a potential target organ in which dissemination of EOC could be 
treated or even prevented.  Yet most of the knowledge of peritoneal function comes 
from studies concerned with peritoneal dialysis and its complications.   
 
The evolution of the coelomic cavity occurred some 550 million years ago and 
enabled organisms to develop an internalised organ system, permitting development 
of the lungs and gastrointestinal tract.  The initial benefit may have been to allow 
segmentation and burrowing abilities of the common ancestor which was likely to 
have been a worm-like organism, however the persistence of the coelom in evolution 
emphasises its importance.  Indeed, morphological studies of several mammalian 
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species have shown that the mesothelium is essentially the same in most mammals.  
The role of the cells lining the coelom is that of a separator such that when opposing 
sides of the coelom come into contact, there is no adhesion between the surfaces.  
Thus the lining of the cavity must be non-adhesive and frictionless.  In the human the 
peritoneum covering the abdominal wall is termed the parietal peritoneum and that 
covering the organs the visceral peritoneum.  The link between structure and function 
of the peritoneum was first documented in the early 18th century by Douglas 
(Douglas, J. 1730) who described it as ; 
 
“everywhere smooth and even and lubricated by a fluid in order to preserve 
it from those inconveniences which otherwise have followed its continual 
attrition with other viscera”. 
 
Anatomically the OSE is intimately related to the peritoneal surface epithelium 
(PSE).  Both OSE and PSE are mesothelial cuboidal single cell layers which meet at 
the ovarian hilum. While the OSE has been extensively characterized, much less is 
known about the PSE.  It covers the entire peritoneal cavity, an area of some 1.8m2 
(Michailova, K.N. et al. 2006) almost the same surface area as the skin.  Effluent 
recovered from the peritoneum following peritoneal dialysis was noted to contain 
significant amounts of a surface active material and subsequent animal research 
showed that the mesothelium was able to produce large quantities of 
phosphatidylcholine, the major constituent of pulmonary surfactant (Dobbie, J.W. et 
al. 1988; Grahame, G.R. et al. 1985; Ziegler, C. et al. 1989).  Electron microscopy of 
the mesothelial cell has revealed two populations of cells: flattened squamous cells 
and less abundant cuboidal cells (Mutsaers, S.E. 2002).  The significant difference in 
ultrastructure between these subtypes is that the cuboidal cells have more numerous 
mitochondria as well as more prominent endoplasmic reticulum and Golgi apparatus, 
consistent with increased metabolic activity. Dobbie and Lloyd described the 
presence of  lamellar bodies within the mesothelial cell vacuoles, similar to those 
seen in type II pneumocytes (Dobbie, J.W. et al. 1989).  Transport across the 




It would appear that the similarity between pneumocytes and mesothelial cells does 
not end with the morphological similarity.  Surfactant protein A (SP-A) is the most 
abundant of the surfactant proteins and plays an important role in the alveolus where 
it regulates phospholipid homeostasis thus helping to lower surface tension.  It has 
also been described in the mesothelium, where it is likely to aid lubrication in a 
similar manner  (Dobbie, J.W. 1996).  However another role of SP-A is in the innate 
immune response.  SP-A is related to the collectin family of lectins, of which 
complement C1q is a member.  By binding to carbohydrate molecules on the surface 
of microorganisms SP-A acts as an opsonin and can activate macrophages and other 
phagocytic cells (Crouch, E.C. 1998).  So the PSE may play an important role in host 
defence as well as acting as a simple lubricating surface.  Subsequently the work in 
this thesis directly examines the ability of the PSE to respond to inflammatory 
stimuli. 
 
The structural similarities between PSE and  OSE are striking as described by 
Blaustein (Blaustein, A. 1984).  Just as Mutsaers has described two types of 
mesothelial cell, Gillett et al have described two populations of OSE cells 
























Figure 1.4.  Electron microscopy of OSE and PSE showing a) two 
distinct cell populations on the ovarian surface; A cells being cuboidal 
and B cells squamous (Gillett, W.R. et al. 1991)  b) fan shaped 
mesothelial cells (large arrows) 24 hours following injury (bar 






The similarities between OSE and PSE are perhaps not surprising given their similar 
embryological origins.  The intraembryonic coelomic cavity arises from the lateral 
plate mesoderm at the end of week three in the human.  Between weeks five and 
seven the coelom undergoes septation to generate a future pericardial cavity, two 
pleural cavities and a peritoneal cavity.  By the end of week seven the peritoneal 







Figure 1.5.  Embryology of the peritoneal cavity (kindly reproduced by 
Ted Pinner).  Origin of the lateral plate mesoderm (top).  Lower figure 
indicates fetal ovary at Carnegie stage 18 (44-49 days) demonstrating 































However there are some significant differences between OSE and PSE. Microvilli 
dominate the surface of the PSE.  The function of these is not clear, but they increase 
the mesothelial surface area and therefore are likely to influence absorption or 
secretion across the cell surface. They may also play a role in the trapping of secreted 
proteins or glycoproteins thus acting as a monitor of the peritoneal environment.  
Alternatively the large surface area simply provides protection of mesothelial 
integrity.  The ability to transport non-coaguable fluid across the peritoneum has 
been put to clinical use as a method of dialysis for patients with renal failure.   
 
Since Hertzler’s observation in 1919, it has been known that different sizes of 
peritoneal wounds take the same time to heal.  Thus it is unlikely that the 
mesothelium regenerates from the wound edge alone.   The hypothesis that peritoneal 
wounds are repopulated by free-floating mesothelial cells was tested by Foley-Comer 
et al using a model of intraperitoneal injury to rat testes (which are in communication 
with the peritoneal cavity through the tunica vaginalis) (Foley-Comer, A.J. et al. 
2002).  Labelled mesothelial cells were injected intraperitoneally into rats following 
testicular injury and the wound site examined at 5 and 8 days post injury.  The 
wounds were completely healed by the labelled cells at 8 days.  Furthermore, there 
were no labelled cells on the wound site if fibroblasts were substituted for the 
mesothelial cells and there was no binding of labelled cells on non-injured surfaces. 
This provides strong evidence for a progenitor cell population of mesothelial cells 
circulating within the peritoneum.   
 
These findings raise further questions: where is the stem cell niche that these 
progenitors arise from?  What signals allow progenitor cells to preferentially adhere 
to the wounded surface?  How is the proliferation of these progenitors switched off?  
Are the progenitor cells able to differentiate into other mesodermal or epithelial 
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phenotypes?  Does the ovary heal in a similar fashion to this model in the human?  
The answers to such questions are important clinically.  The intraperitoneal spread of 
EOC could potentially be prevented if the adhesion of malignant cells to the 
peritoneum could be inhibited.  Indeed in vitro work on mesothelial cell cultures has 
suggested that secreted hyaluron prevents attachment of tumour cells to the 
peritoneal surface (Jones, L.M.H. et al. 1995). Endometriosis could be prevented if 
the local peritoneal environment could be manipulated to become hostile to 
endometrial cells.  Finally peritoneal scarring which causes significant morbidity 
through infertility and abdominal pain could be combated by preferential laying 
down of mesothelial cells rather than scar tissue formation.  There may be a future 
role for autologous transfusion of mesothelial cells in these conditions.  
 
The regeneration of a mesothelial layer is one end result of peritoneal injury.  A more 
serious consequence is the development of intraperitoneal adhesions.  While there is 
little doubt that the mesothelial cell is able to mount an inflammatory response to 
injury (Topley, N. et al. 1994), it is likely that there is also some anti-inflammatory 
activity to prevent adhesion formation.  The deposition of fibrin may be the critical 
factor in determining extent of healing.  Normally fibrin is excluded from the 
peritoneal environment. However in mesothelial injury if blood vessels are injured 
the procoagulant pathway is preferred and if fibrin is not timeously removed, 
fibroblast invasion can occur thus paving the way for adhesion formation (Holmdahl, 
L. 1997).  This allows development of a matrix containing fibroblasts, and over time 
smooth muscle cells and nerve fibres which may explain the chronic symptoms 
experience by patients with severe endometriosis or intra-abdominal adhesions 
(Sulaiman, H. et al. 2001).   
 
The close links between the OSE and PSE are also present in their pathological 
states.  Women who have an hereditary predisposition to EOC are also at increased 
risk of developing primary peritoneal cancer (PPC)(Finch, A. et al. 2006).  Patients 
with PPC present with similar symptoms to EOC (Fromm, G.L. et al. 1990), they 
carry the same risk factors and there is also increased risk in BRCA1/BRCA2 
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mutation carriers.  At a histological level PPC and EOC are indistinguishable leading 
to a probable underdiagnosis of PPC of around 10% (Chu, C.S. et al. 1999) (Cormio, 
G. et al. 2000).  The tumours respond to the same chemotherapeutic regimens with 
similar survival outcomes (Chu, C.S. et al. 1999; Jaaback, K.S. et al. 2006).  From 
many angles, PPC and EOC could be considered the same disease.  Particularly as 
PPC can arise in women without adnexae, the PSE should also be considered a 
candidate for the tissue of origin of peritoneal EOC.  However for this to happen 
there must be some loss of mesothelial phenotype as otherwise the resulting tumour 
would be malignant mesothelioma.   
 
The mesothelium itself appears to behave differently in patients with EOC.  Looking 
at peritoneal biopsies in patients with EOC, Zhang et al noticed that rather than the 
single layer of cells seen in non-EOC patients there was a trend towards a 
discontinuous mesothelium which would contain more than one layer of cells 
(Zhang, X.Y. et al. 1999).  They assumed this was because the mesothelial cell layer 
reacted to the presence of disease by shedding mesothelial cells.  It is highly likely 
that an increase in mesothelial proliferation is a consequence of EOC, however it is 
not yet clear what stimulates such a response.  One criticism of this study is that is 
not apparent whether the peritoneal biopsies were taken from similar anatomical 
areas in the EOC and non-EOC patients.  Also it is possible that the discontinuous 
mesothelial layer in the EOC patients could have been a result of surgical handling as 
the timing of the biopsy in relation to the surgery is not defined.  Nevertheless the 
mesothelium is likely to play an important role in the response to EOC 
dissemination. 
    
As alluded to above, an understanding of the interaction between tumour and PSE is 
an essential requisite to be able to prevent peritoneal spread of cancer.  Once the 
cancer has grown large enough to be able to shed tumour cells from its surface, the 
free-floating metastasis must be able to attach to the peritoneal surface for further 
progression of the cancer to occur.  These metastatic cells are often aided in their 
transport by an increase in intraperitoneal fluid, ascites.  The mechanism by which 
 
 33
malignant ascites is produced is not clear.  In contrast to non-malignant conditions 
where reduced plasma oncotic pressure or raised hepatic portal vein pressure leads to 
an accumulation of a transudate, malignant ascites has a high protein concentration 
(similar to serum) implying active transport of protein across the peritoneal 
membrane.  The stimulus for the generation of ascites is not known but there are 
potentially many compounds that are involved.  In a study of ascites from various 
primary tumours vascular endothelial growth factor (VEGF) was markedly increased 
in all cancers compared to non-malignant ascites (Zebrowski, B.K. et al. 1999).  
Furthermore, ovarian cancer ascites had significantly higher VEGF levels compared 
to ascites from colon and gastric cancer patients.  Mesothelial cells and cancer cells 
themselves have been implicated in the production of  VEGF (Stadlmann, S. et al. 
2005).  These findings provided an indication for trialling the monoclonal VEGF 
antibody bevacizumab in ovarian cancer.  While the response rate has varied from 8-
100% in phase II trials, there has also been a reported rate of bowel perforation of 
over 5% as a serious side-effect (Han, E.S. et al. 2007).  VEGF can be regulated 
through up-regulation of hypoxia inducible factor-1α (HIF1α) so the low oxygen 
tension environment of tense ascites may have a role to play in the up-regulation of 
VEGF.   
 
However as a consequence of these studies the manipulation of the peritoneal 
environment does appear to be a successful strategy for some EOC patients.  Other 
studies looking at the composition of ascitic fluid in patients with EOC have 
demonstrated high levels of tumour necrosis factor α (TNFα), IL-6, IL-10, IL-12, and 
neopterin compared to serum (Melichar, B. et al. 2006; Moradi, M.M. et al. 1993; 
Zeimet, A.G. et al. 1998).  Neopterin is a pteridine compound produced following 
breakdown of guanosine triphosphate (GTP) by GTP cyclohydrolase I, an enzyme 
up-regulated in macrophages by interferon-γ (IFNγ) (Huber, C. et al. 1984).   
 
The peritoneum plays an important role in immune surveillance.  The description of 
small whitish spots on the serosal surface of the greater omentum led to further 
investigation as to their nature.  These “milky spots” are tiny accumulations of 
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lymphoid tissue and are a component of the lymphoreticular system.  The 
mesothelial layer is disrupted at these milky spots and the lack of a basement 
membrane allows migration of lymphoreticular cells such as macrophages and 
lymphocytes.  Thus an immune response can be initiated rapidly to any antigenic 
challenge from within the peritoneum.   
 
Despite the close relationship the peritoneum has with the immune system, most 
EOCs evade a significant immune response until they become quite advanced.  A 
major component of the immune presenting cells in the peritoneum is the 
monocyte/macrophage population.  The cell component of the milky spots consists 
of 50% macrophages.  The literature regarding the immune response to ovarian 
cancer is rather contradictory with some studies suggesting that the response to the 
tumour is suppressed while others suggest an up-regulation.  This may simply reflect 
the considerable heterogeneity that exists not only amongst cancers but also amongst 
patients’ immune systems.  Comparing monocyte/macrophage populations in chemo-
naïve patients with EOC and healthy subjects, Gordon provided evidence that these 
cells have impaired function (Gordon, I.O. et al. 2006).  Using assays of 
phagocytosis and antibody-dependent cytotoxicity, they demonstrated that both these 
mechanisms of cell death were impaired in EOC.  Furthermore the macrophage 
cultures from patients with EOC produced IL-6, IL-8, IL-10 and TNFα.  So these 
data would suggest that impaired monocyte function could explain tumour 
progression of EOC.  There was some evidence of an anti-tumour effect in this study 
however as co-culture with macrophages (from EOC patients) inhibited growth of an 
EOC cell line.  The authors postulated that this growth suppression was due to TNFα.   
 
While the innate immune system may affect tumour progression there is a greater 
potential for therapeutic intervention by enhancing adaptive immunity.  Although 
tumours present antigens that can be targeted by the cellular immune mechanisms, 
they are rarely removed altogether.  The failings of the anti-tumour response are also 
exemplified by the inability of tumour vaccines to resolve malignancy as well as the 
phenomenon of immune tolerance.  Ascites of patients with EOC has a significant 
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number of T regulatory cells (TREG) compared to their blood or ascitic fluid form 
patients with non-malignant ascites (Curiel, T.J. et al. 2004).  These TREG are also 
more abundant in EOC tumours than in normal ovaries.  In vitro TREG caused 
suppression of T cell proliferation.  Finally TREG content of the tumours were 
correlated with poor survival even after controlling for stage and surgical debulking.  
There is therefore reasonable optimism that inhibiting TREG function in EOC tumours 
is a realistic strategy for therapy in the future.  
 
The peritoneum’s ability to heal has further clinical relevance in the condition 
endometriosis.  Here, areas of endometrial glandular tissue are ectopically sited 
within the peritoneal cavity.  Depending on the extent of the disease the clinical 
sequelae may include pain, infertility and adhesion formation.  However there is a 
paradox between symptoms and extent of disease.  Some studies have shown 
evidence of  endometriosis at sterilization in women without symptoms of up to 22% 
(Moen, M.H. et al. 1991), leading to some authors to suggest that it is so common 
that it should not be considered a disease (Evers, J.L.H. 1994).  Indeed in one study 
that examined outcomes in 39 women with endometriosis diagnosed incidentally at 
laparoscopic sterilization there was a higher rate of pelvic pain in the matched 
control group (Moen, M.H. et al. 2002).  However the experience of pain is complex 
and asymptomatic women with endometriosis may have different coping strategies 
or reasons not to report pain as a symptom, making the correlation between 
symptoms and histology difficult.  Endometriosis requires further consideration as it 
has many features of a pre-malignant disease, is associated with EOC and causes 
damage to the peritoneal surface epithelium. 
 
1.3.2 EOC and Endometriosis 
The origins of endometriosis have not been conclusively defined but Sampson’s 
theory of endometrial implantation (Sampson, J. 1927) appears to carry more weight 
than the alternative hypothesis first suggested in 1898 that endometriosis arises from 
metaplasia of the peritoneum (Iwanoff, N. 1898).  However there are enough 
differences between endometriosis and endometrium to suggest that the endometrium 
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may not be the source of endometriosis (Redwine, D.B. 2002).  Multiple studies have 
demonstrated an increase in pro-inflammatory mediators in patients with 
endometriosis.  In keeping with the theme of this thesis where inflammation is 
postulated to predispose to EOC, it is perhaps not surprising that these patients are at 
increased risk of developing EOC.   
 
Several studies have suggested an increased relative risk or odds ratio for EOC in 
patients with endometriosis and these are critically reviewed by Vigano (Vigano, 
2007).   In an extensive study based in Sweden, women with a diagnosis of 
endometriosis had an increased risk of developing EOC at >10years with a 
standardised incidence ratio (SIR) of 2.5 (Brinton, L.A. et al. 1997).  Further analysis 
revealed that the site of endometriosis was important as women with ovarian 
endometriomata had a SIR of >3.0.  However the cases in this study were women 
who had been hospitalized as a result of their endometriosis. If it is accepted that the 
majority of cases of endometriosis are asymptomatic then the inpatient cohort are 
perhaps an inaccurate representation of disease incidence.  Moreover if these 
asymptomatic women were included in the analysis it is probable that the prevalence 
of EOC would drop.  Thus the selection of inpatients as cases may bias the outcome 
and a more extensive study involving ever diagnosed endometriosis would give a 
more accurate assessment of causality in EOC.     
 
A recurring feature of studies examining concomitant endometriosis in women with 
EOC is the consistent correlation between presence of endometriosis and the 
endometrioid / clear cell histological subtype.  The odds ratios in these studies varied 
from 3.4 to 35.4 (see figure 1.7)(Fukunaga, M. et al. 1997; Jimbo, H. et al. 1997; 
Ogawa, S. et al. 2000; Oral, E. et al. 2003; Sainz de la Cuesta, R. et al. 1996; 




   
 
Figure 1.6.  Studies demonstrating evidence of an association between 
endometriosis and endometrioid/clear cell EOC (Vigano, 2007).  The 
horizontal axis represents odds ratio and horizontal lines the 
confidence interval, the size of the box is proportional to the sample 
size. 
 
A consequence of the doubling in risk of EOC with endometriosis is a debate over 
how individual patients with endometriosis should be counselled.  The overall 
lifetime risk of developing EOC remains small and the risk of surgical complications 
is of a similar order.  It would seem unwise currently to recommend prophylactic 
BSO in women with endometriosis, however a large prospective trial may be helpful 
in deciding whether such an intervention would be indicated in these women.  If 
endometriosis had a significant role in overall EOC risk then Beral’s Million Women 
Study should have uncovered a preponderance of endometrioid/clear cell EOCs in 
women on oestrogen only HRT in a manner similar to development of endometrial 
adenocarcinoma (Beral, 2007).  However the only subtype that appeared to be 
increased with HRT use was serous, although the association with endometriosis was 
not specifically looked for.  In Ness’ study of 767 cases of EOC, 66 (8.4%) had a 
history of endometriosis, which was higher than the matched controls (85 out of 
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1367 (6.2%))(Ness, R.B. et al. 2000).  This gave an odds ratio of 1.7 (CI 1.2-2.4) for 
endometriosis as a risk factor for EOC.  In addition Ness and co-workers 
demonstrated a risk reduction with tubal ligation and hysterectomy, which, if reflux 
menstruation causes endometriosis, would reduce incidence of endometriosis.  So 
although some of the cancers may have been attributable to previously undiagnosed 
endometriosis, the overall contribution of endometriosis to EOC development is 
likely to be less than 10%.  The association with inflammation lends some biological 
plausibility to endometriosis being a risk factor for EOC.  The other potential 
mechanism is through sex steroid receptor signalling as ER and PR are both present 
in endometriosis although levels are not synchronous with those in the endometrium 
which alter with the menstrual cycle (Metzger, D.A. et al. 1988). 
 
 Purdie’s study of Australian women demonstrated that it was protection from the 
ovulatory events in a woman’s 20s that had the most significant effect on reducing 
risk of EOC in later life (Purdie, D.M. et al. 2003).  By inference this would suggest 
that ovulation between the ages of 20-29 carries the highest risk of causing disease.  
Yet EOC is principally a disease of older women with the majority of cases 
occurring after the menopause.   One explanation for this anomaly is that the first 
“hit” of genetic damage is caused in the OSE during the reproductive years and there 
is a second hit that occurs after the menopause.  It is possible that it is the stem cell 
component of the OSE that is damaged during the reproductive years but which only 
begins to replicate following the hormonal changes at the menopause.  The obvious 
endocrine protagonists following the menopause are the gonadotrophins which 
become significantly and persistently raised (Cramer, D.W. et al. 1983).   Yet in vitro 
work has suggested that follicle stimulating hormone (FSH) and luteinising hormone 
(LH) do not cause any increase in OSE proliferation (Ivarsson, K. et al. 2001).   
 
Rather than inhibition of ovulation being the protective mechanism of the COCP, an 
alternative hypothesis is that it is the steroid component of the pill that has a more 
dominant effect against EOC.  There is overwhelming evidence for the protective 
effect of the COCP on EOC but the mechanism for this is unknown (Collaborative 
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Group on Epidemiological Studies of Ovarian, C.; Greer, J.B. et al. 2005; Gwinn, 
M.L. et al. 1990; Siskind, V. et al. 2000).  The most likely beneficial component of 
the COCP is the progestin moiety.  The reasons for suggesting this are firstly that 
some other protective factors for EOC also have prolonged raised progesterone levels 
e.g. pregnancy.  In addition twin pregnancy, where the maternal progesterone is 
raised more than in singletons (Haning, R.V. et al. 1985), carries a higher protective 
effect than a singleton pregnancy (Whiteman, D.C. et al. 2000). Secondly, 
progesterone has demonstrable anti-inflammatory effects in OSE, where it inhibits 
the rise in COX-2 following IL-1α treatment (Rae, M.T. et al. 2004).  Thirdly, COCP 
preparations with higher efficacy progestins have a greater protective effect on EOC 
risk than those with low potency progestins (Schildkraut, J.M. et al. 2002).  Finally, 
the other component of the COCP, synthetic oestrogen, appears to be mitogenic in 
OSE and therefore unlikely to protect against EOC (Gotfredson, G.S. et al. 2007; 
Syed, V. et al. 2001). 
 
While sex steroids may protect against EOC if taken pre-menopausally, they appear 
to increase the risk of developing EOC when taken post-menopausally in hormone 
replacement therapy (HRT) (Beral, V. 2007; Lacey, J.V., Jr. et al. 2002; Riman, T. et 
al. 2002; Rodriguez, C. et al. 2001) although this is disputed by some (Purdie, D.M. 







Figure 1.7  Relative risk of developing EOC by HRT Use. (Beral, V. 2007) 
 
Using data from the Million Women Study group, which was set up to investigate 
links between HRT use and breast cancer, Beral found that risk of developing EOC 
was increased amongst users of HRT for longer than 5 years (Beral, V. 2007). There 
were a significantly greater number of serous tumours in the HRT users group but no 
difference in other histological subtypes.  Interestingly there was also a higher rate of 
serous borderline tumours in the HRT users.   The study also demonstrated that 
unlike COCP use, where the protective effects appear to last many years after 
cessation of use, previous HRT use appeared to have no residual effect on disease 
risk.  In Beral’s analysis users of HRT were also more likely to have been COCP 
users, suggesting that the protective effects of the COCP are abrogated by HRT use.   
 
The mechanism by which HRT use increases EOC risk is unclear.  Both HRT and 
COCP involve administration of exogenous oestrogens and progestins, but they act 
in quite different endocrine environments.  Ethinyl-estradiol in the COCP inhibits 
gonadotrophin induced production of estradiol from the ovary, while HRT users have 
high gonadotrophin levels but minimal ovarian production of estradiol.  It may 
therefore be the dynamics of estradiol production that predispose to cellular 
transformation rather than absolute dose.  So the COCP may be protecting the ovary 
from rapid swings in potentially harmful estradiol levels.   
 
A glaring question from the Million Women Study is not why are HRT users at 
increased risk of developing EOC but what stops the majority of HRT users from 
developing EOC?  The incidence of the disease is still small in users compared to 
non-users (2.6 per 1000 women versus 2.2 per 1000 women) so if exogenous 
oestrogen is the cause of EOC there must be protective mechanisms in place to offset 
its effects.  An interesting study yet to be undertaken should measure serum estradiol 
and correlate this with risk of developing EOC.  If HRT is causative for EOC then a 
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dose response effect should be seen, with higher estradiol levels being associated 
with greater risk of developing EOC.     
 
The potential for oestrogen to cause EOC should prompt a search for other 
mechanisms by which estradiol could impact on ovarian tissue.  While in the 
younger woman ovarian production of estradiol is predominantly via 17β-
hydroxysteroid dehydrogenase, in the post-menopausal state the cytochrome P450 
enzyme aromatase synthesizes predominantly estrone from androstenedione. 
Inhibitors of this pathway are widely used in breast cancer treatment (ATAC 
Trialists' Group 2005).  One study described aromatase in the OSE and on measuring 
activity demonstrated that levels were higher in normal tissue than in EOC tumours 
(Cunat, S. et al. 2005).  Furthermore data from Phase II trials have indicated that 
patients with EOC and ER-positive tumours might benefit from aromatase inhibitor 
(AI) therapy (Bowman, A. et al. 2002).  Indeed this was then confirmed by Smyth et 
al who described a disease stalling effect of the AI letrozole in a phase II trial of 
women with ER-positive EOC(Smyth, J.F. et al. 2007).  One study has demonstrated 
that estradiol and estrone cause down-regulation of the progesterone receptor (PR) in 
both OSE and EOC cancer cell lines (Mukherjee, K. et al. 2005).  Patients positive 
for PR appear to have a better prognosis than those negative for PR (Hempling, R.E. 
et al. 1998; Lee, P. et al. 2005; Sevelda, P. et al. 1990).  Therefore ER and PR typing 
may assist patient care by their use in treatment decision algorithms.   
 
It is unlikely that the natural history of EOC will be definitively documented in the 
human as such a study allowing confirmed early malignant disease to be observed 
without treatment would be unethical.  However with increasing use of ultrasound as 
an investigative tool in gynaecology it has become apparent that not only are ovarian 
cysts a common finding in postmenopausal women, but they also have a low risk of 
becoming malignant (Bailey, C.L. et al. 1998; Castillo, G. et al. 2004; Kroon, E. et 
al. 1995; Modesitt, S.C. et al. 2003; Valentin, L. et al. 2003).  What protects some 
patients from developing ovarian cancer while others remain susceptible?  The 
answer to this is undoubtedly complex and multifactorial however genetic 
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1.3.3 The Fallopian Tube  
An alternative hypothesis to the argument that the OSE is capable of transforming 
into other epithelial cell types is that these separate histologies have different cells of 
origin.  Thus the mucinous subtype has a gastro-intestinal source, clear cell and 
endometrioid tumours arise from explanted endometrial tissue and serous from the 
Fallopian tube.  Furthermore, there is increasing evidence that the Fallopian tube 
may have a role in the development of ovarian cancer (Crum, C.P. et al. 2007; 
Kindelberger, D.W. et al. 2007; Lee, Y. et al. 2007).  Firstly, in women with BRCA1 
or BRCA2 mutations undergoing prophylactic salpingo-oophorectomy, there is an 
increased risk of having an occult Fallopian tube carcinoma (Finch, A. et al. 2006).  
Secondly, women with BRCA1 or BRCA2 mutations whose ovaries alone are 
removed have an increased risk of developing primary peritoneal carcinoma than 
those undergoing complete salpingo-oophorectomy (Paley, P.J. et al. 2001).  Thirdly, 
there are histological similarities between the Fallopian tube luminal epithelium and 
ovarian papillary serous adenocarcinomas.  The proximity of the fimbrial ends of the 
Fallopian tubes to the ovarian surface also provides a biological explanation for the 
discovery of ciliated tubal-like cells within ovarian inclusion cysts.  The extension of 
a Fallopian tube carcinoma to involve the adjacent ovary could be an early step in the 
progression of such a malignancy and by the time of surgery the origin of the 
primary tumour may be difficult to ascertain.  Indeed this situation would explain 
why a step-wise progression of ovarian cancer is not seen in the OSE. 
 
1.4 Histological Subtyping of EOC 
The prognosis for patients diagnosed with EOC is heavily dependent on stage at 
initial presentation (table 1.1).  However tumour grade and histological subtype also 
influence prognosis and response to treatment.  While it is standard practice to use 
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the FIGO staging system in the United Kingdom to describe the clinical stage of the 
disease, TNM staging is also used internationally, and is directly comparable to the 
FIGO system (table 1.2) 
 
FIGO     UICC   
   T   N  M 
Ia  T1a  N0  M0 
Ib    T1b  N0   M0 
Ic   T1c  N0   M0 
IIa   T2a  N0   M0 
Iib  T2b  N0   M0 
IIc   T2c  N0   M0 
IIIa  T3a  N0   M0 
IIIb  T3b   N0   M0 
IIIc   T3c  N0   M0 
   any T   N1   M0 
IV     any T  any N  M1 
 
Table 1.2 Comparison of FIGO and International Union Against 
Cancer (UICC) staging systems for EOC. 
 
A consequence of the uniform cuboidal appearance of the OSE is that some authors 
assume that this means the OSE is in an undifferentiated state (Auersperg, N. et al. 
2001).  The transition from a simple cuboidal phenotype to a more mesenchymal 
phenotype is well documented, and this ability to undergo metaplasia gives support 
to the possibility that the OSE can differentiate into cell types resembling those from 
the reproductive tract.  Furthermore during the transformation into cancerous tissue 
the histological subtypes found in cancers reflect the epithelial components found 
throughout the genito-urinary tract, such that serous tumours represent the Fallopian 
tube, endometrioid tumours the endometrium, clear cell histology the transitional 
epithelium of the bladder, and mucinous tumours the endocervix (figure 1.9).  In 
most series of advanced ovarian malignancy, such as that described by the 
Gynecologic Oncology Group (Omura, G.A. et al. 1991), the most common form is 
serous (60%) then endometrioid (16%), and more rarely mucinous (4.5%) and clear 
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cell (3.7%).  Mixed histologies can also arise (6%) as well as undifferentiated forms 
(4.1%).    
 
Figure 1.8.  Examples of the most common histological subtypes of 
EOC (haematoxylin and eosin, magnification A-C X10, D X40).  A) 
Serous carcinoma B) Mucinous carcinoma C) Endometrioid carcinoma 
D) Clear cell carcinoma. Pictures courtesy of Dr A Williams.  
 
While this is an appealing and tidy model, there are several arguments suggesting 
that this view is too simplistic.  Firstly, although mesenchymal transformation of 
cultured OSE cells can be demonstrated there have been no studies demonstrating 
metaplasia of OSE to endometrial, endocervical, or tubal epithelial cell types.  
Secondly, the OSE does not arise from the Mullerian duct. Thirdly, there is growing 
evidence that rather than EOC being a disease arising from one particular cell type it 
is more likely that it is a heterogeneous disease with different risk factors for 
different histological subtypes.  For some time it has been apparent that many 
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mucinous tumours are derived from gastro-intestinal primary cancers, in particular 
appendiceal adenocarcinoma (Fujii, S. et al. 1986; Seidman, J.D. et al. 1993; Skaane, 
P. et al. 1986; Sumithran, E. et al. 1992; Thorsen, P. et al. 1991; Young, R.H. et al. 
1991). Furthermore, mucinous tumours appear to differ from non-mucinous tumours 
in their epidemiological risk factors, with oral contraceptive pill use being less 
protective for the mucinous group and ovulation being a much greater risk factor in 
non-mucinous tumours, while family history of EOC increases risk for non-mucinous 
but not the mucinous subtypes  (Purdie, D.M. et al. 2003).  Similar discrepancies in 
risk factors between different subtypes can also be seen for other histologies.  In a 
study examining development of EOC and previous gynaecological surgery, 
hysterectomy and tubal ligation were found to be protective for EOC, but only for 
endometrioid and clear cell carcinomas (Rosenblatt, K.A. et al. 1996).  One 
weakness of this study is that although the odds ratios suggested a protective effect, 
the confidence intervals crossed unity.  Whether the risk factors differ for individual 
histological types of EOC is controversial and there are almost equal numbers of 
studies for and against.  In one of the largest, involving 767 women with EOC and 
1367 age-matched controls, there were no significant differences in reproductive risk 
factors amongst the different histologies, however once these subtypes were 
analysed, the number of cases (52 mucinous cases for example) may have been too 
small to be able to demonstrate a true difference; an accusation denied by the authors 
in their discussion (Modugno, F. et al. 2001).  A study looking for loss of 
heterozygosity (LOH) in only stage I ovarian cancers demonstrated similar allelic 
loss, resulting in grouping of endometrioid, clear cell and grade 3 tumours (Wang, V. 
et al. 2005).  This appeared to suggest that there is considerable heterogeneity 
amongst ovarian cancers.   A final unexplained observation is why the incidence of 
the histological subtypes is skewed in favour of serous adenocarcinomas.  
Presumably if the OSE is truly capable of differentiation during malignant 
transformation then the type of tumour should be equally prevalent. 
 
The means by which different EOCs could arise are likely to be multiple but one 
common pathway may be through disruption of  homeobox (HOX) genes (Cheng, 
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W. et al. 2005).  The genes Hoxa9, Hoxa10 and Hoxa11 are known to control 
differentiation of the Mullerian ducts into Fallopian tubes, uterus and cervix.  Cheng 
et al. demonstrated firstly that although the HOX proteins are differentially 
distributed throughout the Mullerian tract in the human, there are none detectable by 
immunohistochemistry on the human OSE.  Secondly, on examining a panel of 
ovarian cancers, HOXA9 protein was found in serous, endometrioid and mucinous 
EOCs, HOXA10 in endometrioid and mucinous but not serous and HOXA11 only in 
mucinous tumours.  After transfecting a mouse OSE cell line (MOSEC) with these 
individual HOX genes, they created a mouse model of ovarian cancer by intra-
peritoneal seeding of the transfected cells.  On histological assessment of the tumours 
those expressing Hoxa9 developed tumours resembling papillary serous EOC, those 
expressing Hox10 developed glandular tumours resembling endometrioid carcinoma 
and those expressing Hoxa11 had tumours with cells containing clear cytoplasm 
much like mucinous EOC.  Inoculation of mice with MOSEC cells transfected with 
Hoxa7, which appeared to be important for determining degree of differentiation 
rather than tissue type of differentiation, also resulted in low-grade tumours.  While 
this study still does not provide direct evidence for the OSE being the tissue of origin 
for EOC, it does provide an explanation for the multiple histologies seen in this 
disease.  
 
The existence of borderline tumours of the ovary (BOT) (Schaner, M.E. et al.) 
throws up some difficult questions as to their role in the genesis of EOC.  Thus they 
behave clinically like benign tumours and although they can recur the prognosis for 
patients with borderline tumours is often excellent.  The histological characteristic of 
the tumour is a lack of invasion beyond the basement membrane of the epithelial 
tissue.  The majority of these tumours are serous and share many features of the 
Fallopian tube epithelium but a mucinous subtype may also be reported (see figure 
1.10).  They are staged in an identical fashion to EOC and can have peritoneal 
implants, which if they become invasive result in poorer outcomes (Prat, J. et al. 
2002).  Molecular analyses of serous BOTs (SBOTs) do not show the same genetic 
profile as malignant tumours: there is no characteristic TP53 mutation in SBOTs 
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(Kupryjanczyk, J. et al. 1995; Zheng, J. et al. 1995).  Gene expression profiling 
shows that serous and mucinous BOTs are distinct entities and that there is 
considerable heterogeneity amongst mucinous tumours, possibly implying different 
oncogenic events (Wamunyokoli, F.W. et al. 2006).  Whilst ras mutations are 
common in both mucinous BOT and mucinous EOC, they occur in serous BOT but 
not carcinomas.  These observations suggest that while mucinous EOC could arise 
from a mucinous BOT it is very unlikely that such a process occurs in serous EOC.  
Looking at loss of heterozygosity (LOH) and K-RAS mutations in a series of 
SBOTs, Sieben et al have provided evidence that the implants in SBOT are from 
clonal expansion of the disease rather than the generation of multiple tumours 
(Sieben, N.L. et al. 2006).  Further investigation of K-RAS and BRAF mutations in 
SBOTs by microarray showed a high rate of mutations in these genes but none or 
low rates in serous carcinomas of the ovary (Sieben, N.L.G. et al. 2005).  The high 
rate of these mutations in SBOTs implicated the RAS-RAF-MEK-ERK-MAP kinase 
signalling pathway and further analysis of the genes involved in this pathway showed 
a significant difference between EOC and SBOTs.  In these borderline tumours there 
appears to be an uncoupling of the proliferative and invasive components of 
malignancy.  Prime suspects for tissue invasion are the matrix metalloproteinases 
(MMPs). Although Sieben et al showed a significant difference in extracellular 
matrix (ECM) associated gene expression between SBOTs and EOC, the difference 
was a down regulation of all genes in SBOTs apart from tissue inhibitor of 
metalloproteinase-1 (TIMP-1).  However follow-up quantitative real-time PCR 
demonstrated only a 1.6-fold up-regulation of this gene and zymography showed 
MMP-9 activity in the cancers, but the published zymogram is not convincing and 
pro-MMP-9 is present in the SBOTs.  Nevertheless further research into molecular 
mechanisms of control of ECM degradation is indicated to explain the differences 
between SBOT and EOC.  This has considerable potential for gene therapy where 
aberrant EOC cells could be made non-invasive by switching off their MMP 




Figure 1.9.  Histology of serous (A) and mucinous (B) borderline 
tumours of the ovary.  H&E, magnification X40. Images courtesy of Dr A 
Williams.   
 
Another way of distinguishing different types of EOC is by tumour grade; G1, low 
grade being well differentiated, G2, moderately differentiated, and G3 high grade 
and poorly differentiated.  It has been proposed that low grade tumours are anteceded 
by borderline tumours given the similarity of genetic alterations in low grade and 
BOTs whilst high grade tumours have less genetic mutations identified apart from 
p53 mutations that are found in high grade serous and carcinosarcomas (Shih Ie, 
2004).  This scheme of characterization moves away from the traditional surgical 
methods of disease staging and considers the disease in terms of genetic alterations 
that influence the cellular biology.  This emphasises the observation that what is 
currently termed “ovarian cancer” is more likely to be a collection of different 
diseases arising from different sources and different genetic mutations rather than 
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one disease.  By moving towards this way of thinking it is probable that the methods 
of treating the disease in the future will be more tailored to individual patients based 




1.5 OSE in ovarian biology 
 
In the female of reproductive age the single layer of mesothelial cells that cover the 
surface of the human ovary is necessarily disrupted on a monthly basis by the release 
of an oocyte from the ovarian cortex.  This event results in significant trauma to the 
ovarian surface which must be repaired quickly in time for the next ovulation.  While 
it is clear that the endocrine signalling responsible for the timing of ovulation is 
precisely controlled there is also evidence that the OSE has its own intracrine 
mechanisms to aid this reparative process.  However the exact sequence of events 
that occur at the time of ovulation remain vague.  During enlargement of the 
dominant follicle in the first half of the menstrual cycle, hydrostatic pressure 
increases the convexity of the ovarian surface.  While some authors propose that the 
OSE undergoes apoptosis prior to ovulation (Murdoch, W.J. et al. 2002), it is far 
from clear how this is regulated.  There may be a physical stimulus from increasing 
tension between OSE cells as the cortex enlarges, or there may be paracrine signals 
arising from the follicle itself.  For ovulation to occur there has to be proteolytic 
breakdown of the ovarian surface by matrix metalloproteinases.  While there is 
evidence that the OSE is capable of synthesising such enzymes it is not clear what 
the relative contributions of OSE, ovarian stroma and oocyte complex are in 
collagenase/proteinase production.  Recent work in OSE demonstrates that this tissue 
is capable of synthesising both MMP-9 and Lysyl oxidase (LOX), an enzyme 
necessary for tissue remodelling and collagen cross-linking (Rae, M.T. et al. 2008).   
Furthermore the synthesis of these compounds is influenced by interleukin-1α and 
the potent anti-inflammatory steroid cortisol (Kendall’s compound F). Therefore the 
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local degradative effect of these enzymes causes thinning of the ovarian cortex and 
stigma formation from where the oocyte complex can breach the ovarian surface.  It 
is clear from direct visualization of this process in the human at laparoscopy that 









Figure 1.10.  Inflammation of the ovarian surface following ovulation 
(picture courtesy of Prof SG Hillier). 
 
However the pro-inflammatory cascade caused at ovulation must also be quickly 
resolved in order to repair the ovarian surface and prepare the ovary for its next 
ovulatory episode.  Examination of the effect of IL-1α in primary cultures of human 
OSE allowed Yong et al to conclude that there are also anti-inflammatory 
mechanisms initiated at the time of ovulation that limits local tissue disruption and 
allows resolution of inflammation (Yong, P.Y. et al. 2002).  They measured levels of 
11-beta hydroxysteroid dehydrogenase (11βHSD1) mRNA and enzyme activity in 
cultures of human OSE in the presence and absence of IL-1α to simulate 
inflammation in vitro. The principal action of this protein in the human is the 
conversion of inactive cortisone to the potent anti-inflammatory steroid cortisol by 
reduction of the 11-keto group.  Although it is part of the alcohol dehydrogenase 
superfamily, 11βHSD1’s behaviour in vivo appears to be mainly as a reductase. The 
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converse reaction is catalysed by 11-beta hydroxysteroid dehydrogenase type 2 















Figure 1.11.  In vivo mechanisms of action of the 11βHSD isoforms 
demonstrating interconversion of cortisone (E) and cortisol (F), and the 
dependence on the cosubstrates NADP/H and NAD/H.  α-bonds (below 
the plane of the molecule) are indicated by dotted triangles and β-
bonds (above the plane of the molecule) by solid triangles. 
 
The addition of cytokine caused a significant rise in 11βHSD1 mRNA in a dose-
dependent fashion and could be abrogated by the addition of the IL-1 receptor 
antagonist (IL-RA).  The mRNA rise was replicated in the 11-oxoreductase activity 
of these cells, suggesting that the OSE is able to increase local levels of cortisol 
following an inflammatory insult and hence aid in the resolution of tissue damage.   
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Further work on the anti-inflammatory signals in the OSE by Rae et al confirmed the 
rise in 11βHSD1 mRNA with IL-1α treatment but when cortisol was also added 
concomitantly there was a further rise in 11βHSD1 mRNA expression (Rae, M.T. et 
al. 2004).  Assuming this is reflected in the level of the enzyme, it would appear that 
there is a positive feedback mechanism in place whereby in a background of 
inflammation cortisol is able to enhance its own production.  There was no change in 
levels of the inactivating enzyme 11βHSD2 upon treatment in these experiments so 
any alteration in glucocorticoid metabolism was likely to have arisen from the effects 
on 11βHSD1. By examining cyclo-oxygenase-2 (COX-2) expression in their OSE 
samples the substantial anti-inflammatory effect of cortisol could be confirmed.  
COX-2 mRNA levels rose with IL-1α but were returned to near control levels by the 
addition of cortisol.  Interestingly, progesterone was demonstrated to have similar 
anti-inflammatory properties and inhibited the rise in COX-2 mRNA after IL-1α 
treatment.  The pro- and anti-inflammatory paradigm displayed by the OSE can be 






Figure 1.12.  Summary of inflammation-associated events in the OSE at 
ovulation. 
The anti-inflammatory mechanisms within the OSE may explain the rapid resolution 
of ovulation-associated inflammation in the ovary that exists in order to prepare for 
the subsequent cycle of follicle maturation and ovulation should pregnancy not 
occur.  However although most of the work has focused on events surrounding 
ovulation, there is less understanding of how the OSE heals itself.  Is there 
centripetal healing from the wound edge or is there healing by circulating 
mesothelial cells, as in the peritoneum?  The latter would seem to be the quickest 
method but there is no evidence for this in the OSE. If progenitor cells do repopulate 
the ovarian wound where do they come from? Are there niches of OSE stem cells 
close by or could the mesothelial progenitor initially “plug the gap” and then 
differentiate into an OSE type cell?    
 
1.6 11βHSDs and Mechanism of Glucocorticoid Action 
The existence of two isoforms of the 11βHSD enzyme means that levels of cortisol 
can be controlled at a local level by the balance of the type 1 and 2 isozymes.  
Therefore tissues expressing high levels of type 2 11βHSD e.g. kidney will have low 
tissue levels of cortisol (allowing aldosterone exclusive access to the 
mineralocorticoid receptor), whereas a relative abundance of type 1 11βHSD allows 
local cortisol to be generated.  Levels of 11βHSD2 are also significantly higher in 
placenta which may protect the fetus from maternal cortisol.  Initial studies of the 
pure 11βHSD1 enzyme were achieved in the liver where it acts to generate 
glucocorticoids by reductase activity on 11-ketosteroids (figure 1.12).  Whereas the 
11βHSD1-containing cellular fractions and microsomes appear to have bi-directional 
catalytic activity, intact cells appear only to show unidirectional metabolism of 
cortisone to cortisol.  It is probable therefore that the latter situation reflects in vivo 
action in the OSE more accurately. Furthermore it is likely that the unidirectional 
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activity of 11βHSD1 exists because of its compartmentalised location within the 
endoplasmic reticulum, where it relies on NADPH as a co-substrate.  It is clear that 
11βHSD1 levels can be increased in response to inflammation in many other tissues 
as well as the OSE : aortic smooth muscle (Cai, T.-Q. et al. 2001), pre-adipocytes 
(Tomlinson, J.W. et al. 2001), endometrium (McDonald, S.E. et al. 2006), 
trophoblast (Li, W. et al. 2006) and fetal membranes (Sun, K. et al. 2003).  There is 
growing evidence for a switch in isozyme production in pre-adipocytes (Bujalska, 
I.J. et al. 2002) and endometrium (McDonald, S.E. et al. 2006).   These studies 
suggest that tissues are able to switch from 11βHSD1 to 11βHSD2 production given 
the correct signals.  This strengthens the case against dehydrogenase activity of 
11βHSD1 occurring in vivo as it would appear that if dehydrogenation of  the 11-
hydroxyl group is required, the tissue preferentially induces 11βHSD2 production 
rather than alter co-substrate availability in order to induce dehydrogenase activity of 
11βHSD1 .  The reductase activity of the Characteristics distinguishing 11βHSD1 
and 11βHSD2 are shown in table 1.2.   
Within the ovary, cells other than the OSE have been extensively studied with regard 
to their ability to influence glucocorticoid levels. In granulosa cells which have not 
been exposed to LH, mRNA for both the MR and 11βHSD2 are expressed (Tetsuka, 
M. et al. 1999; Tetsuka, M. et al. 1997). Following luteinisation however there is no 
detectable expression of 11βHSD2 mRNA or protein and the predominant isoform is 
11βHSD1 (Michael, 1997).  In addition the steroid receptor profile changes from MR 
to GR.  This may give an insight to the mechanism of follicular development where 
water follows sodium transport mediated by the MR.   
The hypothesis develops that abnormal accumulation of fluid within pathological 
ovarian cysts could arise from deregulation of MR or 11βHSD2 expression and an 






Table 1.3.  Summary of properties of 11βHSD1 and 11βHSD2  after 
(Draper, N. et al. 2005). 
 Type 1 Type 2 
Tissue Distribution Liver, lung, pituitary, brain, 
gonad, adipose tissue 
Kidney, colon, placenta, 
salivary glands 
Direction of Reaction  Bi-directional (in vitro) 
Reductase (in vivo) 
Uni-directional 
(dehydrogenase) 




17-27 μmol l-1 
300 nmol l-1 
 
14-60 nmol l-1 
∞ 
Chromosome location 1q32.2 16q22 
Gene size 30kb, 6 exons 6.2kb, 5 exons 
Protein size 292aa, 34kDa 405aa, 44kDa 











TNFα, PPARΔ,Hypoxia  
Co-substrate NADP(H) NAD(H) 













An important feature that influences 11βHSD1 enzyme efficiency is co-substrate 
availability.  The generation of NADPH is dependent on hexose 6-phosphate 
dehydrogenase (H6PDH) which catalyses the first two steps of the pentose phosphate 
pathway (Clarke, J.L. et al. 2003) as summarised in figure 1.14.    H6PDH lies within 
the smooth endoplasmic reticulum (ER) (Bublitz, C. et al. 1987), which is 
impermeable to pyridine nucleotides, and is dependent on glucose 6-phosphate (G6P) 
transport into the ER by glucose 6-phosphate translocase for generation of NADPH.  
This relationship is not purely one-sided as experiments in rat live microsomes 
demonstrate not only that H6PDH stimulation (by G6PD) increased cortisol 
production but addition of cortisone increased H6PDH activity (Czegle, 2006).  
These data also suggested a significant pool of latent NADPH within the liver as 
addition of cortisone caused a measurable increase in production of cortisol.  
However this may be a feature of glucose/glycogen rich tissues such as the liver, and 
peripheral tissues could conceivably have reductase activity impaired by an absence 
of NADPH through reduced glucose availability.  Thus cell type may be a 
determinant of whether 11βHSD1 acts as a reductase or dehydrogenase.  In cell 
culture work, omission of glucose from culture medium reduces keto-reductase 
activity of 11βHSD while there appears to be an increase in dehydrogenase activity 
(Ferguson, 1999).  This fuel deprivation could be exacerbated further in tissues such 
as cancer where demand as a result of disinhibited growth could exceed supply. 
 A consequence of the interdependence of 11βHSD1 and H6PDH is that mutations in 
H6PDH will lead to diminished NADPH production and thus reverse the reaction 
direction of 11βHSD1, resulting in reduced cortisol production and a syndrome of 
apparent 11βHSD1 deficiency.  This scenario has been elegantly demonstrated by 
Draper et al in a series of 3 patients, the females of which presented with symptoms 
normally associated with polycystic ovarian syndrome (PCOS) i.e. hirsutism, acne, 
obesity, oligoamenorrhea and infertility (Draper, N. et al. 2003).  While 11βHSD1 
has long been suggested as a target for anti-obesity agents, perhaps H6PDH should 








Figure 1.13.  Mechanism of co-substrate involvement in 11βHSD1 
activity. GT, glucose 6-phosphate translocase; G6P, glucose 6-
phosphate; 6PG, 6-phosphogluconolactonate. 
 
The generation of cortisol by 11βHSD1 provides a ligand for the glucocorticoid 
receptor (GR).  Due to the high lipophilic natures of cortisol, the GR does not require 
to be on the cell membrane and instead can be found within the cytoplasm and on the 
nuclear membrane.  Activation of GR can have several different outcomes, 
depending on the target tissue and its current milieu.  The GR is believed to have 
evolved from a common ancestor around 400 million years ago (Thornton, J.W. 
2001) and shares similarities with other steroid receptors from the nuclear receptor 
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superfamily of transcription factors that also includes receptors for 
mineralocorticoids, oestrogen, androgen, progesterone, vitamin D and retinoic acid. 
Through its effect on transcription the GR can influence a vast array of cell processes 
including proliferation, apoptosis, immune response, neuronal signalling and 
vascular tone.  Rather than there being a simple ligand-receptor interaction with a 
clear cellular effect, with GR signalling there are myriad possibilities by which the 
signalling process can be altered.    Classically the GR resides in the cytoplasm 
within a complex of proteins including hsp90, which maintains the ligand binding 
site, along with several others.  Binding of glucocorticoid causes dissociation of this 
complex and alters the GR complex to allow its translocation to the nucleus.  Once 
inside GR homodimers can interact with Gene Response Elements (GRE) to either 
promote or inhibit gene transcription. Furthermore it would appear that the activated 
GR complex can also interact by protein to protein binding with other transcription 
factors, such as activator protein-1 (AP-1), nuclear factor-κB (NFκB), Sma and Mad 
related protein (SMAD) and signal transduction and activator of transcription 
(STAT). While GR to DNA binding occurs within the nucleus, these protein-protein 
interactions can occur within the cytoplasm. This sequence of events clearly has 
points at which signalling could be disrupted and there are further mechanisms by 
which GR function might be upset.  The gene for GR is composed of 10 exons and 
lies within chromosome 5q31-32.  Alternative splicing of exon 9 gives rise to two 
isoforms GRα and GRβ.  GRα protein consists of 777 amino acids while GRβ is 
identical for the first 727 amino acids but the carboxy terminal amino acids are 
replaced resulting in a protein of 742 amino acids.  In the human GRα appears in 
almost all tissues while GRβ is present at much lower levels but always within the 
nucleus.  GRβ is not transcriptionally active but appears to act as an inhibitor of 
GRα.  There is some evidence that an imbalance in relative amounts of these two 
isoforms occurs in some disease states, and may play a role in glucocorticoid 
resistance, particularly in asthma (Hamid, Q.A. et al. 1999).  A further splice variant 
GRγ (an insertion of an additional arginine between exons 3 and 4) has been 
implicated in childhood acute lymphoblastic leukaemia suggesting that GR 
dysregulation can play a role in the malignant process (Beger, C. et al. 2003).  
Further potential disturbance to GR signalling can arise from post-translational 
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processing of GR such as phosphorylation, ubiquitination and SUMOylation (Duma, 
D. et al. 2006).  Therefore in cell-based science any glucocorticoid effect may be the 
result of many different signalling pathways and be dependent on the immediate 
cellular environment.  This makes cell culture based research using glucocorticoids 
not only difficult to predict but also difficult to translate to the clinic.   
 
1.7  11βHSD And Cancer 
 
Rabbitt et al have suggested that a switch in 11βHSD isozyme production could 
underlie alterations in cell proliferation and thus be implicated in the development of 
cancer (Rabbitt, E.H. et al. 2003).  Using stable tranfects of either 11βHSD1 or 
11βHSD2, they were able to demonstrate a higher rate of proliferation in cells 
transfected with the type 2 isozyme (Rabbitt, E.H. et al. 2002).  While the study is 
clear in its findings, the overall relevance of transfecting a human gene into a rat 
osteosarcoma cell line to human pathology is questionable.  Nevertheless Rabbitt 
describes several other studies suggesting a link between overexpression of 
11βHSD2 and malignancy, for example in pituitary adenomas (although these are not 
invasive tumours) (Korbonits, M. et al. 2001) and colon cancer (although 11βHSD2 
was also present in normal tissues) (Takahashi, K. et al. 1998).    Rabbitt’s 
hypothesis would suggest that raised 11βHSD2 levels (and thus low cortisol levels) 
in tissues would stimulate cell proliferation.  This is in keeping with the pro-
differentiation and anti-proliferative effects seen with cortisol in vitro.  However in 
the OSE glucocorticoids have been shown to have no effect (Karlan, B.Y. et al. 
1995) or stimulate cell proliferation (Salamanca, C.M. et al. 2004).  If these studies 
are relied upon then the tumorigenic effect of 11βHSD2 could instead be explained 
by a glucocorticoid independent action, perhaps by activation of an oncogene.  This 
thesis examines Rabbitt’s hypothesis directly by assessing the relative quantities of 
type 1 and 2 11βHSD in normal OSE and samples of EOC.  The evidence supporting 
Rabbitt’s hypothesis has been further added to with regard to ovarian cancer by a 
study which appeared to suggest higher 11βHSD2 activity in tissue samples of 
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ovarian cancer compared to normal ovaries (Temkin, S. et al. 2006).  Herein lies a 
major stumbling block for ovarian cancer research using primary tissues: what tissue 
to refer to as normal?  If the source of EOC is the OSE, as these authors imply, then 
the tissue that should be used for comparison with cancers should be the OSE and not 
whole ovary.  The considerable steroidogenic potential of the ovary invalidates its 
use as a comparator.  An additional criticism of Temkin’s study is that the samples 
were homogenized and additional NAD was added to the assay mixture. Firstly, the 
disruption of the cells releases 11βHSD1 from its location in the ER as described 
above, and secondly addition of NAD artificially raises dehydrogenase activity 
compared to the intact cell.  However this was undertaken for control tissue (post-
menopausal ovary) also and no such rise was seen.  
The issue of choice of normal tissue as a comparator is an important one as results of 
any comparative study could be dramatically altered by use of the wrong control 
tissue.  Whole ovary is widely used in studies looking for differences between 
normal and malignant ovarian tissue (DiFeo, A. et al. 2006; Newton, T. et al. 2006; 
Szlosarek, P.W. et al. 2006; Welsh, J.B. et al. 2001; Widschwendter, M. et al. 2004), 
but if the authors believe that EOC arises from the OSE then it is illogical to use 
whole ovary as the comparator instead of the OSE.  As the OSE makes up such a 
minute contribution to the ovarian volume, the use of whole ovary could influence 
any comparison due to the considerable amount of stromal tissue in the ovary.  In 
addition the small foci of highly steroidogenic cells within ovarian follicles could 
also skew data.  In a clever microarray study Zorn et al investigated differences in 
gene expression between different cells used as ‘normal’ comparators with EOC 
(Zorn, K.K. et al. 2003).  Looking at whole ovary, uncultured OSE brushings, and 
cultured primary and immortalized OSE cells, they demonstrated that gene clustering 
was found between the primary tissues and also between the cultured cells showing 
that exposure to tissue culture conditions may affect gene expression in OSE.  
Further examination showed the whole ovary samples clustering differently to the 
OSE brushings showing the effect of large quantities of stromal cells in the sample.  
Overall it would appear that the most ideal normal control is OSE brushings without 
any culture.  There are considerable practical problems with use of this tissue 
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however as the numbers of cells obtained at each brushing is of the order of several 
thousand so the quantity of RNA that can be extracted is tiny. 
 
The discovery of 11βHSD1’s important role in response to inflammation in the ovary 
coupled with the knowledge that inflammation is a probable causative agent in EOC 
(Fleming, J.S. et al. 2006) lead Gubbay et al to investigate inflammatory signalling in 
ovarian cancer cell lines (Gubbay, O. et al. 2005).  Looking at baseline levels of 
mRNA, they demonstrated a significantly lower level of 11βHSD1 in three of the 
four cancer cell lines selected compared to OSE, but a higher level of 11βHSD2 in 
all cancer cell lines.  Furthermore when the cells were treated with IL-1α, there was 
no significant induction of 11βHSD1 in three of the four cancer cell lines.  
Interestingly the one cell line that showed a response to IL-1α, PE-14, was the same 
cell line with relatively normal 11βHSD basal levels.  This cell had been derived 
from a patient with a histologically well differentiated cancer whereas the three other 
cell lines were from poorly differentiated tumours.  The question then arises – does 
poor tumour differentiation cause dysregulated 11βHSD expression or does aberrant 
11βHSD production determine tumour differentiation?   
 
It is unlikely that the answer to this question will arise from work on ovarian cancer 
cell lines, as the cells used have been selected for their ability to replicate without 
differentiation and as such are poorly representative of primary ovarian tumours.   In 
contrast, primary cancer cell cultures are derived directly from histologically proven 
tumours, have not undergone multiple passages and are therefore characteristic of the 
“real-life” disease.  What is lost by not using cell lines is the predictable, repeatable 
and uniform behaviour of a particular cell but what is gained in primary cell culture 
is the increased probability of being able to translate research findings into clinically 
relevant interventions.  Established cell lines do undoubtedly have a place in cancer 
research, however their ease of use has meant they are often preferred to the more 
labour-intense process of working with primary tissue.  In some situations this has 
had a detrimental effect on whole bodies of research, in particular when evidence 
shows that contamination of some cell lines by a more virulent type has meant 
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researchers have been making conclusions about a different cell type than the one 
they set out to study (Nelson-Rees, W.A. et al. 1981; van Bokhoven, A. et al. 2001).  
Furthermore in the field of ovarian cancer research one cell line, SW626, that has 
been extensively used as an example of ovarian cancer now appears to be of colonic 
origin (Furlong, M.T. et al. 1999). In deriving a cell line, the process selects a clone 
of cells that have achieved immortality.  However even primary tumour cells are not 
immortal once placed in culture.  Thus the relationship between the primary tumour 
and the cell line is likely to be remote.  It is quite clear that ovarian cancer tissue 
contains dynamic DNA mutations occurring in different areas of tumour, suggesting 
that, far from being a monoclonal entity, tumour development is a constantly 
evolving process (Khalique, L. et al. 2007; Tanaka, K. et al. 1989).  This tumour 
heterogeneity is in contrast to the monoclonal nature of cell lines.   
 
The ability of a cell line to replicate the in vivo tissue becomes even more tenuous 
when “transformed” cells are used to simulate normal tissue.  Widely used 
techniques to create these “normal” cell lines include insertion of papillomavirus E6 
and E7 genes or the human telomerase reverse transcriptase (hTERT).  Yet once 
immortalized the cells cease to be normal (Ziltener, H.J. et al. 1993) and have taken 
on characteristics of malignancy.  Despite this, these cells are often referred to as 
normal (Choi, J.-H. et al. 2005), in the same way that EOC cell lines are often 
described as “ovarian cancer”.  Not only is it likely that such dependence on these 
cellular examples of Frankenstein’s monster is misguided, it is probable that the 
understanding of some biological processes has been set back by over-reliance on 





1.8 Genetics of Epithelial Ovarian Cancer 
 
The transformation of a normal cell into a cancerous cell can theoretically occur 
through a variety of mechanisms, but for many patients the precise sequence of 
events may never be known.  The common feature in many cancers is an alteration in 
the DNA sequence.  The change in DNA can be passed through the germline as a 
susceptibility for developing cancer or may arise spontaneously in the somatic tissue.  
It has more recently become apparent that another mechanism by which gene 
expression may be altered in cancer is not by disruption of the gene sequence itself 
but by an epigenetic effect, DNA methylation, that inhibits gene transcription 
(Baylin, S.B. et al. 2006).  Almost 1% of the genes in the human genome have been 
implicated with development of cancer (Futreal, P.A. et al. 2004).  In ovarian cancer 
this can involve the activation of oncogenes or the inhibition of tumour suppressor 
genes.  In addition the purity of the genome has to be maintained with cell division 
so interference with the DNA repair mechanisms may also be an initiating or pre-
disposing step in cancer development.   
 
1.8.1 Hereditary Ovarian Cancer 
 
Most cases of ovarian cancer are stochastic events and less than 10% of cases of 
EOC are familial (Risch, H.A. et al. 2001).  In affected families where genetic 
profiling has been undertaken, the genes most commonly associated with ovarian 
cancer are principally BRCA1 (70-75% of familial cases), BRCA2 (20%), hereditary 
non-polyposis colorectal coli (HNPCC, 2%) and others (5%).  Despite BRCA1 first 
being implicated in breast and ovarian cancers nearly 13 years ago (Miki, Y. et al. 
1994), and BRCA2 the following year (Wooster, R. et al. 1995), functions for the 
gene products are only now becoming clear.  Both genes are predicted to give rise to 
complex yet distinct proteins which appear to localize in the nucleus.  BRCA1 spans 
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80kb on chromosome 17q12-21, encoding multiple protein products, the most 
commonly studied of which is p220, while BRCA2 lies within 13q12-13 and encodes 
a predicted protein of 3418aa.  A product of alternative splicing of the BRCA1 gene 
has been shown to modify DNA replication.  Suppression of the 1399aa gene product 
BRCA1-IRIS reduced rate of cellular DNA replication while its overexpression 
stimulated DNA replication (ElShamy, W.M. et al. 2004).  
  
The precise roles for BRCA1 and BRCA2 have not been identified but they are 
implicated in the maintenance of chromosomal structure (Venkitaraman, A.R. 2002).  
However given that this role is required in all tissues, it is a mystery as to why 
mutations in these genes preferentially predispose to breast and ovarian cancer.  
Some light has been shed on this by Hu et al who demonstrated that an inverse 
relationship between Brca1 expression and aromatase activity exists in murine 
ovaries (Hu, Y. et al. 2005).   In addition they demonstrated that knockdown of 
BRCA1 in a granulosa cell line caused significant up-regulation of aromatase 
mRNA.  Thus mutations in BRCA1 could increase aromatase activity locally in the 
ovary and in adipose tissue, therefore elevating tissue oestrogens and driving mitosis.  
A local oestrogenic stimulus may also explain the preference for EOC cells to 
metastasise to and thrive in the omentum.  More recently evidence has arisen that 
BRCA1 may cause silencing of the X chromosome in female animals (Ganesan, S. et 
al. 2002; Silver, D.P. et al. 2007), although another group has implied that these 
experiments are not reproducible (Xiao, C. et al. 2007).   
 
In comparison to other tumours the cancers that patients with BRCA1 mutations 
develop tend to be serous and have better prognoses (Rubin, S.C. et al. 1996).  It is 
possible that knowledge of increased risk causes patients to present at an earlier stage 
than their counterparts thus making their outcomes appear more favourable.  
However there may be significant differences in the mechanism of onset of EOC in 
patients with a familial predisposition to developing cancer to those who develop the 
disease by chance.  Yet because they form an easily studiable group patients with a 
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heritable predisposition to EOC are an ideal cohort with whom studies of 
preventative interventions can be carried out. 
 
Of course, not all patients with BRCA1/2 mutations will go on to develop cancers 
and like HRT users discussed earlier it is likely that there are other mechanisms in 
place to protect some predisposed women from developing EOC.     
 
1.8.2 Sporadic Ovarian Cancer 
 
While there may be overlap with BRCA1 in sporadic EOC, the genetic background 
to most cancers is unknown.  The list of genes that have been associated with 
sporadic EOC is vast and too extensive for discussion here.  However there are a few 
candidates that require further elaboration. 
 
1.8.3 Putative Oncogenes 
1.8.3.1 Met/HGF Receptor 
The tyrosine kinase receptor Met is an ideal candidate for an oncogene in EOC.  
After binding with its ligand hepatocyte growth factor (HGF), it dimerises and is able 
to induce a variety of pathways to bring about invasive growth (Comoglio, P.M. 
2001).  In OSE cultures, the phenotype becomes progressively more neoplastic with 
higher levels of Met and ERK1/2 activation (Wong, A.S.T. et al. 2004).  Corps et al 
described 20-fold higher levels of the met protein in SKOV-3 cells compared to 
another cell line, CH1 (Corps, A.N. et al. 1997).  When HGF was added to the 
culture motility, migration and 3[H]-thymidine incorporation were all increased in the 
SKOV-3 cells but not the CH1 line.  This showed that Met/HGF signalling was intact 
in the SKOV-3 cell line, but this is difficult to translate to the in vivo situation of 
EOC.  The same group also demonstrated that ascitic fluid contains high levels of 
HGF (Sowter, H.M. et al. 1999).  Met appears to be overexpressed in ovarian cancer 
and is associated with a poor prognosis (Di Renzo, M.F. et al. 1994; Sawada, K. et 
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al. 2007).  NK4, which acts as an inhibitor of Met, suppresses tumour formation and 
increases survival in mouse xenograft models (Saga, Y. et al. 2001).  These findings 
would therefore suggest that the Met/HGF pathway is ideal for therapeutic targeting. 
 
1.8.3.2 RAS/RAF 
The ras family of proteins act as a relay downstream of tyrosine kinase receptors and 
upstream from the RAS-RAF-MEK-ERK-MAP kinase signalling pathway.  The 
proto-oncogene K-Ras has been implicated in many cancers.  Activating mutations 
have been discovered at codons 12, 13 and 61, but codon 12 is the most common 
mutation site in gynaecological cancers.    The most common histological subtype 
affected is mucinous EOC, where it is mutated in 50% of cases (Enomoto, T. et al. 
1991; Gemignani, M.L. et al. 2003).  This is of interest given that it is also a 
common mutation in gastro-intestinal cancers. RAF genes code for one of three 
serine/threonine kinases which bind RAS.  Mutations in BRAF exist in the same 
types of tumour as KRAS mutations, but are rarely present simultaneously in the 
same tumour, suggesting a common mechanism of tumorigenesis.  Interestingly one 
study showed evidence for KRAS mutations in borderline serous tumours but 
absence of KRAS mutation in invasive serous tumours suggesting that borderline 
tumours may not be pre-cursors to invasive cancers (Mayr, D. et al. 2006).   
 
1.8.3.3 EGFR/HER2 
The epidermal growth factor receptor (EGFR) is a member of the ErbB family of 
tyrosine kinases that includes HER2 (ErbB2).  It is selectively activated by binding 
its ligands EGF or TGFα, upon which it dimerises or pairs with another member of 
the ErbB family to stimulate intracellular tyrosine kinase activity. The EGFR has 
been linked with EOC for over twenty years (Gullick, W.J. et al. 1986) and appears 
to be overexpressed in some ovarian cancers although mutation of the sequence 
appears to be uncommon (Lassus, H. et al. 2006).  An alternative splice product of 
EGFR (sEGFR) has been discovered in the serum and if used in conjunction with 
 
 67
CA125 may provide a means for EOC screening (Baron, A.T. et al. 2005).  While 
the link between HER2 and EOC appears weaker than in breast cancer there is 
evidence that HER2 over-expression is a poor prognostic indicator (Serrano-Olvera, 
A. et al. 2006; Verri, E. et al. 2005).  Reports of HER2 positivity vary widely and 
depend on whether protein or gene amplification is being measured.  However in 
Phase II trials the response to  HER2 monoclonal antibody therapy (trastuzamab) is 
disappointing with a response rate of only 7% (Bookman, M.A. et al. 2003).  As this 
study was undertaken in patients previously treated for EOC, it does not exclude a 
future role for anti-HER2 treatment in early cancers or as first line therapy.  However 
this group of receptors does provide an ideal target for drug therapy. 
 
1.8.4 Tumour Suppressor Genes (TSG) 
1.8.4.1 p53 
The tumour suppressor p53 (encoded by the gene TP53) is one of the most widely 
investigated in cancer research.  It has been implicated in many epithelial cancers, 
where mutations of p53 have been described in 50% of cases (Levine, A.J. 1997).  
Missense mutations make up the majority of p53 mutations in 80% of cancers. In 
EOC, several small studies show high incidences of both over-expression and 
mutation of TP53 (Kmet, L.M. et al. 2003).   p53 is found in low levels in normal 
cells and it is targeted for degradation by MDM2, so levels are kept low by its 
relatively short half-life of twenty minutes (Levine, A.J. 1997).   Cell stressors such 
as DNA damage, loss of cell contact signals and hypoxia can all inhibit MDM2 
production therefore preventing p53 breakdown and a rapid rise in intracellular p53.  
This mediates a number of downstream events culminating in cell cycle arrest or 
apoptosis.  A loss of p53 function can therefore result in unimpeded cell 
proliferation.  In many tumours with a p53 mutation, there is an equivalent level of 
overexpression of that mutated protein, suggesting that p53 production is being 
driven but its mutant form is unable to become active and switch off the driving 
signal.  In a study of 197 cases of invasive ovarian cancer, Schildkraut et al found 
that women whose cancers had high p53 expression were more likely to have had a 
high number of lifetime ovulations (Schildkraut, J.M. et al. 1997).  This finding 
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raises this possibility of different mechanisms of tumorigenesis for different tumour 
types, because if number of lifetime ovulations was a risk factor for all tumours there 
should have been no difference between the p53 positive and negative groups.  
Rather than being a necessary initiating feature however it is possible that p53 
mutation is picked up as a tumour develops.  Evidence for such a mechanism arises 
from pooled studies of p53 expression in ovarian cancer (Kmet, L.M. et al. 2003).  In 
this paper, the authors mention that 42 studies examined p53 status and stage of 
disease and overall p53 was detected in 39% of the early FIGO stage tumours but in 
55% of FIGO stage 3 or 4 tumours.  Higher grade tumours also had higher frequency 
of p53 overexpression.  In addition, borderline tumours were p53 positive in 17% of 
cases while benign ovarian cysts were positive in 7%.  The authors also highlighted 
the considerable variation in p53 immunopositivity given that over 7 different 
antibodies were used to detect p53 across the studies.  For such a plethora of 
investigation, many questions about p53 remain.   
 
The prevalence of TP53 mutations in EOC raises the theoretical possibility of gene 
therapy where administration of an attenuated adenovirus carrying functional wild 
type TP53 could be used to restore the p53 status of the cell, thus altering the 
malignant phenotype.  This has also been attempted in head and neck cancers where 
the treatment is injected directly into the tumour.  In the EOC setting results of such 
an approach are still in the early stages.  Trials have failed to demonstrate any 
significant response to therapy and most patients develop flu-like symptoms with 
adenovirus therapy (Vasey, P.A. et al. 2002).  There are some potential problems 
with such an approach to gene therapy.  Firstly an immune response to the vector 
may adversely affect the treatment outcome.  Secondly, loss of p53 function may not 
be simply due to gene mutation. Thirdly, the adenovirus itself may alter cellular 
function so that p53 expression is impaired.  Fourthly, even if gene therapy works at 
a cellular level there are potential problems delivering the agent to the tumour. In 
intraperitoneal therapy the outermost surface of the tumour is exposed to the 
treatment however the majority of the tumour mass may be well hidden suggesting 
that the therapy should also be administered intravascularly, where greater side 
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effects would be anticipated.  Based on current evidence it is difficult to envisage 
gene therapy for EOC becoming standard treatment in the near future.  
 
Whereas activation of an oncogene can permanently switch on cell replication and 
hence development of a tumour, inactivation of a tumour suppressor gene is a more 
complicated process.   Traditionally it has been thought that this requires two hits to 
inactivate such a gene, following Knudson’s classic model (Knudson, A.G. 2000).  
However it has become clear that inactivation of a gene can occur by inactivating its 
promoter sequence through DNA methylation of the CpG island (Baylin, S.B. et al. 
2006).  Thus there are now appearing a whole raft of “new age” tumour suppressor 
genes where the DNA sequence of the gene is not altered but gene transcription is 
suppressed.  Unlike genetic mutations DNA methylation can occur through 
environmental agents which may last a lifetime.  For example, in gastric cancer, 
previous exposure to Helicobacter Pylori caused DNA methylation which was 
maintained after the infection was cleared (Ushijima, T. et al. 2006).  This 
mechanism of cancer development could explain the delay between the inflammatory 
insult of ovulation in a woman’s reproductive years and the development of EOC 
later in life.  
 
1.8.4.2 PTEN 
PTEN (phosphatase and tensin homolog) was identified as a TSG in several cancers 
by LOH (Li, J. et al. 1997).  This localised PTEN to 10q23.  Mutations in PTEN 
appear to occur in endometrioid and clear cell ovarian cancers but not serous (Obata, 
K. et al. 1998).   In an exceptional study using a mouse model of endometriosis 
Dinelescu et al. inoculated mouse OSE with K-Ras mutations using an adenovirus 
vector and were able to induce endometriosis-like lesions (Dinulescu, D.M. et al. 
2005).  By combining K-Ras and PTEN mutations the lesions that occurred became 
malignant and spread throughout the peritoneal cavity – much like EOC in humans.  
This elegant study gives a potential mechanism for development of endometrioid 
EOC, which may explain why not all patients with endometriosis go on to develop 
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EOC, as this may be conditional on a second PTEN mutation.  In addition it gives a 
potential target for therapeutic manipulation.   
 
1.8.4.3 OPCML and the IgLONs 
LOH studies indicated that a tumour suppressor could reside on chromosome 11q 
(Davis, M. et al. 1996; Foulkes, W.D. et al. 1993; Gabra, H. et al. 1995).  More 
detailed LOH analysis refined the potential genes to the locus 11q25 and 
subsequently demonstrated LOH of  49% at D11S4085 (Sellar, G.C. et al. 2003).  
This lay within the second intron of the gene for opioid-binding cell adhesion 
molecule-like protein (OPCML or OBCAM).  Quantitative RT-PCR demonstrated 
that OPCML expression was abrogated in a panel of primary ovarian tumours and 
cancer cell lines but not in normal whole ovary.  As previously discussed use of 
whole ovary as a normal comparator could be criticised in this study as the authors 
imply that they believe the OSE to be the source of ovarian cancer, yet the OSE 
contribution to the whole ovary is minimal.  Using methylation-specific PCR, Sellar 
et al went on to demonstrate that OPCML was unmethylated in normal ovaries 
(although they did not examine OSE specifically), but methylated in 83% of primary 
ovarian cancers and 82% of ovarian and non-ovarian cell lines.  Furthermore when 
transfected into the ovarian cancer cell line SKOV-3, OPCML caused significant 
suppression of tumour growth both in vitro and in vivo following inoculation of nude 
mice.  This was the first description of OPCML as a candidate tumour suppressor in 
EOC, however soon after its publication a similar paper provided evidence that a 
related family member limbic system associated membrane protein (LSAMP) acted 
as a TSG in clear cell renal cell carcinoma (Chen, J. et al. 2003).   
 
Following on from this work Ntougkos examined the expression of OPCML and its  
related family members in primary ovarian cancer tissue, looking for correlation 
between tumour phenotype and clinical outcomes (Ntougkos, E. et al. 2005).  
OPCML is a member of the IgLON family of immunoglobulin (Ig) domain 
containing superfamily comprising Limbic System Associated membrane Protein 
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(LSAMP), OPCML, Neurotrimin (HNT) and Neuronal Growth Regulator 1 
(NEGR1) also known as Kindred of LON (Kilon).  Ntougkos and co-workers 
demonstrated that OPCML, LSAMP and neuronal growth regulator-1 (NEGR1) 
expression was reduced in samples of ovarian cancer compared to normal ovary.  In 
addition it appeared that LSAMP expression was an indicator of poor prognosis and 
negatively associated with survival.    
 
Prior to these studies, interest in the IgLONs was primarily focused on neurological 
research, particularly in chick brain development.  OPCML or OBCAM was first 
purified from bovine brain in 1986 and subsequent cDNA analysis revealed an amino 
acid sequence of 345aa (Cho, T.M. et al. 1986).  As a consequence of its three 
immunoglobulin domain-like structures and homology with neural cell adhesion 
molecule (NCAM) it was named OBCAM.  Initial studies hinted that the protein 
might have a role in opioid binding given that the purified protein showed stereo-
specific opioid binding, (Cho, T.M. et al. 1986) and monoclonal antibodies to 
OBCAM and anti-sense cDNA inhibited 3[H]-diprenorphine binding (Ann, D.K. et 
al. 1992; Roy, S. et al. 1988).  Subsequent cloning of the human form of OBCAM 
revealed a complete open reading frame of 1038bp with 93% homology to the rat 
cDNA and 98% homology with the rat protein, with similar values for the bovine 
form.  In addition, OBCAM was mapped to chromosome 11 (Shark, K.B. et al. 
1995).  Using monoclonal antibodies to OBCAM, Hachisuka et al localised the 
expression of OBCAM across five different species.  They also suggested that 
OBCAM was a glycosyl phosphatidylinositol (GPI)-anchored membrane protein, 
possibly sited within lipid rafts, as it could be released from the cell membrane by 
treatment with phosphotidylinositol specific phospholipase C, and not a G protein 
coupled receptor like the main group of opioid receptors (Hachisuka, A. et al. 1996).  
They suggested the weight of the protein was 34kDa but following differential 
glycosylation two isoforms existed, with molecular weights of 51 and 58 kDa.   
 
Following the discovery of OBCAM it became clear that another similar protein 
existed in primary rat neurones and a further member of the family, called 
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neurotrimin after its three Ig-like domains, was described in 1995(Struyk, A.F. et al. 
1995).  At the same time a protein distributed in the rat limbic system, LSAMP 
(limbic system associated protein) also appeared to be homologous with OBCAM 
and neurotrimin (Pimenta, A.F. et al. 1995).  A subsequent search for this in the 
human confirmed that it had 99% homology with the rat protein and that the degree 
of conservation indicated an important role (Pimenta, A.F. et al. 1996).  Due to the 
high degree of homology between LSAMP, OBCAM and neurotrimin the authors 
suggested that these proteins were a novel family of proteins and collectively 
designated them IgLONs.  The characteristics of the IgLON proteins can be seen in 
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Table 1.4  Characteristics of IgLON genes and gene products (from 




A 55kDa protein,GP55, was discovered in chick brain and is likely to be the chick 
equivalent of OBCAM (Wilson, D.J. et al. 1996) while CEPU-1, also discovered in 
the chick seems to be a likely candidate for the chick form of neurotrimin 
(Spaltmann, F. et al. 1996). While a 50kDa protein, AvGp50 was also deemed to be 
a member of the IgLON family (Hancox, K.A. et al. 1997).  A further member of the 
family was added in 1999 when a Japanese group discovered, Kilon,  a 46kDa 
protein with many similarities to OBCAM (Funatsu, N. et al. 1999).   
 
From much of the work in neurological development it appears that the IgLONs have 
an important role in neuronal development and can influence cell proliferation, 
migration and differentiation (Brummendorf, T. et al. 2001).  Knowledge of how the 
IgLONs interacted with each other was scant until Reed et al demonstrated the 
binding preferences of the IgLONs in cerebellar granule cells (Reed, J. et al. 2004).  
In a series of experiments examining both homo and heterodimers formation it 
became apparent that LSAMP/OBCAM had the highest binding affinity and 
LSAMP/LSAMP dimers, the lowest.  It appeared that most of the IgLONs 
preferentially bound as heterodimers and that homodimerization was weak and 
uncommon except in the case of CEPU-1(Neurotrimin).  The frequency of 
dimerization led the authors to suggest that DIgLON (dimeric IgLON) would be an 
appropriate term to use for the combined molecule.   
 
While the considerable majority of work on IgLON biology has been undertaken in 
the field of neurological sciences, the question that arises from their association with 
cancer is; what role do the IgLONs play in normal tissue?  While some scepticism 
might arise for any ovarian role for a group of molecules acting predominantly in the 
central nervous system, the finding of functional neuropeptides in the ovary is not 
without precedence (Anderson, R.A. et al. 2002; Dees, W.L. et al. 2006; Spears, N. 
et al. 2003).   A further site in the genital tract where OPCML is found is Fallopian 
tube (Dr G Sellar, personal communication).  The highly complex signalling that 
occurs when the fimbrial end of the Fallopian tube locates the ovulatory stigma at 
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ovulation could imply a potential role for IgLON interaction in this process.  
Furthermore given recent evidence for the Fallopian tube as a potential source of 
peritoneal carcinomatosis (Crum, C.P. et al. 2007; Kindelberger, D.W. et al. 2007; 
Lee, Y. et al. 2007) coupled with evidence of TSG function of OPCML and LSAMP, 
further research into the role of these proteins in reproductive tissues is warranted. 
 
1.9 Project rationale 
 
Epithelial ovarian cancer (EOC) carries a high mortality and little has been achieved 
to improve the prognosis of women affected by the disease in the past three decades.  
It provides the biggest challenge of all the gynaecological malignancies where, 
unlike many other epithelial cancers, the natural history of EOC remains a mystery.   
The overarching aims of this thesis are to explore the ovarian cancer phenotype and 
inflammation associated responses of normal tissue. 
 
1.9.1 An investigation of glucocorticoid metabolism in primary 
ovarian cancer. 
 
There are consistent epidemiological data showing that an increase in the number of 
ovulations in a woman’s lifetime increases her risk of developing epithelial ovarian 
cancer.  Combining this with evidence that ovulation is an inflammatory process 
causing repetitive cyclical damage to the ovarian surface epithelium (OSE, the 
putative source of ovarian cancer) gives credence to the hypothesis that 
inflammation-associated injury of the OSE is a causal factor in the development of 
EOC.   
 
Following on from extensive previous research demonstrating the role of 11βHSD1 
as an anti-inflammatory mediator in the OSE, it was hypothesised that loss of 
11βHSD1 was an important step in the development of EOC.  In order to investigate 
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this, a system for primary culture of EOC was established thus allowing comparison 
of inflammatory signalling in these cultures with primary cultures of normal human 
OSE.     
 
1.9.2 Anti-inflammatory signalling in the peritoneal surface 
epithelium (PSE).  
 
The OSE and PSE share similar embryological origins and are morphologically 
similar.  Their carcinomatous counterparts epithelial ovarian cancer and primary 
peritoneal cancer are essentially indistinguishable.  It was hypothesised that the OSE 
and PSE would share the ability to increase local cortisol production via upregulation 
of 11βHSD1.  In order to test this, a method for primary culture of human PSE was 
established, creating cell culture based systems for investigating the effects of the 
inflammatory cytokine interleukin-1α on 11βHSD1 and inflammation associated 
genes. 
 
1.9.3 The effect of inflammation on expression of OPCML and the 
IgLON family in primary cultures of human ovarian surface 
epithelium. 
 
The OSE is the most likely candidate tissue for the source of EOC.  The mechanism 
by which this transformation occurs is not understood, however one potential route is 
through the inactivation of a tumour suppressor gene (TSG).  OPCML is a candidate 
TSG lying within 11q25, a chromosomal region with a high rate of loss of 
heterozygosity in EOC.  In light of the OSE being the likely source of most EOCs it 
was important to investigate the expression of OPCML in primary cultures of human 
OSE to test the hypothesis that OPCML is switched off by inflammation, thus 
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2 Materials and Methods 
2.1 Primary Cell Culture 
2.1.1 Cancer Tissue Collection and Culture 
Patients attending for initial laparotomy for suspected ovarian cancer were 
approached pre-operatively and asked to donate tissue for research in accordance 
with good clinical practice guidelines.  The study was approved by the local ethics 
research committee (COREC reference S1103/44, Chief Investigator Dr K S Fegan) 
and all patients taking part provided written evidence of informed consent.  Copies of 
patient information sheets and consent forms are detailed in Appendix I.  Relevant 
clinico-pathological information is shown in table 3.3. 
At initial laparotomy ascitic fluid was collected in a 2 litre sterile vacuum container 
and transferred to the laboratory at room temperature.  Where possible the sample 
collected was the initial aspirate in order to reduce contamination by blood.  During 
surgery the excised specimens were placed in sterile polythene bags and transferred 
to the pathology laboratory for specimen dissection by a consultant pathologist.  This 
step was important firstly to ensure that the sample was truly representative of 
tumour tissue and secondly to prevent interference with the final pathology result.  
The obtained samples were placed immediately in a sterile universal container 
containing 20ml PBS (Gibco, Paisley, Scotland, UK) and placed on ice for transfer to 
the laboratory. 
In a Class 2 tissue culture hood in the laboratory, 10 to 15mls of ascites was mixed 
with an equal volume of HOSE1  (table 2.2) and placed in 75cm2 tissue culture flasks 
(Corning BV Life Sciences, The Netherlands), using a modification of Dunfield’s 
published method (Dunfield, L.D. et al. 2002).  Media were changed twice weekly 
until confluent. 
Primary cultures from solid ovarian cancer tissue were treated using a modification 
of the method described by Wilson (Wilson, A.P. 2004).  In the aseptic environment 
of a Class 2 tissue culture hood, tumour was placed in a 5cm diameter Petri dish and 
divided in two.  One piece was placed in 4% normal buffered formalin (NBF) for 
 
 79
later histological use and the second piece then minced using two sterile scalpel 
blades.  The minced tumour was then transferred to a 50ml Falcon tube (Corning) 
containing 0.25% trypsin (Gibco), 0.004% DNAseI (Sigma),  in 20ml cold HOSE2 
medium (serum-free to prevent denaturing of enzyme activity), known as “digestion 
mix”.  The flask was left mixing overnight at 4°C.  The following morning the solid 
components were allowed to settle and the supernatant aspirated, mixed with HOSE1 
to inactivate the trypsin, centrifuged at 500g for 5minutes and the subsequent pellet 
resuspended in 15ml HOSE1 medium and placed in a 75cm2 tissue culture flask, the 
sample labelled as IW (initial washings).  The remaining minced tumour was mixed 
with a further 20ml aliquot of digestion mix and placed in an agitated water bath at 
37°C for 30minutes.  Following this, the supernatant fluid was aspirated, inactivated 
with equivalent volume HOSE1 and centrifuged as above to form a pellet.  The 
cellular pellet was then resuspended in 15ml and transferred to a 75cm2 tissue culture 
flask.  The tumour mince was washed and pelleted a further two times so that a total 
of four flasks was obtained from every piece of solid tumour.  Flasks were left 
undisturbed for one week in a humidified atmosphere of 5%CO2, 95% air at 37°C  to 
allow cells to attach. If no cells were attached by this time the culture flask was 
discarded.  Successful cultures then had HOSE1 media changes twice weekly until 
confluency was reached. 
   
2.1.1.1 Methods Used to Identify a Malignant Cell Culture 
Ascitic fluid and solid tumour specimens consist of a variety of cells including 
mesothelial cells, fibroblasts and immune blood cells.   Ascites and solid tumour was 
examined independently by a consultant histopathologist and the diagnostic 
pathology result was known in all cases.  Thus malignant primary cultures were 
confirmed as originating from ascites containing malignant cells.  Attempts were also 
made to confirm the malignant nature of (assess the relative tumour cell component 





1. Monolayer Morphology 
Tissue culture flasks were inspected daily and epithelioid colonies were identified.  
Flasks containing heavy contamination fibroblasts-looking cells were not used for 
final analysis.  Cell and colony characteristics were assessed and features such as 
disorganised colony formation, large nuclear:cytoplasmic ratio, spheroid formation 
and absence of fibroblast-looking cells were used to intimate relative quantities of 
tumour cells in the primary culture. 








Figure 2.1.  Photomicrograph of uniform colonies of borderline 
malignant cells from solid tissue (magnification x4).  
 
2. Cytokeratin Immunohistochemistry 
Tissue culture flasks containing cell monolayers were washed in 10ml PBS and 
disaggregated using trypsin/EDTA (0.05% w/v, Invitrogen) at 37°C for 5 minutes.  
Cells were collected by centrifugation and the pellet washed and resuspended in 
fresh HOSE 1 medium.   Cell number and viability were assessed by Trypan blue 
staining (Sigma) and counted by haemocytometer.  Cells were transferred to 
individual wells of 8-well chamber slides (VWR International) in 200-500μl volumes 
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of HOSE-1 medium (40 000 – 200 000 cells) and incubated overnight at 37°C in a 
humidified incubator.  The following day the medium was aspirated and the 
chambers washed with PBS.  The cells were then fixed in cold methanol at -20°C for 
10 minutes.  After washing in PBS, the chambers were pre-treated with Normal Goat 
Serum solution consisting of Goat serum (20%v/v) and bovine serum albumin (0.5% 
w/v) in PBS, at room temperature for 30 minutes.  The primary antibody was then 
added and incubated overnight at 4°C.  Primary antibodies were anti-human 
cytokeratins 5, 6, 8, 7,19 (M0821, Dako, Denmark) and anti-human cytokeratin 7 
(M7018, Dako, Denmark).  A mouse IgG was used as a negative control.  The next 
day, the secondary biotinylated antibody (goat anti-mouse, Dako) was applied for 30 
minutes, followed by an avidin-biotin complex conjugated to horseradish peroxidase 
for 30 minutes.  Staining was achieved using DAB chromogen system 
(DakoCytomation).    
 
3. CA125 Measurement 
By gradually increasing the number of cells and length of time of exposure of 
medium, CA125 levels could be measured in the primary cultures in 10ml of HOSE1 
medium left in contact with a confluent flask monolayer for one week.  CA125 was 
analysed by magnetic separation chemilluminescence on the Siemens Advia Centaur 
Immunoassay System (Siemens Healthcare Diagnostics, Deerfield, USA).  While 
CA125 was detectable and raised in confluent flasks containing EOC primary 
cultures, it became clear that CA125 was also measurable in some flasks of OSE (see 
table 3.2).  Indeed on review of the literature most tissues of the female genital tract 
are capable of secreting CA125, although interestingly it appears absent from the 














CA125 Level in 
Medium (IU/L) 
Patient 2 4990 Ascites 131.7 
Patient 4 2647 Ascites 184 
  Tumour 47 
  Metastasis 41 
Patient 7 90 Washings <15  
Patient 6 108 Ascites 118.3 
Patient 8 4264 Ascites 2123.9 
  Metastasis 118.2 
    
  HOSE1 Medium 1.2 
  Human OSE 140.6 
 
Table 2.1  CA125 level in primary cultures of EOC, OSE and HOSE1 
culture medium. 
 
4. Matrigel Invasion Assay 
Two experiments were carried out to investigate differences in invasive properties 
between the invasive cancer cell line SKOV-3 (passage 50), primary cultures of 
HOSE cells and two separate primary cultures of ovarian serous adenocarcinoma 
through a Matrigel basement membrane (BD Matrigel Invasion Chambers, BD 
Biosciences) using non-matrigel coated membranes as controls (BIOCOAT Cell 
culture Control inserts, Becton Dickinson).  Experiments were carried out with the 
help of Dr Mick Rae. Cell suspensions were prepared at 100 000 cells/ml in serum-
free HOSE-2 medium.   The chambers were filled with 50 000 cells with and without 
test reagent and the wells with the chemoattractant serum containing HOSE-1 
medium.  The plates were incubated for 22 hours in a humidified incubator at 37°C, 
5% CO2, 95% air.  Non-invading cells were scrubbed from the membrane using a 
cotton wool bud.  The cells were then fixed in ice-cold methanol for two minutes 
then stained with haematoxylin.  The membranes were air-dried and then mounted in 
immersion oil on a glass slide.   Invading cells were counted under the microscope in 
six areas across each membrane.  As several membranes had uneven distribution of 
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cells i.e. denser distribution at the periphery, the median of the six counts was used 
for data analysis rather than the mean.  The percent invasion was determined by: 
 
% Invasion =  Median number of cells invading through Matrigel membrane            
  Median number of cells migrating through control membrane 
 
Invasion Index was determined by: 
 
Invasion Index = % Invasion of Test Cell 
   % Invasion of Control Cell 
 
 
2.1.2 OSE Collection 
 
Normal OSE was collected from patients undergoing surgery for benign 
gynaecological conditions with local ethics committee approval (COREC reference 
S1103/36, Chief Investigator Dr K S Fegan) and informed consent (patient 
information sheet and consent forms are included in Appendix I).  Patients were pre-
menstrual and over 16years of age.  Exclusion criteria included intercurrent 
malignancy, gynaecological inflammatory states such as current pelvic inflammatory 
disease or endometriosis and use of gonadotrophin-releasing hormone agonists or 
antagonists.  While the use of hormonal contraception was not an exclusion criterion, 
knowledge of exogenous hormone use was documented in patient data files.  All 
samples were allocated a research number and were then anonymised but linked.   
Following recruitment, OSE was collected by gently brushing the ovarian cortex 
early in the surgical procedure using a sterile Aylesbury spatula at laparotomy or a 
Tao cytobrush (Cook, Ireland) at laparoscopy.  During surgery handling of the 
ovaries was minimised by the surgeon to prevent loss of the OSE layer.  The 
collecting instrument was rinsed in 15ml pre-warmed HOSE1 medium (see table 2.2) 
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to dislodge the cells and then transferred to the laboratory at room temperature.  The 
medium was then aspirated and transferred to a 75cm2  tissue culture flask (Corning 
BV Life Sciences, Schipol-Rijk, The Netherlands) pre-coated with donor calf serum.  
Flasks were inspected using phase-contrast microscopy to confirm presence of OSE 
“flakes”, then incubated for up to 42 days in a humidified atmosphere of 5%CO2, 
95% air at 37°C.  The flasks were inspected daily and HOSE1 medium was changed 
weekly until confluency reached. 
 
 
Additive Quantity Supplier 
Medium 199:MCDB 105 1:1 (v/v) Gibco, Paisley





Table 2.2  Components of HOSE1 Medium.  pH was established at 7.30 










Additive Quantity Supplier 
Medium 199:MCDB 105 1:1 (v/v) Gibco, Paisley 
Bovine Serum Albumin 0.01% (w/v) Sigma-Aldrich 
L-glutamine 1mmol/l Sigma-Aldrich 
Penicillin 50IU/ml Sigma-Aldrich 
Streptomycin 50μg/ml Sigma-Aldrich 
 
Table 2.3  Composition of HOSE2 medium, which was similar to HOSE1 
medium but the Fetal Calf Serum was replaced with a solution of 
Bovine Serum Albumin to achieve similar oncotic pressure. pH was 
established at 7.30 by titrating with 10M sodium hydroxide.   
 
2.1.3 PSE Collection 
Samples of PSE were collected in a similar manner to that previously described for 
OSE by gentle sweeping of the peritoneal surface using either a cytobrush (Cook, 
UK) or sterile Aylesbury spatula.  Care was taken not to apply significant pressure at 
sampling to ensure firstly that the underlying tissue was not traumatised and 
secondly that only surface epithelial cells were collected and not stromal cells which 
could lead to contamination of the culture.  Two sites for sampling were chosen: the 
anterior abdominal wall (designated ‘A’ cells) and the body of the uterus (designated 
‘B’ cells).  The reasoning for choosing two separate sites was firstly to investigate 
whether there was any variation in cell phenotype between visceral and parietal 
peritoneal cells and secondly whether cells covering a Mullerian tract derived organ 
(the uterus) differed from peritoneal cells with no contact with any Mullerian 





2.1.4 A Comparison of Outcomes of OSE and PSE Cultures  
 
Qualitative inspection of the PSE flasks prior to incubation suggested that the 
number of cells collected from the anterior abdominal wall was markedly less than 
that collected from the body of the uterus.  In order to investigate whether this 
affected cell culture growth, the outcomes of PSE cultures (n=121) over the study 
period were audited and compared to outcomes for OSE cells (n=193) over the same 
time period.  Flasks were considered to be ‘used’ if they were involved in any 
experimentation, passaging, or freezing.  Use was not limited to confluent flasks.  
The indications for discarding flasks were not specifically examined, however 
possible reasons include infection, inadequate growth and stromal contamination. 
 
 
Sample Used Discarded Total 
OSE Left 57 39 96 
OSE Right 55 42 97 
OSE Total 112 81 193 
PSE 'A' 19 42 61 
PSE 'B' 31 29 60 
PSE Total 50 71 121 
 
Table 2.4  Outcomes of primary cell culture according to cell type and 
site of sampling. 
These data are shown in graph format to highlight the rate of attrition in these 




Figure 2.2.  Outcomes of PSE Primary Cultures. 
The high discard rate of the PSE ‘A’ samples of 69% is likely to reflect the low 
number of cells initially collected.  A two-sided Fisher’s exact test returned a P value 
of 0.027 suggesting that the difference between the A samples versus B samples is 
unlikely to be due to chance alone, all other things being equal. 
 
As PSE samples were always collected at the same time and from the same patients 
as OSE samples it is reasonable to ask whether there is a difference in outcome 
between OSE and PSE.  As it has been established that the PSE A samples have poor 
growth outcomes compared to the B samples the outcomes of OSE and PSE B 
samples were compared.  Using Fisher’s exact test the P value does not reach 






2.1.5 PSE Morphology 
On the day of collection, flakes of PSE a single cell thick could be clearly seen 
suspended in the culture medium (figure 2.5).  These were morphologically indistinct 
from flakes of OSE.  Furthermore following in vitro incubation these flakes settled to 
form epithelial colonies which quickly expanded to cover the base of the flask in a 
confluent monolayer that also demonstrated the classic cobblestone appearance of 
the OSE in culture. 
 
       
Figure 2.3.  Morphological similarities between the ovarian surface 
epithelium and the peritoneal surface epithelium on day of collection 




In addition to these morphological similarities PSE cells stained positive for low-




Figure 2.4.  Chamber slide immunohistochemistry localizing cytokeratin 
in PSE cells (magnification x40). Inset demonstrates matched IgG 








2.1.6 Experimental treatment of OSE,PSE and EOC 
 
Once OSE monolayers had become confluent the flasks were rinsed twice with 10ml 
phosphate buffered saline (PBS) (Gibco, Paisley) then incubated with 5-10ml 
trypsin/EDTA (0.05%, w/v) (Invitrogen) for 5 minutes at 37°C until cells had 
detached from the flask base.  The cell suspension was then aspirated, mixed with the 
same volume of warmed HOSE1 to inactivate the trypsin, and sedimented by 
centrifugation at 800g for 5minutes.  The cell pellet was resuspended in 2ml of 
HOSE1 medium and cell number and viability assessed by Trypan Blue (Sigma-
Aldrich) and counted with a haemocytometer.  The cells were then diluted in HOSE1 
medium to a density of 100,000 – 125,000 cells/ml.  Four to five mls of this 
suspension was used to seed each well of a six-well plate (Corning) and the flasks 
returned to the 37°C incubator overnight.  The plates were inspected the following 
morning to confirm cell attachment and the medium changed to serum-free culture 
medium (HOSE2), containing 0.01% bovine serum albumin (BSA)(Sigma-Aldrich).  
Cells were kept in this serum-free environment for a further 24 hours. 
 
Experimental treatments were made up fresh using HOSE2 as the diluting medium.  
Treatments included interleukin-1α (IL-1α )(0.5ng/ml, unless otherwise stated, R&D 
Systems Europe Ltd, Abingdon, Oxon), cortisol (1μM) and progesterone (1μM), and 
a combination of IL-1α and each steroid.  Steroid treatments were made from stock 
solutions of 100μM in ethanol, so control wells received HOSE2 medium containing 
ethanol at a similar concentration (1%v/v).  Concentrations of steroid were derived 
from previous published data of follicular steroid concentrations, as the experimental 
milieu was attempting to represent the peri-ovulatory environment (Andersen, 1991; 
Andersen, 1994).  Four ml of treatment solution was added per well and left at 37°C 
for 48 hours unless otherwise stated.   At the end of the experiment the wells were 
inspected to assess morphological changes due to treatment.  The medium was then 
aspirated and stored and the cells treated as described below. For RNA extraction 
cells in 6-well plates were lysed with 350μl of lysis buffer made from: RLT (Qiagen 
RNeasy kit) /β-mercaptopurine (Sigma, UK) (100:1 v/v). Commonly the experiments 
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took place over a working week, with the cell cultures being set up on day one, the 
medium changed to HOSE 2 on day 2, the treatments added on day three and then 
left for 48 hours until day 5, when the samples were placed in RNA lysis buffer, 
homogenized and frozen at -180°C prior mRNA isolation at the beginning of the 
next week (see below). 
 
2.2 mRNA Isolation and Quantification 
2.2.1 mRNA Isolation 
Total RNA was extracted and DNaseI treated using RNeasy minispin columns 
(Qiagen, Santa Clara, CA) as per manufacturer’s instructions.  Once the lysed 
samples were thawed, there followed a series of ethanol washes, on column DNAseI 
treatment and final elution in 30μl RNAse free water. One μl aliquots were taken for 
quantification and quality assessment using the Agilent 2100 Bioanalyzer System for 
total RNA in combination with RNA6000nano chips (Agilent technologies, Cheshire, 
UK).  Only samples attaining RNA Integrity Numbers (RIN) >9 were used for 
quantitive RT-PCR.  
 
2.2.2 Rotorgene Light Cycler Quantitative RT-PCR 
Quantitative RT-PCR was undertaken with the Rotorgene thermal cycler (Corbett, 
Australia).  The total reaction volume of 15μl constituted 40ng of DNAseI-treated 
total RNA, 0.3μM of forward and reverse primer and the Quantitect SYBR Green 
one step RT-PCR kit (Qiagen, UK), as per the manufacturer’s instructions.  Primer 
sequences for genes of interest are given in table 2.5.  Primers were intron spanning 
and designed using Primer3 v0.2 software by Dr E Ntgoukos.  Reactions were 
carried out in triplicate for standard curve samples, quadruplicate for experimental 
samples and for no template controls and duplicate for no reverse transcriptase 
controls.  Fluorescence was detected using the FAM channel and analysis performed 
using Rotorgene v5 software.  Quantification of RNA was calculated by 
extrapolating from the standard curve and comparison to β-actin levels within the 
same sample.  Cycling conditions were as follows:  30 minutes at 50°C for reverse 
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transcription, 15 minutes at 95°C for activation of polymerase, then 40 cycles of 15 
seconds at 94°C for denaturation, 30 seconds at 54°C for annealing and 30 seconds at 
72°C for extension.  After final extension at 72°C for 1 minute, the products were 





Primer Sequence (5’ to 3’) 
OPCML Forward TACCATAGATGACCGGGTAA 
OPCML Reverse CTATTAGGTGAACCCGGGAC 
β-Actin Forward CTACGTCGCCCTGGACTTCGAGC 
β-Actin Reverse GATGGAGCCGCCGATCCACACGG
 
Table 2.5  Primer sequences used in Light cycler RT-PCR.  
 
 
2.2.3 Taqman Quantitative RT-PCR 
DNaseI treated total RNA (200ng) was reverse transcribed (random hexamer kit; 
Applied Biosciences) and 2μl of cDNA added to a total assay volume of 25μl 
containing commercially available primers and Taqman hybridisation probes (see 
Table 2.6).  All primers and probes had been previously validated.  For the IgLON 
analyses pre-validated primer/probe mixes were purchased directly from Applied 
Biosystems (Assays-on-demand, Taqman Gene Expression Assays) and primer 
sequences were not made available by the company.  Sample reactions were set up in 
triplicate.  Controls included no template (water) controls for both cDNA synthesis 
and Taqman assays, as well as negative controls for cDNA synthesis where reverse 
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transcriptase was omitted from the reaction.  Each experimental plate also contained 
a standard RNA control, depending on the gene of interest.  These RNAs included 
Liver (11βHSD1, COX2, IL1R), placenta (11βHSD2, GRα) and Fallopian tube 
(OPCML, NEGR1, LSAMP, HNT).  Fluorescence was detected by the Taqman RT-
PCR system (ABI PRISM 7900 Sequence Detection System; Applied Biosystems, 
UK).  The mRNA of interest was quantified in relation to the abundance of 18S 




No. Forward Primer Reverse Primer 
HSD11B1 NM 181755 AAGATGTTCCTGCATGGATTTC AGCTCTGCGCCAAGAAGAAGT 
HSD11B2 NM 000196 GGCCAAGGTTTCCCAGTGA GTTGTGCCAGGAGGGTGTTT 
PTGS2 
(COX2) NM 000963 CCTTCCTCCTGTGCCTGATG ACAATCTCATTTGAATCAGGAAGCT 
 
IL1R1 NM 000877 TGTCACCGGCCAGTTGAGT GCACTGGGTCATCTTCATCAATT 
NR3C1 
(GRα) NM 000176 GCGATGGTCTCAGAAACCAAAC GCAGAGGATAACTTCCTCTGTAATCTC 
 




2.2.4 OPCML Western blotting 
Total protein concentration was established by Bradford assay.  Twenty μg of protein 
was mixed with 3Xsample buffer and heated at 95°C for 5 minutes prior to 
separation on a 10% acrylamide gel under standard conditions.  Electroblotting was 
carried out in Tris, glycine and 10% SDS.  The membrane was then pre-treated with 
0.5% blocking agent in tris-buffered saline with Tween 20 (TBS-T) for one hour then 
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incubated with the OPCML primary antibody (custom-made IgY polycloncal 
antibody, raised in chick against an OPCML peptide sequence, Biosource) at 1:2000 
dilution overnight at 4°C.  The membrane was then incubated with a secondary 
antibody (goat anti-chick, Abcam) conjugated to horseradish peroxidase for one hour 
and finally in luminol substrate (Roche) for one minute.  Chemiluminescence was 
detected by X-ray film (Amersham). β-Actin was detected using a commercially 
available antibody (1:50 000, Calbiochem) with a goat anti-mouse secondary 
antibody (1:4000, Calbiochem). 
 
2.3 11-Oxoreductase Assay 
 
11-oxoreductase activity was assessed by quantification of conversion of [1,2,6,7-
3H]cortisone to [1,2,6,7-3H]cortisol, as described previously (Yong, P.Y. et al. 2002).  
Primary cell culture was carried out as described in  section 2.1.6.  When a culture 
was ready for use the medium was aspirated and the monolayer disaggregated with 
trypsin/EDTA as previously described.  Following quantification of cells with the 
haemocytometer, the cells were seeded into 12-well plates (Corning) at a density of 
2x105 cells/0.5 ml HOSE1 medium.  The plates were incubated at 37°C in a 
humidified atmosphere of 5%CO2, 95% air overnight.  The following morning the 
culture medium was changed to serum-free HOSE2 medium and incubated for a 
further 24 hours.  Treatment with IL-1α (0.5ng/ml) in HOSE2, or HOSE2 medium 
alone as control was then added and incubated for 48 hours, as induction of 
11βHSD1 has been shown to be maximal at this time (Rae, M.T. et al. 2004).  The 
media were then aspirated and replaced with 0.5ml of HOSE2 containing [1,2,6,7-
3H]cortisone for a specific activity of 2.5x105 Bq per well, and 50pmol cortisone as 
carrier steroid (total substrate concentration 0.1μM) for eight hours.   Tritiated 
cortisol was prepared by Dr AF Howie as follows.  Five MBq of [1,2,6,7-3H]cortisol 
(Perkin Elmer, Cambridge, UK) were dried down under nitrogen and reconstituted in 
100% ethanol (Fisher, UK).  To this placental microsomes were added (gift from Dr 
T Bramley) and 100mmol/l potassium phosphate (pH7.3) solution with 10mmol/l 
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NAD.  The solution was vortexed and left overnight at 37°C. The following morning 
the steroid component was extracted using three diethylether washes. The organic 
solvent was then dried down under nitrogen and the residual steroids reconstituted in 
dichloromethane (Fisher, UK), spotted onto a silca-backed gel plate and underwent 
thin layer chromatography in a 92:8 chloroform:ethanol solvent (both Fisher,UK), 
with cortisol and cortisone markers. The site of cortisol migration was then identified 
and excised and dissolved in ethanol. After filtering, the radio-activity of the solution 
was measured, labelled and stored at -5°C for future use.   
 
Following incubation, the media were collected and vortexed with 5ml 
dichloromethane (Fisher Scientific, Loughborough, Leicestershire, UK) to extract 
steroid.  The aqueous phase was discarded and the organic phase evaporated to 
dryness under a nitrogen stream.  The dry steroid extract was then reconstituted in a 
small volume of fresh dichloromethane and spotted onto silica gel precoated sheets 
(Sigma-Aldrich).  These were then placed in chloroform:ethanol (92:8, v/v) and the 
steroid component separated by thin layer chromatography.  The radio-labelled 
steroid was identified on the chromatogram and quantified using a Bioscan 200 
imaging detector (Lablogic Systems, Sheffield, UK).   
 
2.4 Immunohistochemistry (IHC) 
2.4.1 Chamber Slide IHC 
Cells were obtained from 75cm flasks as already described (section 2.1.2). Following 
viability assessment and quantification cells were seeded into 8-well chamber slides 
(VWR International, Lutterworth, Leicestershire) at a density of 5-10x104 cells/0.5ml 
medium and incubated  at 37°C overnight.  The medium was aspirated and wells 
rinsed with PBS then the cells were fixed with methanol.  Following further triplicate 
PBS washes the cell monolayer was blocked with non-immune goat serum and then 
the primary antibody applied (see table 2.7).  Negative controls were treated with 
same concentration non-immune mouse IgG.  The wells were next washed with 
PBS+0.01% Tween 20 (3 washes for 3 minutes each) and the secondary antibody 
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applied.  Further triplicate washes with PBS+ 0.01% Tween were undertaken before 
incubating with Vector ABC Elite reagents and visualisation with diaminobenzidine 
(DAB).   
 
Antibody Source Dilution 
Incubation 
time 
Low Molecular Weight 
Cytokeratins (5,6,8,17,19)
DAKO, Denmark 1:1000 4°C, overnight 
Cytokeratin-7 DAKO, Denmark 1:1000 4°C, overnight 
Progesterone receptor DAKO, Denmark 1:50 1hr room temp 
Glucocorticoid receptor α Santa-Cruz, 
Germany 
1:100 1hr room temp 
 
Table 2.7  Details of Primary Antibodies used in chamber slide 
immunohistochemistry. 
 
2.4.2 Tissue Immunohistochemistry 
Portions of tissue from samples of ovarian and omental tumour to be used for 
primary cell culture were fixed in 4% neutral buffered formalin (NBF) overnight and 
soaked in ethanol (70% v/v) prior to paraffin blocking.  Serial sections of 3-5μm 
thickness were transferred to glass slides and dewaxed, rehydrated and washed in 
PBS.  Antigen retrieval was carried out by pressure cooking in citrate buffer at pH 6 
for 5 minutes then 20 minutes at rest.  Following avidin/biotin blocking (Vector 
Laboratories, Burlingame, California, USA) slides for 11βHSD1 and GRα were 
blocked with normal goat serum (NGS, Diagnostics Scotland, Edinburgh, UK) 
diluted in PBS with bovine serum albumin (BSA, Sigma-Aldrich, 5%w/v) and those 
for 11βHSD2 with normal rabbit serum/PBS/BSA (NRS, Diagnostics Scotland) for 
30 minutes and 120 minutes respectively.  Primary antibodies raised against 
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11βHSD1 (1:50, Cayman Chemical Co.), 11βHSD2 (1:200, in-house) and GRα 
(1:50, Santa Cruz, Germany) were added and incubated overnight at 4°C.  Negative 
controls were treated with matched rabbit IgG (11βHSD1 and GRα, DAKO) and 
sheep IgG (11βHSD2, Santa Cruz).  Sections were then washed twice in PBST for 
5minutes and secondary antibodies were applied (goat anti-rabbit, diluted 1:200 in 
NGS/PBS/BSA, DAKO, for 11βHSD1 and GRα; rabbit anti-sheep 1:200, DAKO for 
11βHSD2).   Fluorochromes streptavidin, Alexa fluor 488 (Molecular Probes, 
Invitrogen) (11βHSD2 and GRα) and tiramide Cy3 (Perkin Elmer, UK) (11βHSD1) 
were applied to sections for 60 minutes then washed twice in PBST.  Nuclear 
counterstains propidium iodide (11βHSD2 and GRα) and sytox green (Invitrogen) 
were applied and sections washed in PBS then coverslips mounted with permafluor 
(Permafluor; Beckman Coulter, High Wycombe, UK).  Images were captured using a 
LSM 510 Axiovert 100M confocal microscope (Carl Zeiss Ltd., Welwyn Garden 
City, UK). 
 
2.5 Statistical Analyses 
The choice of statistical tests is discussed in individual chapters.  Statistical analyses 
were undertaken using GraphPad Prism version 4.00 for Windows, GraphPad 
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Inflammation has been implicated as a causative factor in many epithelial cancers 
(Coussens, L.M. et al. 2002)(table 3.1).  Epithelial ovarian cancer is no exception 
and it has long been suggested that the “incessant” inflammation associated with 
ovulation may create an oncogenic environment (Fathalla, M.F. 1971).  Although the 
local inflammatory processes that arise in the ovary at the time of ovulation have 
been elucidated, the mechanisms by which these could give rise to cancer are poorly 
understood.  As described in Chapter 1, the ovarian surface epithelium (OSE) from 
which most ovarian cancers are thought to be derived, is able to generate an anti-
inflammatory response to inflammation by up-regulating 11βHSD1 and therefore 
increase local cortisol production.  The hypothesis that arises is that it is the loss of 
the OSE’s inflammation-quelling ability through disruption of 11βHSD1 expression 
that pre-disposes the tissue to malignant transformation.  
 
Work with EOC cell lines has previously suggested that the 11βHSD1 response to 
inflammation was lost in the malignant cells and that 11βHSD2 levels were raised in 
cancer compared to OSE (Gubbay, O. et al. 2005).  However these differences may 
have been due simply to the comparison of cell lines with primary human cells.  Yet 
Gubbay’s findings corroborate Rabbitt’s hypothesis that increased cortisol 
production via raised 11βHSD1 activity gives an “anti-proliferative, pro-
differentiation stimulus”, while raised type 2 is “pro-proliferative” (Rabbitt, E.H. et 
al. 2003).  Consequently there is a need to investigate the balance of the 11βHSD 
isozymes in primary ovarian cancer tissue.  Thus the initial focus of this work was to 
establish primary cell cultures from human ovarian cancers.  Subsequently these cells 
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were then utilised to investigate the status of their responsivity to inflammation, with 
particular reference to 11βHSD isozyme expression. 
 
  
Pathological Condition Associated Neoplasm Aetiological Agent 
Asbestosis, silicosis Mesothelioma, Lung carcinoma Asbestos, silica 
Bronchitis Lung carcinoma Smoking 
Cystitis Bladder carcinoma Urinary catheter 
Gingivitis Oral carcinoma  
Inflammatory bowel disease, 
Crohn's disease, 
chronic ulcerative colitis 
Colorectal carcinoma  
Lichen sclerosis Vulval carcinoma  
Chronic Pancreatitis Pancreatic carcinoma Alcohol, trypsinogen gene mutation
Reflux oesophagitis, 
Barrett's oesophagus 
Oesophageal carcinoma Gastric secretions 
Sialadenitis Salivary gland carcinoma  
Sjogren syndrome, 
Hashimoto's thyroiditis 
MALT lymphoma  
Skin erythema Melanoma Ultraviolet irradiation 
 
Table 3.1.  Cancers with a probable inflammatory aetiology (Coussens, 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.1 Effects of Interleukin-1α and Cortisol (F) on mRNA 
expression. 
Having successfully established methods for primary culture of EOC, these cells 
were then used to compare the response to inflammation with primary ovarian 
surface epithelial cells.   
 
3.2.1.1 Comparison of EOC and OSE Primary Cell Cultures 
Using samples from 16 different EOC patients (n=26) (further details presented in 
table 3.3) and 11 different patients with no or benign pathology donating OSE, the 
effects of the pro-inflammatory cytokine interleukin-1α (IL-1α) and anti-
inflammatory steroid cortisol (F) were examined (figure 3.2).  Taking all experiments 
together, cortisol alone caused a significant up-regulation of 11βHSD1 in both OSE 
and EOC compared to untreated control samples (8.5-fold and 4.2-fold respectively, 
P<0.001).  Treatment with 0.5ng/ml IL-1α induced an up-regulation of 11βHSD1 in 
both OSE and EOC (28.4-fold and 6.8-fold respectively, P<0.001).  There was a 
significant difference in fold change after IL-1α between the two cell types with OSE 
giving the higher degree of induction (P<0.05).  The combination of IL-1α and 
cortisol caused an up-regulation of 11βHSD1 in OSE and EOC greater than IL-1α 
alone (63.3 and 16.4-fold respectively, P<0.001).  Again the fold change for OSE 
was significantly higher than for EOC (P<0.05).   
There was no statistically significant change in 11βHSD2 mRNA expression 
compared to untreated cells after any treatment in EOC and OSE (figure 3.2b).   As a 
consequence there was no significant difference in fold-change of 11βHSD2 between 
the two cell types.   
The anti-inflammatory steroid cortisol had no effect on COX2 expression in either 
OSE or EOC (figure 3.1c).  The pro-inflammatory cytokine IL-1α, however, 
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significantly up-regulated COX2 expression in both OSE and EOC (11.6-fold and 
29.2-fold, P<0.001).  There was no significant difference in magnitude of these cell 
types’ fold-change response to IL-1α.  By combining IL-1α with cortisol the fold-
change of COX2 expression was not significantly raised over control for OSE (2.5-
fold) but was raised slightly for EOC (3.16-fold, P<0.01).  There was a significant 
difference in COX2 mRNA expression for both OSE and EOC when comparing IL-1 
treatment to the IL-1+F treatments (P<0.001).  
Data (CT values) were analysed using a repeated measures one-way ANOVA for 
each cell type, with Bonferroni post-test correction, having tested that the data were 
normally distributed and were effectively matched using an F test.  As the 
experimental set-up involved the comparison of OSE and EOC cells on each 
occasion, the question was then asked whether there were significant differences in 




Figure 3.1. The 11βHSD1 response to inflammation is attenuated in EOC 
compared to OSE.  11βHSD1, 11βHSD2 and COX2 mRNA expression by 
quantitative RT-PCR comparing responses to 1μM cortisol (F) +/- 
0.5ng/ml interleukin-1α (IL-1α) between OSE (n=11) and EOC primary 
cultures (n=27).  Dissimilar superscripts indicate statistically significant 
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effects of treatment compared to control samples within cell type. NS = 
not significant. Asterisk indicates significant differences in fold change 
between cell types (*=P<0.05).  
 
3.2.1.2 Analysis of OSE versus EOC from Ascites and Solid Tumour 
 
Type 1 11βHSD mRNA levels were significantly increased by cortisol compared to 
control in primary cultures derived from both ascites (4.4-fold, P<0.01) and solid 
tumour (4.2-fold, P<0.01)(figure 3.2).  There were no significant differences in fold 
change amongst these two cell types and OSE.  IL-1α caused significant increases in 
11βHSD1 in both ascites (8.6-fold, P<0.001) and solid tumour (4.5-fold, P<0.01) 
derived cells.  Again there was no difference in fold change in 11βHSD1 to that seen 
with normal OSE.  The combination of cortisol and IL-1α significantly raised 
11βHSD1 mRNA levels in ascites (19.3-fold, P<0.001) solid tumour (14.9-fold, 
P<0.001) and OSE (63.3-fold, P<0.001), however there were no significant 
differences in fold change amongst the three cell types. 
Type 2 11βHSD mRNA levels were not significantly altered by cortisol, IL-1α or 
both combined in any of the cells treated.  There was no significant difference in 
response amongst OSE, ascites or solid tumour preparations. 
COX2 mRNA expression was not changed by cortisol treatment alone in any of the 
three cell types examined.  IL-1α caused a significant up-regulation of COX2 mRNA 
expression in OSE, ascites and solid tumour cultures (mean fold induction 11.5, 
P<0.001; 29.2, P<0.001; and 26.5-fold, P<0.05 respectively). Co-treatment of all 3 
cell types with cortisol abrogated the ability of IL-1 to up-regulate the expression of 
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Figure 3.2.  Histograms of quantitative RT-PCR results showing 
changes in 11βHSD1, 11βHSD2 and COX2 in response to 1μM cortisol 
(F), 0.5ng/ml IL-1α and IL-1α+F in primary cultures of EOC derived from 
ascites and solid tumour in comparison to OSE. Bars indicate 
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Mean/SEM. Dissimilar superscripts indicate significant difference due 
to treatment. NS=not significant.   
 
3.2.1.3  IL-1α Treatment Time Course 
 
The effect of increasing length of exposure of the malignant cell cultures to IL-1α 
(0.5ng/ml) on mRNA expression was investigated using five different time points 
(0,6,12,24, and 48hours)(figure 3.4). 
These data demonstrate that 11βHSD1 mRNA expression increased with time and 
reached maximal levels at 48 hours.  11βHSD2 mRNA expression was unchanged 















































































































































Figure 3.3.  The effect of time exposed to 0.5ng/ml IL-1α in an EOC 
primary culture. Line graphs showing 11βHSD1, 11βHSD2 and COX2 
mRNA expression changes with time exposed to IL-1α (0.5ng/ml) by 





3.2.1.4 IL-1α Dose Response 
 
These experiments were initially attempted (n=4 patients) with IL-1α concentrations 
of 0.01, 0.05, 0.1, 0.5ng/ml.  Thereafter further experiments were carried out using 
equivalent IL-1α concentration escalations (0.02, 0.1, 0.5ng/ml)(n=4 patients).  The 
first set of data (figure 3.4a) suggests that 1μM IL-1α achieves the highest response 
in 11βHSD1 mRNA (51.2-fold).  In addition COX2 mRNA was greatest above 
0.1ng/ml (51-fold at 0.5ng/ml and 28-fold at 1.0ng/ml). However these data have 
large variances and thus statistical testing does not achieve a P-value <0.05.  
Therefore type II statistical errors may have been present as it is biologically likely 
that there is a rise in both 11βHSD1 and COX2 with IL-1α at concentrations above 
0.1ng/ml.  The second set of data demonstrates that there is an increase in 11βHSD1 
with increasing doses of IL-1α with maximal effect at 0.5ng/ml (21.2-fold mean 
induction) (figure 3.5a).  These data also suffer from the same problem with variance 
and the experiments did not include samples treated at 1ng/ml.  Data were analysed 
using one way ANOVA having tested for normal distribution, with Bonferroni post 
test comparison. The absence of statistical significance reflects the low number of 
samples used.  There are no significant changes in type 2 11βHSD mRNA expression 
with increasing dose of IL-1α, whereas COX2 mRNA expression rises significantly 



















































































































































Figure 3.4 Quantitative RT-PCR data indicating the effect of increasing 
dose of on a)11βHSD1, b)11βHSD2 and c)COX2 mRNA expression after 
48hours of exposure in EOC primary cultures (n=4).  Bars indicate 















































































































































Figure 3.5.  Quantitative RT-PCR data indicating the effect of increasing 
dose of on a)11βHSD1, b)11βHSD2 and c)COX2 mRNA expression after 
48hours of exposure in EOC primary cultures (n=4).  Bars indicate 
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mean/SEM.  Asterisks indicate significant effect due to treatment 
(***=P<0.001). 
3.2.1.5 Cortisol Dose Response 
The effect of three different cortisol concentrations on the inflammatory genes of 
interest was examined in the presence and absence of IL-1α (n=2) (figure 3.6).  Data 
were unable to be analysed using statistical software due to the inadequate number of 
samples.  Cortisol itself had little effect at the lowest concentration (0.01μM), but 
caused a minor rise in 11βHSD1 mRNA expression at 0.1μM and 1μM (2.3 and 2.2-
fold, respectively). However in the presence of IL-1α, cortisol caused a greater rise in 
11βHSD1 expression (2.9-fold at 0.01μM, 4.8-fold at 0.1μM, and 6.3-fold at 1μM.) 
Neither cortisol at any dose nor IL-1α had any effect on 11βHSD2 mRNA 
expression. 
COX2 mRNA expression was highest in the presence of IL-1α and absence of 
cortisol (13-fold induction over untreated control), at 0.01μM cortisol plus IL-1α the 
COX2 mRNA level was only moderately raised over the control sample, and at 














































































































































Figure 3.6.  Effect of increasing concentration of cortisol. Quantitative 
RT-PCR of a)11βHSD1, b)11βHSD2 and c) COX2 mRNA expression in 




3.2.1.6 IL-1R mRNA 
 
To investigate whether the IL-1 receptor (IL-1R) mRNA was present in both EOC 
and OSE and whether there was any difference in IL-1R mRNA response to 
inflammation in both tissues, quantitative RT-PCR was undertaken on a subgroup of 
samples (figure 3.7).  Data were analysed after testing for normal distribution using a 
one way ANOVA and Bonferroni post-test comparison.  These data indicated that 
firstly there was no significant effect of any treatment on either cell type and 
secondly that there was no significant difference in fold change between the two cell 
types (figure 3.7a).  Although the data sets were small any change in IL1R appears to 
have been maximal at 6 hours where a rise in mRNA level was noted (figure 3.7b).  
However after 48 hours incubation IL-1α suppressed IL-1R mRNA with a greater 
effect at lower dose.  Incubation with cortisol after 48hours did not appear to have a 










































































































































































Figure 3.7.  IL-1R mRNA expression in EOC primary cell 
cultures.Quantitative RT-PCR data demonstrating a) effect of 1μM 
cortisol(F), 0.5ng/ml IL-1α and IL-1α+F on IL-1R expression in OSE (n=2) 
and EOC (n=14), b) response of IL-1R mRNA expression following IL-1α 
treatment over time (n=1), c) effect of 5-fold changes of IL-1α 
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concentration (n=3), and d) effect of 10-fold variation in cortisol 
concentration in the presence and absence of IL-1α (n=1). 
 
3.2.2 Absolute mRNA levels in primary cultures of EOC and OSE. 
 
Whilst quantitative RT-PCR has been helpful in revealing dynamic changes in cell 
culture samples following IL-1α and cortisol treatments over time, the reference 
sample for each of the test samples is the untreated control samples from that cell 
type.  Therefore it was not possible to deduce from the experiments described above 
whether there was any difference in absolute mRNA quantities between different 
patient’s samples, only whether a treatment had an effect on any one particular cell 
culture.  To investigate whether basal messenger RNA levels varied between the 
cancers and normal samples and indeed between the individual samples themselves, 
cDNA was synthesised from a standard quantity of RNA from a selection of control 
tissue samples, and quantitative RT-PCR performed.  These data then gave some 
idea of the relative levels of the genes of interest amongst samples from different 
patients and thus an idea whether there was any gross derangement of any of these 
genes between the normal and malignant cells.  Samples were collected 
prospectively therefore two such studies were undertaken during the research period 


































































































































































































































































































































Figure 3.8  Quantitative RT-PCR demonstrating variation of a)11βHSD1, 
b)11βHSD2 c)COX-2 and d) IL1R mRNA expression between OSE 
samples (n=9,blue bars) and EOC samples (n=27,red bars) relative to a 
standard RNA sample.  EOC samples are labelled by patient ID number 
and letter indicating source of cell culture (A=ascites, T=primary 
tumour, M=omental metastasis). 
These data indicate that mRNA quantity ranges widely between tumours and also 
between normal OSE samples (figure 3.8).  The samples from patient 13 stand out 
for their low 11βHSD1, high 11βHSD2 and absent COX-2 mRNA levels compared 
to the other tissues.  There appears to be a trend that samples with high type 1 levels 
have low type 2 levels and vice versa, however investigation of these data for 
correlation fails to demonstrate any statistical significance.  There was further 
evidence of a switch in 11βHSD isozyme expression with samples with low type 1 
having the highest levels of type 2 (sample 32M) and samples with low type 2 having 


































































































































































Figure 3.9.  Scatter plots showing mRNA Expression in EOC (red 
circles) and OSE (blue squares).  Data are relative mRNA expression 
values by quantitative RT-PCR, that have been Log transformed to 
examine for statistical differences in their mean values.  11βHSD1(A), 
11βHSD2 (B), COX2 (C), IL1R (D), and GR(E).  Horizontal bars indicate 
Mean/SEM and asterisk indicates significant difference between the 
Means (P<0.05).   
 
As shown in figure 3.9, there are no statistical differences in mean relative 
expression between EOC and OSE for 11βHSD1, COX2, IL1R  and GR.  The data 
were Log transformed to allow normal distribution and subsequent parametric 
testing.  An unpaired t-test indicated a small but significant difference in 11βHSD2 
mRNA expression with EOC having the higher expression (P=0.0464). This could be 
explained by type 1 error however this finding agrees with Rabbitt’s hypothesis.  The 
numbers of samples used in the analysis of IL1R and GR is explained by insufficient 




There was highly significant correlation between 11βHSD1 and COX2 mRNA 
expression in EOC specimens  (Spearman correlation co-efficient rs= 0.90 (95%CI = 
0.78 to 0.96), P<0.001) (figure 3.10).  There was no other statistically significant 
correlation between the other genes of interest other than a positive correlation 
between COX2 mRNA and GR mRNA expression (rs= 0.76, CI=0.35 to 0.93, 
P<0.01)(figure 3.12). 
 



















Figure 3.10  COX2 mRNA against 11βHSD Type 1 mRNA quantity in 




















Figure 3.11 COX mRNA expression against GR mRNA expression in 




3.2.3  11β-Hydroxysteroid dehydrogenase enzyme activity 
3.2.3.1 11-oxoreductase activity 
Seven separate experiments were undertaken to compare the relative reductase 
activities of 11βHSD1 in OSE and EOC.  Every experiment included one OSE 
sample and up to three EOC samples (all in triplicate), an example of the read-out 
given in figure 3.15.   
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a) EOC Control b) EOC + IL-1α
SCOTT: 3HE13HA.R01 

































































Figure 3.12.  11-oxoreductase activity in EOC (a & b), OSE (c) and 
control well with no cells (d).  Graphs indicate readout from TLC plates 
where y-axis indicates counts of radioactivity and x-axis distance along 
the plate.   The less polar cortisone travels further along the plate as it 
is more soluble in the organic solvent giving rise to the second peak on 
reading from left to right. 
 
The results indicate that 11-oxoreductase activity was equivalent in both OSE and 
EOC untreated cultures (mean activities 1.58pmole/hour and 1.71pmole/hour 
respectively, P>0.05).  Furthermore both OSE and EOC significantly increased 
levels of 11βHSD1 activity in response to IL-1α treatment (2.09pmole/hour, 







































Figure 3.13.  11-oxoreductase activity in OSE (n=7) and EOC (n=13) +/- 
IL-1α per well of 2x105 cells.  Bars indicate Mean+SEM.  Asterisks 
indicate significant difference due to treatment (**=P<0.01, ***=P<0.001). 
3.2.3.2 11-dehydrogenase activity 
11-dehydrogenase activity was also assessed using tritiated cortisol.  Despite varying 
cell density, length of time of incubation and carrier steroid concentration the only 
sample where definite dehydrogenase activity could be demonstrated was from 
patient 28 (figure 3.17).  There did not appear to be any increase in activity in 





Figure 3.14.  Evidence of 11-dehydrogenase activity in EOC sample +/- 
IL-1.  Figures indicate readout from TLC plates where x-axis indicates 
counts of radioactivity and y-axis distance along the plate.  The large 
peak represents cortisol and the smaller peaks in figures a) and b) 




Selected tumour representative of different histological subtypes and normal ovary 
samples were used to investigate expression of 11βHSD1, 11βHSD2 and GR (figure 
3.18).  Positive controls included liver (11βHSD1 and GR) and kidney (11βHSD2).  
In addition there was a tumour negative control sample included where antibody was 




The 11βHSD1 antibody was assessed by Western blotting, where two separate 
antibodies were assessed for suitability, an in house polyclonal antibody (kind gift 
from Dr K Chapman) and a commercially available polyclonal antibody (Cayman 
Chemical, Bambridge, UK).  Both identified a band at around 34kDa the predicted 
size of 11βHSD1, however the in house antibody appeared to show additional bands.  












B) Cayman Antibody 
 
Figure 3.15  Western blots of protein from Lane 1: CHO cells 
transfected with 11βHSD1, Lane 2: CHO cells transfected with 3βHSD2, 









Figure 3.16. Immunohistochemistry collages from control samples, 
tumour samples and normal OSE. 40x Magnification. 11βHSD1 is shown 
by red and nuclear counterstain is green.  11βHSD2 is shown by green 
with red nuclear counterstain.  GR is shown by red with green 
counterstain. Some GR images show nuclear counterstain (top left), GR 





3.3.1 Tissue Collection and Culture 
Only two patients of the 37 who were approached to donate ovarian cancer tissue 
declined to take part in the study.  Tissue was not obtained from four patients who 
had consented to the study; two because a pathologist was not available to dissect 
tissue, one due to the theatre list running late and one because there was no overt 
pathology. Of the 29 samples collected, eight were benign tumours and there was one 
borderline tumour with non-invasive implants.  As the goal of tissue collection was 
to maximise numbers of malignant cell cultures these data emphasise the difficulty of 
predicting malignant pathology pre-operatively.   
Inadvertently these findings highlight the difficulties that exist in screening for 
ovarian cancer.  Many of these patients would still have been scheduled for surgery if 
ultrasound and CA125 were used as a screening modality.  However particularly in 
the elderly population morbidity and also mortality from abdominal surgery is 
significant.  If a sensitive and specific test was available to distinguish benign from 
malignant ovarian cysts then some of these elderly women could be managed 
conservatively and therefore escape the risks associated with laparotomy.  In the 
PLCO study of ovarian cancer screening of the 1706 patients who went forward for 
surgery 541 did not have cancer (Buys, S.S. et al. 2005).  However the authors did 
not disclose the morbidities associated with surgery in this group.  While patients 
presented in this thesis with grossly elevated CA125 levels (>1000) always had 
malignancy, women with low CA125 levels (patients 6, 7 and 23; 108, 90 and 46iu/l 
respectively) had cancer while some women with mildly raised CA125 levels did not 
(patients 11, 19 and 20; 337, 154 and 150iu/l respectively).  This is in agreement 
with the conclusion that serum CA125 alone is a poor screening tool for ovarian 
cancer. 
In this study, of the 19 ovarian or primary peritoneal malignancies 17 were stage III 
or IV (90%).  The mean age of women with ovarian or primary peritoneal 
malignancies was 61.5 years (range 42-88 years).  There was one patient who was 
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discovered to have a breast primary malignancy which had metastasised to the 
ovaries (patient 23). 
 
With regard to the primary cultures used in this study, criticisms could be made of 
the inability to provide cultures of pure tumour cells.  Indeed in many instances cell 
morphology suggested the presence of more than one phenotype. However in other 
cases the tumour cells were the only cell type present (this was especially noticeable 
in samples from patients 13 and 21).  Furthermore it may have been helpful to 
attempt to quantify cell components of primary culture flasks using a technique such 
as flow cytometry.  Newer techniques have become commercially available which 
allow purification of cell cultures by targeting cells expressing a particular antibody.  
For example immunomagnetic microbeads that select cells expressing the human 
epithelial antigen-125 (HEA-125) have been used to successfully purify primary cell 
cultures from ascites in patients with EOC (Chan, J.K. et al. 2007).  In Chan’s study 
some of the starting samples prior to purification consist of 60% tumour cells which 
would suggest that the malignant cells contribute most to the culture characteristics.  
Immunohistochemistry studies of the cultured cells suggested a high percentage of 
cytokeratin-positive cells.  While some of these cells could have been mesothelial in 
origin, the irregular shaped cells and high nuclear:cytoplasmic ratio suggests that 
malignant cells made up a significant proportion of the culture.  
The rationale for using primary cultures of EOC in this study is that they are more 
likely to reflect the primary tumour and disease than cell lines which have undergone 
myriad genetic mutations since their initiation.  Therefore the presence of some non-
tumour cells that have nevertheless been isolated from the initial cancer material may 
be important in providing a supportive role for the malignant cells.  Indeed, there is 
evidence of communication between tumour and host immune cells in EOC (Gordon, 
I.O. et al. 2006; Hagemann, T. et al. 2006).  This may be of more relevance in the 
glucocorticoid metabolism studies than the RNA studies, where a heterogeneous 





3.3.2 Comparison of EOC and OSE Response to Inflammation 
Looking at mRNA levels, primary cultures of EOC were tested for their responses to 
inflammation in 27 separate experiments.  In eleven of these experiments primary 
cultures of OSE were simultaneously available to provide a direct comparison in the 
response to cortisol and IL-1α.  The nature of prospective tissue collection meant that 
confluent cultures of OSE were not always available for experimentation when EOC 
cultures were confluent.  In addition as cells sourced from different tissues from the 
same patient were often confluent at different times, experiments on same-patient 
samples were not always able to be conducted concurrently.  In light of these issues 
of timing, the results were initially analysed with each experiment taken 
independently.  In addition it may have been erroneous to assume that samples from 
the same patient would give identical responses.  It is for these reasons therefore that 
the in toto analysis was undertaken.   
These results show that although 11βHSD1 mRNA was significantly up-regulated by 
F, IL-1α and F+IL-1α in the EOC samples, the degree of fold change with the IL-1α 
treatments was significantly less than in the OSE cell population.  This implies that 
the EOC phenotype may be less responsive to IL-1α than the untransformed OSE 
cell.  These data are also in agreement with Gubbay et al.’s findings that EOC cell 
lines have significantly less induction of 11βHSD1 with IL-1α than OSE, although 
the difference was less marked in this current study (Gubbay, O. et al. 2005).  These 
new data hint at a difference between cell lines and primary cultures, where the cell 
lines have reached immortality and may have acquired further genetic mutations and 
therefore do not reflect the true in vivo characteristics of cancer.      
Separation of the data by origin of cell culture into solid and ascitic components was 
important to assess whether there was any marked difference in cellular response due 
to the cell culture technique.  This revealed that ascitic and solid tumour cultures 
behaved in a similar manner with respect to 11βHSD1, 11βHSD2 and COX2. 
However on statistical analysis the difference between malignant and normal cells in 
the 11βHSD1 response to IL-1+/-F was lost.  This can be explained by a reduction in 
statistical power as a result of reducing “n”, but also hints at there perhaps being little 
real difference between these tissues and perhaps type II error could have arisen. 
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The relatively low number of specimens used in these experiments does raise the 
possibility of statistical tests being insufficiently powered to demonstrated significant 
effects of treatments.  While the data were tested for normality prior to the use of 
parametric testing, it is accepted that the low number of samples has the potential to 
mislead.  This notwithstanding, the level of statistical significance is likely to equate 
with biological significance.  It can be more confidently stated that IL-1α increases 
11βHSD1 and COX-2 mRNA levels in EOC and OSE (where P<0.001), than the 
fold-change in 11βHSD1 is greater in OSE than EOC (where P<0.05).  It is certainly 
possible that the difference between OSE and EOC is an example of a type I error, 
where a significant difference is seen but this may be the result of a sampling error. 
Conversely the small sample size could also lead to a type 2 error for the 11-
oxoreductase assay, which is discussed in more length below.  
Following the mRNA studies, 11βHSD1 protein expression was assessed by 
functional studies of enzymic activity.  11βHSD1 acts primarily in vivo as a 
reductase enzyme and metabolism studies using tritiated cortisone as substrate gave a 
direct quantification of enzyme quantity.  Overall there was no significant difference 
in 11βHSD1 activity between OSE and EOC untreated samples.  Both OSE and EOC 
had significantly higher enzyme levels in response to IL-1α compared to their 
untreated controls, which was predicted from the mRNA analysis.  However the 
difference in 11βHSD1 seen at the mRNA level was not demonstrated at the enzyme 
level, and the normal and malignant tissues had equivalent enzyme activities.  One 
explanation for this could be that Taqman quantitative analysis is a more sensitive 
test and is better able to highlight differences.  The 11-oxoreductase assay may be 
more prone to variation due to the larger number of biological variables that 
influence enzyme activity.   
While attempts were made to keep some experimental conditions the same for both 
mRNA and protein studies, there were slight differences.  Firstly, the mRNA studies 
used fresh primary cells that had not undergone any trypsinisation or passage.  In 
order to guarantee a constant supply of OSE and to allow synchronisation of OSE 
and EOC cultures reaching confluency at the same time, a stock of frozen OSE was 
created and divided into multiple cryovials.  These were then thawed and cultured to 
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achieve confluence at the same time as the EOC cultures.  This had the added benefit 
of increasing the reproducibility of the assay, as each OSE sample used had the same 
patient origin, and allowed a quality control assessment of the enzyme assay.  
Secondly, the density and number of cells used in each type of experiment differed, 
the enzyme assay using 2 x105 cells per well (2 x105 per ml) but in triplicate while 
the mRNA studies included 4-5x105 cells per solitary well (1.0-1.25 x105 per ml).  
While it is unlikely that this difference in cell number had any significant effect, 
there remains the possibility that the lower density of cells could influence cell 
response. Enzyme activity is also influenced by other significant variables including 
co-substrate availability, temperature and carrier steroid concentration.  As steroid 
extraction and TLC techniques were identical for all experiments any inter-
experimental variation was more likely to be related to differences in co-substrate 
availability.  One way of overcoming this would have been to drive the reaction by 
providing an abundance of NADPH.  However this would detract further from the 
attempt to emulate the in vivo actions of this enzyme and limited co-substrate 
availability itself could be characteristic of some tumours.  Furthermore the 
proliferative nature of malignant tissue in vivo results in high oxygen demands which 
often outstrips the ability of the local vasculature to supply.  This explains the areas 
of necrosis that is commonly found within tumour tissue.  It seems likely therefore 
that the redox state of cancerous tissue is altered and as such co-substrate availability 
which is dependent on adequate oxygenation may be disrupted.  This reasoning 
raises a caveat to the 11-oxreductase assay performance.  In the setting of the in vitro 
assay the numbers of cells is equivalent between normal and malignant cultures as 
well as all other tissue culture variables.  The situation in the human body may be 
quite different.  While normal OSE is likely to be well perfused, malignant tissue 
will have a gradient of oxygenation from capillary to tumour centre.  The poor 
oxygenation in the malignancy may reduce NADPH availability in these tissues and 
11βHSD1 may not function as a reductase. Thus although levels of type 1 enzyme 
may be equivalent in the normal and malignant tissues it is highly probable that 
weight for weight activities in the tissues are not.  This probable imbalance in co-
substrate in malignant tissue could result in the enzyme acting as a dehydrogenase, 
thought to be solely an in vitro action.   There are also limitations in the 11-
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oxoreductase assay which could explain why no difference was seen between the 
tissues.  The assay followed previously published methods where OSE cells had been 
investigated for cortisol activity (Yong et al., 2002).  A time course of 1, 4, 8 and 12 
hours was set up initially to assess the best time point to end the reaction. At one and 
four hours there was no detectable reductase activity and it only became detectable at 
8 hours. This was therefore chosen as the standard time for all experiments.  The 
difficulty with this is that by this time a large proportion of the substrate may have 
already been utilised and the enzyme kinetics no longer first order.  It would have 
been ideal to have identified the linear part of the reaction prior to commencing the 
study, with multiple concentrations of steroid.  Analysis of the 11βHSD1 enzyme is 
complicated further by its low affinity for cortisol and potential to catalyse both 
directions of the reaction, as well as its dependence on the cosubstrates NADP+ and 
NADPH.  Thus once the reaction has been running for some time, there is less 
cortisone but also less NADPH and the redox status of the tissue culture flask may 
favour the conversion of cortisol to cortisone.  The enzyme assay can be set up to 
investigate this additional step by the deuterated cortisol tracer method described by 
Andrew et al. (Andrew et al., 2002). 
A further factor affecting tissue levels of cortisol is cortisol binding globulin (CBG).  
In the circulation over 90% of cortisol is bound to CBG, with lesser amounts bound 
to albumin and sex hormone binding globulin (SHBG) (Andersen, 2002).  Cortisol 
has 10-fold higher binding affinity than cortisone to CBG.  In addition progesterone 
is able to dissociate cortisol from CBG by competing for the active binding site.  It is 
hypothesised that the protective effect of the contraceptive pill is through the 
displacement of cortisol by exogenous progestins, further reducing inflammation 
within the ovary.  Therefore relative levels of albumin, CBG and progesterone could 
all affect tissue glucocorticoid distribution in malignancy.   
    
As predicted from earlier studies the type 2 11βHSD isoform is unlikely to play a 
significant role in normal OSE function, as the level of mRNA is low and its levels 
are not affected by inflammatory stimuli (Rae, M.T. et al. 2004).  Furthermore, it is 
difficult to detect any 11-dehydrogenase activity in cultured OSE cells (Gubbay, O. 
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et al. 2005).  Both these observations are held up by these studies comparing EOC 
and OSE.  The absence of any induction of 11βHSD2 mRNA in OSE and EOC 
means that any alteration in tissue glucocorticoid is consequent to alteration in 
11βHSD1 expression.  This is analogous to the expression of the cyclo-oxygenase 
enzymes where COX1 is a constitutionally expressed enzyme while COX2 can be 
rapidly induced and therefore alter tissue prostaglandin concentration when signalled 
to do so.  In a large series of primary cultures of both OSE and EOC only one sample 
gave any positive evidence of 11βHSD2 enzyme activity.  This suggests that 
11βHSD2 over-expression is not a necessary requisite of EOC development, yet it 
remains possible that it might be of importance in some cancer subtypes.  The tissue 
which appeared to have measurable 11βHSD2 activity (28T, a poorly differentiated 
serous adenocarcinoma) had the fourth highest type 2 11βHSD mRNA levels in the 
series (figure 3.10).  Assuming this is not a spurious result (as it was replicated in 
triplicate), the increased activity could be explained by increased availability of co-
substrate. 
Other approaches could have been to homogenize the tissue and drive the reaction 
with additional co-substrate. This is less appealing as, although it might represent the 
potential enzymic activities of each sample, it is far removed from actual tissue 
metabolism especially as it would disrupt intracellular compartmentalization of the 
enzymes and their co-factors.  One explanation for the 11βHSD2 enzyme assay 
findings could be that the assay was simply not sensitive enough to detect differences 
in enzyme activity between tissues.  In retrospect it would have been prudent to 
include a positive control sample such as placenta to assess the assay’s performance.   
 
3.3.3 Comparison of Absolute mRNA quantities 
Having established the response of primary cancer cell cultures to inflammation, it 
was then important to investigate whether there was any difference in absolute 
mRNA levels between EOC and OSE.   The study highlighted that one patient’s 
samples (patient 13) contained very low levels of type 1 11βHSD and COX-2 but the 
highest quantities of type 2 11βHSD.  Of note was the histological finding that this 
patient’s tumour was poorly differentiated (figure 3.15).  Whilst this is case study 
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evidence, it was also noted that cultures form this patient’s samples were highly 
proliferative and morphologically identical, producing confluent homogeneous 
monolayers of small rounded cells.  The reassuring feature of these results is that the 
samples from each tissue source (i.e. ascites, primary tumour and omental 
metastases) behaved identically providing justification that similarly malignant cells 
can be cultured from both ascites and solid tumour.   
Analysis of the median quantities of mRNA in EOC and OSE did not reveal any 
significant differences between the two tissue types, although there was a trend 
towards higher levels of both 11βHSD1 and 11βHSD2 in the cancer samples.  
Importantly there was no significant difference in IL-1R mRNA expression between 
the two samples suggesting that the reduced responsivity to IL-1α in EOC compared 
to OSE was not due to IL-1R expression, although it would be necessary to quantify 
the receptor protein before this can be stated with absolute confidence.  In the 
dynamic studies, IL-1 receptor (IL1R) mRNA was unchanged by IL-1α or cortisol at 
48 hours in both EOC and OSE.  The time course of IL-1 effect however suggests 
that IL1R mRNA expression in response to IL-1α may be maximal at 6 hours, 
therefore any effect at 48 hours post-treatment may have been lost. 
 
It was also apparent that the sample with the highest type 2 11βHSD (patient 32) also 
had one of the lowest levels of type 1 11βHSD mRNA.  Furthermore there was 
evidence of a switch in isozyme expression when the samples were ranked by mRNA 
quantity.  Thus those samples with high type 2 11βHSD mRNA levels tended to have 
low type 1 mRNA levels and vice versa. Correlation analysis showed that despite 
switches in expression of 11BHSD1 and 2 mRNA in some individual cancer cases 
there is no statistical correlation.   
There is a reproducible correlation between 11βHSD1 and COX2 mRNA expression 
in the EOC specimens (figure 3.1).   This might have been anticipated by the 
demonstration of IL-1α up-regulating both 11βHSD1 and COX2 in the cell culture 
experiments.  The pro-inflammatory pathway may be dominant in these malignant 
cells as a primary rise in 11βHSD1 would be anticipated to reduce levels of COX2, 
assuming that COX2 expression remains responsive to anti-inflammatory agents in 
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malignant tissue.  However looking at the time profile of the up-regulation of these 
genes shows that COX-2 is maximally up-regulated at 6 hours whereas the 11βHSD1 
response takes 48 hours to reach its highest level.  This is in keeping with previously 
published data showing that prostaglandin synthesis is closely linked to 11βHSD1 
production in human granulose cells (Jonas et al., 2006).  Furthermore this could 
explain the events surrounding ovulation where acute inflammation is allowed to 
occur then switched off by a slower rising anti-inflammatory mechanism via 
11βHSD1.  In addition if this anti-inflammatory response is primed by prostaglandin 
production the size of the response will be proportional to the preceding pro-
inflammatory stimulus and a homeostatic feedback cycle initiated.  In the context of 
malignancy, if the type 1 11βHSD response is impaired then only the pro-
inflammatory mechanism is allowed to dominate, and if the type 2 enzyme 
dominates there will be a further decrease in tissue cortisol.  These finding therefore 
provide further impetus to Rabbitt’s hypothesis that type 2 11βHSD predominance 
predisposes to the development of malignancy. 
There is evidence that COX2 expression is deregulated in several cancers as 
reviewed by Zha (Zha, S. et al. 2004). In EOC studies have examined COX2 
expression and survival with conflicting results.  In advanced serous EOC Ali-Fehmi 
and co-workers concluded that increased COX2 expression was associated with 
tumour angiogenesis and poor survival (Ali-Fehmi, R. et al. 2005).  However in a 
subsequent study COX2 negativity was associated with poorer survival (Steffensen 
K.D. , M.W.U.J.E.J.I.B.A.J. 2007).  This Danish study included all histological 
subtypes where the rate of serous tumours was 61%, perhaps explaining these 
differences.  An increase in COX2 expression, like 11βHSD1 expression, does not 
appear to be a pre-requisite for cancer development, although the fact that many 
cancers over express this enzyme may implicate it in the host response to disease. 
COX2 overexpression is likely to play a role in tumour angiogenesis (Kuwano, T. et 
al. 2004).   
On analysis of the mRNA quantities in OSE and EOC, there was no significant 
difference in 11βHSD1, COX2 or GR expression.  However there was a significantly 
higher quantity of 11βHSD2 mRNA in the EOC samples compared to OSE (P<0.05).  
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This is in agreement with Gubbay’s study comparing OSE and EOC cell lines.  In 
addition there is evidence from other malignancies that type 2 11βHSD is up-
regulated in cancer (as summarised by Rabbitt,(Rabbitt, E.H. et al. 2003)) and work 
examining 11βHSD enzyme expression in homogenised tumour material has also 
previously suggested higher levels of type 2 11βHSD in the cancers (Temkin, S. et 
al. 2006). One weakness of the study presented here is the strength of the statistical 
difference which could have been improved by increasing the numbers of OSE 
samples used.  However primary tissue is a rare and valuable resource and the OSE 
samples were limited.   
 
3.3.4 Tissue distribution of 11βHSDs 
The immunohistochemistry (IHC) studies were of value in examining the 
distributions of the 11βHSD isozymes.  Reassuringly, the positive control samples 
indicated that the antibodies were specific for the proteins of interest. In addition 
Western blotting had been undertaken prior to IHC and had confirmed specificity of 
the 11βHSD1 antibody.  Past local experience meant that the 11βHSD2 antibody 
could be used with confidence and indeed it appeared to demonstrate localization of 
the enzyme to the renal glomeruli as previously reported (Kataoka, S. et al. 2002).   
In general, type 1 11βHSD appears to be expressed in most of the tissue tested but 
absent in patients 13, 14, 23 and 29.  This is of particular interest as the mRNA 
studies indicated that patient 13 had a particularly low expression of type 1 11βHSD. 
Strong signals for 11βHSD1 were noted in samples from patients 16, 31, 32, and 35.  
There appears to be little evidence therefore that switching off of 11βHSD1 is 
necessary for EOC to develop.  Indeed the presence of the enzyme and reductase 
activity suggest that local cortisol production is not likely to be impaired in these 
tissues.   
11βHSD2 protein could also be demonstrated in some tumour samples.  It was 
clearly expressed in patients 28,29, 32 and 33.  The high expression of type 2 
11βHSD in patient 28 is corroborated by the finding of 11-dehydrogenase activity in 
this tumour also.  Whilst most of the other tumours did not demonstrate the presence 
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of 11βHSD2 its high expression in some cancers does not exclude a “pro-
proliferative” role for it in some tumours.   
GR appeared to be widely distributed within the nuclei of most tumour samples.  
This implies that cortisol signalling could occur in the malignant tissue.  However 
pre-receptor effects of 11βHSD1 & 2 would also be expected to influence the cellular 
response.  
 
3.3.5 General Discussion 
 
In summary, the data in this chapter demonstrate that it is possible to collect and 
culture primary ovarian cancer cells from ascites and solid tumour, that enables 
comparison to normal untransformed primary OSE.  These results hint at the 
11βHSD1 mRNA response to IL-1α-induced inflammation being attenuated in EOC 
compared to OSE.  However 11βHSD1 enzyme activity appears to be similar in the 
two cell types.  11βHSD2 mRNA levels are unaffected by inflammation in normal 
and malignant ovarian tissues and the only cell type with any demonstrable 
11βHSD2 enzyme activity was from EOC.  11βHSD1 and 2 isozymes are found in 
inverse proportions in EOC samples and there is some suggestion that high 
11βHSD2 expression is associated with higher grade tumours.  Both isozymes can be 
detected by IHC in tissue sections of malignant ovarian tissue.  The final analysis of 
these data has revealed limitations of the experimental set-up and provides 
suggestions for the future. 
From the beginning of the project there was uncertainty as to how successful primary 
culture of EOC was going to be.  The creation of such cultures required the early 
institution of a protocol for tissue handling and this then had to be maintained 
throughout the research time to avoid variation between the cell cultures.  
Experiments were performed on the healthiest and most quickly confluent flasks, so 
some degree of selection bias may have been introduced.  As the project advanced 




It could be argued that OSE was an inappropriate cell type to use for comparison 
because samples were not from the same patient and OSE was collected from pre-
menopausal women whereas nearly all the cancers came from post-menopausal 
women.  Thus the sex steroid backgrounds are likely to have been quite different for 
both tissues.  Nevertheless, OSE is a strong candidate tissue for most EOCs and in 
light of the primary nature of EOC cultures, primary OSE is more relevant as a 
comparator than OSE cell lines.  These suppositions are held up by evidence from 
gene expression profiles of ovarian cancers, primary OSE and cell lines (Hough, 
C.D. et al. 2000).   
Having been satisfied that the correct tissues for comparison had been chosen, the 
evidence presented here hints that deregulation of type 1 11βHSD may occur in the 
development of ovarian cancer, and eventually type 2 11βHSD becomes 
predominant.  The exact mechanisms by which this occurs are not yet clear however 
it may be that there is a mismatch in pro-inflammatory activity and the anti-
inflammatory response, in favour of inflammation.   
 
The relative expression of the pre-receptor glucocorticoid modulators is likely a 
consequence of tumour differentiation and not a cause.  As evidenced by patient 13 
in this study,  tumours which are high grade and poorly differentiated are associated 
with low expression of 11βHSD1.  In addition the cell type of origin may be 
important in determining tumour phenotype.  The fact that epithelial ovarian cancers 
can show such wide heterogeneity could be explained by either each histiotype 
having a separate cell of origin, or alternatively that the different histologies arise 
from the same progenitor or stem cell which has diverse mechanisms of 
differentiation, for example by HOX gene activation.  A unifying cell of origin is an 
appealing concept and potentially provides a target for therapy and preventative 
medicine.  No matter how attractive this idea is, the bottom line is that the natural 
history of EOC remains unknown and until these early steps can be illuminated the 







Anti-inflammatory steroid activity in the human 




4 Anti-inflammatory steroid activity in the human 
peritoneal surface epithelium 
4.1 Introduction 
 
Ovulation has long been considered a naturally occurring inflammatory event 
(Espey, L.L. 1980).  However in 2002 evidence for a corresponding anti-
inflammatory reaction in the OSE was presented (Yong, P.Y. et al. 2002). This paper 
showed an increase in 11βHSD1 in primary OSE cells following stimulation by IL-
1α and subsequently increased local conversion of inactive cortisone to the more 
active anti-inflammatory steroid cortisol (see figure 1.10).  It was hypothesised that 
the creation of this anti-inflammatory milieu would then allow the ovarian wound to 
heal in preparation for the next round of ovulation.  A unique property of the ovary is 
its ability to recover from injury without the formation of scar tissue on its external 
surface.  This may reflect the fact that ovulation-associated injury is a natural 
phenomenon rather than inflammation associated with trauma, infection or disease 
processes such as endometriosis or cancer.  The peritoneum is not exposed to 
frequent episodes of “natural” inflammation so it may have alternative ways of 
responding once an insult has occurred. 
 
Examination of other tissues has revealed that up-regulation of 11βHSD1 mRNA in 
response to cytokine stimulation is not unique to the OSE.  While the first description 
of this phenomenon was in the ovary (Tetsuka, M. et al. 1999; Tetsuka, M. et al. 
1997), subsequent studies have shown that 11βHSD1 is increased following 
inflammatory stimuli in renal mesangeal cells (Escher, G. et al. 1997), aortic smooth 
muscle (Cai, T.-Q. et al. 2001), osteoblasts (Cooper, M.S. et al. 2001), pre-
adipocytes (Bujalska, I.J. et al. 2002; Tomlinson, J.W. et al. 2001), endometrial 
stroma (McDonald, S.E. et al. 2006), fetal membranes (Sun, K. et al. 2003), 
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trophoblast (Li, W. et al. 2006) and macrophages (Gilmour, J.S. et al. 2006).  The 
ability of a cell population to increase 11βHSD1 after inflammation therefore 
appears to be a widespread characteristic.  However the paracrine effect of increased 
11βHSD1 will only result in increased local cortisol if there is no alteration in, or 
down-regulation of 11βHSD2, which catalyses the dehydrogenation of cortisol to the 
inactive metabolite.     
 
The ovarian response to inflammation has been closely inspected not least because of 
links between ovulation, inflammation and the development of epithelial ovarian 
cancer (Espey, L.L. 1994; Fleming, J.S. et al. 2006; Ness, R.B. et al. 1999; Ness, 
R.B. et al. 2000).  In the OSE, 11βHSD1 is up-regulated at the protein level also as 
evidenced by the enzymic conversion of radio-labelled cortisone through 
hydroxylation of the 11-keto group (Yong, P.Y. et al. 2002).  Furthermore 
inflammation in the OSE as demonstrated by increased cylooxygenase-2 (COX2) is 
inhibited in vitro by addition of cortisol and to a lesser extent progesterone (Rae, 
M.T. et al. 2004).   
 
The similar embryological origins of the peritoneal surface epithelium (PSE) and 
OSE as well as the fact that the OSE is a continuation of the PSE at the hilum of the 
ovary raises the question; how similar are these two mesothelial cell types?  
Specifically does the PSE share the OSE’s response to inflammatory cytokines and 
are there also anti-inflammatory mechanisms present in the peritoneal as well as the 





4.2 Cell Collection and Culture 
 
4.2.1 Ethics and Patient Data 
Ethical approval for this study was granted by Lothian Regional Ethics Committee 
03 (REC Reference 04/S1103/36 Chief Investigator Dr KS Fegan).  All patients gave 
written informed consent prior to donating samples (see appendix).  Relevant clinical 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3 Effects of Interleukin-1α and anti-inflammatory steroids 
on 11βHSD1, 11βHSD2 and COX-2 in primary cultures of 
PSE. 
 
In order to examine for effects of the inflammatory cytokine interleukin-1α (IL-1α) 
an experimental cell culture system was established as previously described using 6 
well plates (Chapter 2.1.2).  This ensured consistent and repeatable numbers of cells 
for each experiment and for each treatment within each experiment.  Data (CT 
values) were analysed using a repeated measures one-way ANOVA for each 
treatment, with Bonferroni post-test correction, having tested that the data were 
normally distributed and were effectively matched using an F test.  The first 
investigation assessed the effect of IL-1α on inflammation-associated genes.  
 
 
4.3.1 Dose-dependent effects of IL-1α 
 
To confirm that there was a specific interleukin-1α effect on the PSE cells and to 
establish the maximally effective dose, five-fold increasing concentrations of IL-1α 
were used and corresponding genes of interest examined (n=5) (See figure 4.4).   
4.3.1.1 11βHSD1  
11βHSD1 mRNA expression was increased in a dose-responsive manner by 
increasing concentrations of interleukin-1α. Maximum up-regulation of 11βHSD1 
occurred at a concentration of 0.5ng/ml (8.2-fold change relative to untreated control, 
P<0.001). 
4.3.1.2 11βHSD2   




COX-2 mRNA expression was increased in a dose-dependent fashion by interleukin-
1α.  Maximum mean expression was also at a concentration of 0.5ng/ml (9.6-fold 












































































































































Figure 4.1.  Quantitative RT-PCR data demonstrating the effect of 
increasing concentrations of interleukin-1α on expression of a) 
11βHSD1, b) 11βHSD2 and c) COX-2 (n=5).  Bars indicate mean/SEM. 
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Asterisks indicate significant difference from untreated control 
(**=P<0.01, ***=P<0.001). 
 
4.3.2 Changes in 11βHSD1, 11βHSD2 and COX-2 mRNA 
Expression with IL-1α as a function of time 
 
An examination of IL-1α effects on time dependent gene expression was undertaken 
in PSE from two different patients.  The regulation of the mRNA of interest by IL-1α 
treatment was assessed by comparing the IL-1α sample with the same time-point 
untreated control sample.  Limited access to clinical material curtailed the number of 
these experiments to two and subsequently statistical tests could not be applied. See 
figure 4.5. 
 
4.3.2.1  11βHSD1 
11βHSD1 mRNA expression increased over time with maximum expression 
occurring at 48hours of IL-1α treatment (mean fold change 8.75 compared to 
untreated 48 hour sample). 
 
4.3.2.2 11βHSD2 
There did not appear to be any change in 11βHSD2 mRNA expression over time. 
 
4.3.2.3 COX-2 
In contrast to 11βHSD1, COX-2 mRNA levels appeared to peak at 6 hours (mean 
fold change 43.8) following administration of IL-1α at 0.5ng/ml.  While the extent of 
COX-2 mRNA up-regulation reduced with time, it was still considerably elevated at 









































































































































Figure 4.2.  Effect of duration of IL-1α treatment on a) 11βHSD1, b) 
11βHSD2 and c) COX-2 mRNA expression in PSE as assessed by 




4.3.2.3.1 Effects of Cortisol in the PSE 
 
Having established that 11βHSD1 was up-regulated maximally by 0.5ng/ml IL-1α 
for 48 hours, the effect of cortisol as an anti-inflammatory agent was then assessed 
using this dose and time paradigm.  
 
4.3.2.4 Dose-dependent Cortisol Interactions 
 
PSE cells from two separate patients were treated with ten-fold increasing doses of 
cortisol in the presence and absence of IL-1α at 0.5ng/ml.  The number of samples 
available for this study precluded statistical analysis. See figure 4.6. 
 
11βHSD1 mRNA was successively increased by increasing dose of cortisol alone to 
a maximum mean up-regulation of 23.7 times the untreated control.  This effect was 
enhanced at every cortisol concentration by the presence of IL-1α (at 0.5ng/ml) 
where the maximum mean fold change of 58.2 was reached at 1μM cortisol. 
 
11βHSD2 mRNA was unchanged neither by cortisol treatment at any concentration 
nor by the addition of IL-1α. 
 
Cortisol alone had no effect on COX-2 expression.  As also shown above IL-1α 






However this effect was gradually abrogated by increasing concentrations of cortisol, 
until at 1μM the mean level of COX-2 was 2.7-fold that of the untreated control. 






































































Figure 4.3.  Dose dependent effects of cortisol +/- IL-1α (0.5ng/ml over 
48 hours) on a) 11βHSD1, b) 11βHSD2 and c) COX-2 mRNA expression 






4.3.2.5 Cortisol as an anti-inflammatory agent in the PSE 
 
Thus a system was established whereby the interactions of cortisol at a concentration 
of 1μM and IL-1α at 0.5ng/ml at 48hours incubation could be assessed (figure 4.7).  
Data (CT values) were analysed using a repeated measures one-way ANOVA for 
each treatment, with Bonferroni post-test correction, having tested that the data were 
normally distributed and were effectively matched using an F test.   
Using PSE cultures from five different patients, levels of 11βHSD1 were increased 
by both cortisol (mean fold induction 12.6, P<0.001) and IL-1α alone (mean fold 
induction 9.75, P<0.01).  The simultaneous addition of cortisol and IL-1α caused up-
regulation of type 1 11βHSD (mean fold change 67.9, P<0.001) which was also 
statistically different from cortisol (P<0.01) and IL-1α (P<0.001) alone. 
There was no statistically significant effect of any of the treatments on 11βHSD2 
mRNA expression. 
While cortisol alone had no effect on COX2 mRNA expression the addition of IL-1α 
induced a significant rise (mean fold induction 10.6, P<0.001).  This was returned to 
levels similar to control by co-incubation of IL-1α with cortisol (mean fold induction 









































































































































Figure 4.4.  Quantitative RT-PCR showing the effect of interleukin-1α 
(IL-1, 0.5ng/ml) +/- cortisol (F, 1μM) on expression of 11βHSD1 (a), 
11βHSD2 (b) and COX2 (c).  n=5.  Bars represent mean/SEM. Asterisks 




4.3.3 A Comparison of the Anti-inflammatory Effects of 
Progesterone and Cortisol 
Progesterone is predicted as an anti-inflammatory agent in the PSE from its reported 
effects in the OSE (Rae, M.T. et al. 2004).  Having demonstrated the anti-
inflammatory effect of cortisol in the PSE, next, progesterone was used alongside 
cortisol in a direct comparison of their anti-inflammatory effects in PSE (figure 4.8).   
4.3.3.1 11βHSD1 
In a separate group of patient samples, results from six different individuals 
demonstrated that while treatment with cortisol alone again increased 11βHSD1 
mRNA expression (10-fold induction, P<0.001), progesterone treatment alone had no 
effect on 11βHSD1 expression.  IL-1α at 0.5ng/ml caused a significant increase in 
11βHSD1 message (7.25-fold, P<0.001) which was increased further by the co-
incubation with cortisol (28.3-fold, P<0.01). Concomitant treatment of PSE with IL-
1α and progesterone appeared to further increase 11βHSD1 expression over IL-1α 
alone (11.8-fold) but this difference was not statistically significant. 
4.3.3.2 11βHSD2  
Once again, there was no statistically significant change in 11βHSD2 mRNA 
expression in response to any of the treatments applied.   
4.3.3.3 COX-2 
COX-2 expression was unaffected by treatment with cortisol alone.  IL-1α caused a 
significant increase in COX-2 mRNA (mean fold induction 20.3, P<0.001) which 
was returned to near control levels by the addition of cortisol (mean fold change 4.5 
compared to control).  Similarly, progesterone alone had no significant effect on 
COX-2 expression, and comparing IL-1α treatment with IL-1α and progesterone 
combined, reduced the effect of IL-1α (20.3 to 12.8-fold), though in the case of 















































































































































Figure 4.5.  Quantitative RT-PCR comparing effects of progesterone 
(P4) and cortisol (F) (both at 1μM) +/- interleukin-1α (IL-1) on expression 
of a) 11βHSD1, b) 11βHSD2 and c) COX-2 (n=6).  Differing superscripts 
indicate significant difference due to treatment. 
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4.3.4 The Response to Inflammation in PSE is not affected by Site 
of Sampling. 
 
As discussed in 4.2.2. two separate sites of the peritoneum were chosen for collection 
of PSE cells.  While the success of cell culture was lower in the anterior abdominal 
wall (A) samples due to lower cell numbers at the time of collection, if the sample 
gave rise to a confluent monolayer there was no distinguishable morphological 
difference to the cultures collected from the body of the uterus (B sample).  Separate 
analysis of the data for A and B samples in the experimental cell culture system did 
not demonstrate any difference in 11βHSD1, 11βHSD2 or COX-2 responses to IL-1α 
in the presence or absence of cortisol or progesterone as a consequence of cell source 


































































Figure 4.6.  Quantitative RT-PCR results demonstrating the similar 
responses to IL-1α(0.5ng/ml), cortisol (F) or progesterone (P4) (both at 
1μM) in PSE cells sampled from the anterior abdominal wall (A samples, 
n=6) or the surface of the uterus (B samples, n=8).  Bars indicate 




4.3.5 Expression of Glucocorticoid and Progesterone Receptor 
mRNA and Protein in OSE and PSE. 
 
To demonstrate that both cortisol and progesterone were likely to be biologically 
active in PSE cells, it was important to demonstrate expression of their respective 
receptors; glucocorticoid receptor-α (GRα) and the progesterone receptor (PR).  
Furthermore as the up-regulation of 11βHSD1 by cortisol alone had not been 
previously noted in the OSE a comparison of GRα in these two cell types might 
explain their different responses to cortisol. 
 
4.3.5.1 GRα and PR mRNA expression in the OSE and PSE. 
 
Quantitative RT-PCR was used to investigate the relative quantities of GRα and PR 
mRNA in OSE (n=4) and PSE (n=6).  There was no statistical difference in the 




Figure 4.7.  Relative quantities of GRα and PR mRNA in OSE (n=4) and 







4.3.5.2 Glucocorticoid Receptor-α and Progesterone Receptor Protein 
Expression in OSE and PSE. 
 
4.3.5.2.1 Glucocorticoid Receptor-α  
As demonstrated by immunohistochemistry (IHC) in figure 4.11, GRα was expressed 
in both OSE and PSE. 
 
Figure 4.8 Photomicrograph demonstrating expression of GRα in OSE 
(A) and PSE (C).  Magnification x40, bar represents 20μm.  





4.3.5.2.2 Progesterone Receptor 




Figure 4.9.  Photomicrograph demonstrating nuclear localisation of PR 
in OSE (A) and PSE (C).  Magnification x40, bar represents 20μm.  





4.3.6 Relative quantities of 11βHSD1, 11βHSD2 and COX-2 mRNA 
in OSE and PSE 
 
An attempt was made to assess the relative levels of mRNA in OSE (n=3) and PSE 
(n=4) by quantitative RT-PCR where the level of mRNA was compared to a standard 
RNA sample; liver for 11βHSD1 and COX-2 and placenta for 11βHSD2.  When 
statistical tests were applied there were no differences between PSE and OSE for any 
of the genes studied, however the mean level of 11βHSD1 in OSE was over two 
times greater than that in PSE (0.055 vs. 0.023), whereas the mean level of 11βHSD2 
in OSE was just over half that of PSE (0.007 vs. 0.014) (figure 4.13).  The data were 
too few to be assessed by a normality test, however using non-parametric tests there 




Figure 4.10.  Relative quantities of a) 11βHSD1, b) 11βHSD2 and c) COX-
2 mRNA in OSE (n=3) and PSE (n=4) by quantitative RT-PCR.  Values for 
individual samples are represented by squares (OSE) and triangles 




4.3.7 Effects of Interleukin-1α on 11βHSD1 11-Oxoreductase 
Activity in primary cultures of PSE. 
 
The changes in 11βHSD1 mRNA in the PSE in response to pro- and anti- 
inflammatory agents thus appeared to be remarkably similar to previous reported 
responses in the OSE.  However it could not be assumed that these changes in 
mRNA were also manifested in protein changes, specifically enzymic activity.  As 
the principal action of 11βHSD1 in the ovary is as a reductase, a glucocorticoid 
metabolism assay was established where 11-oxoreductase activity was measured by 
conversion of tritium-labelled cortisone to cortisol.  Results from four separate 
experiments comparing 11-oxoreductase activity in OSE and PSE are shown in 
figure 4.14.  Data are presented as mean cortisol production over 8 hours per 2x105 
cells.  The data were too few to be able to analyse for normality using the 
D’Agostino and Pearson normality test. However statistical significance persisted 
whether parametric or non-parametric testing was used. 
 
Enzyme activity was consistently and significantly higher in untreated OSE samples 
compared to PSE (mean conversion 6.3 pmoles/8hours vs. 1.1pmoles/8hours, 
P<0.01).  In response to IL-1α treatment, 11βHSD1 activity was significantly 
increased in the OSE (6.3 pmoles/8hours to 10.4pmoles/8hours, P<0.05) while there 
was no statistically significant increase in mean activity in the PSE 









































Figure 4.11.  Comparison of 11-oxoreductase activity in OSE and PSE in 
presence and absence of IL-1α (0.5ng/ml) (n=4).  Bars indicate 
mean/SEM. Dissimilar superscripts indicate significant difference due 
to treatment (b=P<0.05).  Asterisks indicate significant differences 




4.4 A Comparison of PSE and OSE Response to 
Inflammation by PCR Microarray 
 
As a result of the above investigations it was hypothesised that the response to IL-1α 
would be no different in OSE and PSE for genes other than those examined above.  
A similar inflammatory signature would provide further evidence that the OSE and 
PSE are essentially the same tissue. 
 
OSE and PSE samples were collected from six patients and experimental plates set 
up as described in Chapter 2.2.  Experimental plates were treated with control 
medium or IL-1α at 0.5ng/ml as previously described and total RNA extracted and 
DNaseI treated.  The remaining steps were undertaken with the assistance of Mrs 
Deborah Price and Dr Mick Rae.  Two μg RNA was reverse  transcribed using the 
manufacturer’s First Strand Kit (tebu-bio, Peterborough, UK) then mixed with PCR 
Mastermix and added to the wells of a customised PCR array plate (RT² Profiler 
PCR Arrays, tebu-bio, Peterborough, UK), where 48 genes of interest were chosen in 
advance (see table 4.3).  Quantitative RT-PCR analysis was undertaken and 
differences in gene expression examined.  Average Ct results from the gene of 
interest and housekeeping gene from each plate were combined and the relative 
expression calculated (using the formula (2 ^ (-ΔΔCt)).   Samples were run in 
quadruplicate to examine differences in basal gene expression between OSE and 
PSE, then attempts were made to examine the effect of IL-1 on gene expression in 
the six experiments.  One sample of PSE RNA was degraded and one plate was lost 
due to machine error. However the analysis was able to compare six samples of OSE 


















NM_002545 OPCML Opioid binding protein/cell adhesion molecule-like 2.39 3.43 2.85 
NM_000877 IL1R1 Interleukin 1 receptor, type I 1.32 -1.03 1.01 
NM_002982 CCL2 Chemokine (C-C motif) ligand 2, MCP-1 1.70 7.25 10.81 
NM_002317 LOX Lysyl oxidase 1.60 2.78 2.60 
NM_002593 PCOLCE Procollagen C-endopeptidase enhancer 3.01 -1.49 -1.67 
NM_005228 EGFR Epidermal growth factor receptor  -1.11 -1.15 1.03 
NM_173808 NEGR1 Neuronal growth regulator 1 1.61 1.18 1.51 
NM_004360 CDH1 Cadherin 1, type 1, E-cadherin -2.17 -7.92 -5.36 
NM_000125 ESR1 Estrogen receptor 1 1.07 1.04 1.78 
NM_000090 COL3A1 Collagen, type III, alpha 1  1.56 1.65 1.74 
NM_024690 MUC16 Mucin 16, cell surface associated -2.47 -1.70 1.16 
NM_000546 TP53 Tumor protein p53  1.12 -1.39 -1.31 
NM_002338 LSAMP Limbic system-associated membrane protein -1.17 -1.40 1.51 
NM_001792 CDH2 Cadherin 2, type 1, N-cadherin  1.77 1.45 1.37 
NM_001437 ESR2 Estrogen receptor 2 (ER beta) 1.38 2.97 1.66 
NM_001844 COL2A1 Collagen, type II, alpha 1  -1.06 1.10 -1.08 
NM_000351 STS Steroid sulfatase (microsomal) 1.11 1.04 1.33 
NM_000413 HSD17B1 Hydroxysteroid (17-beta) dehydrogenase 1 1.38 1.01 1.17 
NM_016522 HNT Neurotrimin 3.60 1.99 1.74 
NM_000589 IL4 Interleukin 4 -172812.14 -1.15 1.01 
NM_000926 PGR Progesterone receptor -1.02 -1.76 -1.79 
NM_005576 LOXL1 Lysyl oxidase-like 1 1.31 1.19 -1.08 
NM_000862 HSD3B1 Hydroxy-delta-5-steroid dehydrogenase 1.27 -3.33 -3.27 
NM_002456 MUC1 Mucin 1, cell surface associated 1.06 -1.15 -1.30 
NM_005525 HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 1.64 8.63 16.22 
NM_000600 IL6 Interleukin 6  1.70 45.12 95.30 
NM_000176 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 1.44 1.67 1.60 
NM_002318 LOXL2 Lysyl oxidase-like 2 3.26 1.59 -1.11 
NM_000198 HSD3B2 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 1.27 1.08 1.02 
NM_003739 AKR1C3 Aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) 2.30 1.00 -1.16 
NM_000196 HSD11B2 Hydroxysteroid (11-beta) dehydrogenase 2 1.12 1.27 -1.26 
NM_000584 IL8 Interleukin 8 4.05 89.61 142.88 
NM_000044 AR Androgen receptor  1.38 -2.37 -1.49 
NM_032603 LOXL3 Lysyl oxidase-like 3 -1.15 1.05 -1.15 
NM_000245 MET Met proto-oncogene (hepatocyte growth factor receptor) 1.68 -1.50 1.81 
X03205 18SrRNA Human 18S ribosomal RNA -29.25 -3.19 -2678.44 
NM_000963 PTGS2 Prostaglandin-endoperoxide synthase 2 ( cyclooxygenase-2) 6.20 9.36 18.66 
NM_000572 IL10 Interleukin 10 -1.80 -1.11 -1326.18 
NM_181446 FSHR Follicle stimulating hormone receptor -2.45 -7.42 -2.42 
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NM_032211 LOXL4 Lysyl oxidase-like 4 1.58 -1.19 -1.67 
NM_000601 HGF Hepatocyte growth factor (hepapoietin A; scatter factor) 8.58 -2.37 -1.67 
NM_001101 ACTB Actin, beta -1.00 -1.00 -1.00 
NM_000962 PTGS1 Prostaglandin-endoperoxide synthase 1 ( cyclooxygenase-1) 1.16 -1.72 1.03 
NM_000758 CSF2 Colony stimulating factor 2 (granulocyte-macrophage) 4.18 94.13 52.27 
NM_000233 LHCGR Luteinizing hormone/choriogonadotropin receptor -1.36 -2.46 -1.57 
NM_006129 BMP1 Bone morphogenetic protein 1 1.02 -1.12 -1.15 
NM_001963 EGF Epidermal growth factor (beta-urogastrone) -1.20 -2.22 -1.10 
 
 
Table 4.2.  Gene expression in OSE and PSE by PCR based microarray.  
Genes up-regulated by IL-1α (0.5ng/ml) are in red and down-regulated in 
blue. 
 
There appeared to be some differences in basal expression of some genes between 
OSE and PSE, specifically OPCML, PCOLCE, HNT, LOXL2, AKR1C3, IL8, 
COX2, HGF and CSF2 being higher in OSE and E-cadherin, MUC16 and FSHR 
being higher in PSE.  β-Actin was chosen as the reference house-keeping gene as its 
expression was more reproducible than the Ct values for 18s RNA.  Two of the 
samples gave no read out for 18s RNA, and the statistical software analysing the data 
gave a value of zero to these wells rather than ignoring the data; therefore it could 
not be used as a housekeeping gene with confidence.  This also occurred for IL4 
giving an apparent 172812-fold lower value in PSE.  The cause of these errors is 
unexplained but could have been related to the plate integrity or human pipetting 
error.  On treatment with IL-1α,  the genes that were up-regulated were the same for 
both cell types; OPCML, CCL2, LOX, ERβ, HSD11B1, IL8, COX2 and CSF2,  as 
were the down-regulated genes E-Cadherin, HSD3B2, AR, IL10, FSHR, HGF, 





This study introduces a novel method for the collection and culture of human 
peritoneal mesothelial cells.  The most commonly described method for primary 
culture of human mesothelial cells is by extraction of cells from samples of omentum 
(Pronk, A. et al. 1993; Robson, R.L. et al. 2001; Stylianou, E. et al. 1990).  This 
strategy carries the risk of including pre-adipocyte, adipocytes, stromal and 
inflammatory cells in the culture.  In addition the use of collagenase and digestive 
enzymes could prejudice the structural microenvironment of the mesothelium which 
is likely to play an important role in mesothelial cell physiology.  The advantage of 
the method described here is that it avoids enzymatic digestion and samples only the 
mesothelial layer, thus maximising the opportunity for pure mesothelial cell 
monolayers with minimal chance of contamination by non-mesothelial subtypes. 
 
An interesting and unexpected finding was the significant difference in “take-rate” 
between the PSE samples sampled from the anterior abdominal wall (A samples) and 
the serosal surface of the uterus (B samples).  Direct visualisation of the tissue 
culture flasks on the day of collection often revealed a clear difference in cellular 
content between the two types of culture.  The scant numbers of PSE flakes seen in 
the A samples is also reflected by the poor outcomes of cultures compared to the B 
samples (31% versus 58%).  It is not possible from these data to deduce why the 
numbers of cells were so much lower in the A samples compared to the B samples 
but this question deserves an answer.  As the technique to collect both types of cell 
was identical, the phenomenon could be explained by either a greater adherence of 
PSE to the underlying stroma or alternatively a greater number of cells being present 
on the uterine peritoneal surface.  This may suggest subtle differences in the 
peritoneum covering Mullerian or non-Mullerian structures or more simply be a 
difference in parietal versus visceral peritoneum.  One further possibility is that the 
mesothelial cell sub-population, as described by Mutsaers (Mutsaers, S.E. 2002) is 
differentially sited within the peritoneum with a higher density of more loosely 
applied columnar cells situated over the uterus and more densely adherent squamous 
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cells on the abdominal wall.  Yet a difference in cell populations also requires an 
explanation from a functional point of view.  The uterus occupies a central position 
within the pelvis and it must be allowed to increase in size when gravid.  A generous 
supply of mesothelial cells on its exterior would therefore minimise adhesions to 
bowel and other intra-peritoneal viscera therefore minimising complications as the 
uterus rises out of the pelvis in pregnancy.   
 
The considerable similarities between the PSE and OSE morphology are also 
reflected in the cellular response to inflammation.  The patterns of the 11βHSD1 
response to IL-1α in relation to both dose and time are identical to those previously 
reported for OSE (Rae, M.T. et al. 2004; Yong, P.Y. et al. 2002).  A multitude of 
cytokines could have been chosen to simulate inflammation but as previous work on 
the OSE had used IL-1α it would not have been logical to stray from its use in PSE, 
particularly as a direct comparison to OSE was being examined.   
 
Results from the time course of IL-1α action provide an insight into the 
chronological events seen at ovulation.  The rapid rise of COX-2 mRNA reaching a 
maximum level within 6 hours shows that the pro-inflammatory effects of IL-1α are 
the first to appear.  11βHSD1 mRNA levels do not peak until 48 hours following IL-
1α treatment indicating that the anti-inflammatory pathway shown in Chapter 1 
(figure 1.12) lags behind the pro-inflammatory pathway.  Thus in the ovary cortisol 
generation is likely to peak some 48 hours following the initial inflammatory 
stimulus, suggesting that inflammation is tolerated and even encouraged in the acute 
phase. 
 
One subtle difference between PSE and OSE is that cortisol alone was able to induce 
11βHSD1 mRNA in PSE which has not been previously reported for the OSE.  An 
explanation for this difference is difficult but the OSE studies described in Chapter 3 
do hint at this effect of cortisol in OSE also.  Rae’s paper from 2004 clearly states 
that cortisol alone had no effect on 11βHSD1 expression.  However the studies were 
performed some years apart with different reagents.  The presence of GRα in PSE 
means that this phenomenon is feasible, but further enquiry of GR signalling, 
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including receptor and second messenger inhibitor studies, is required to investigate 
this effect further.    
 
The other steroid examined in this study was progesterone given its previously 
reported anti-inflammatory and pro-apoptotic effects in the OSE (Rae, M.T. et al. 
2004; Rodriguez, G.C. et al. 2002; Syed, V. et al. 2003).  The concentration used in 
the experiments was 1μM, which is equivalent to that present in follicular fluid at the 
time of ovulation (Andersen, C.Y. 1991).  There was no effect on any of the genes 
studied of progesterone alone and although there is evidence of a trend progesterone 
did not conclusively affect 11βHSD1 expression.  The down-regulation of IL-1α 
induced COX-2 expression is in keeping with the anti-inflammatory effect of 
progesterone seen in the OSE.  However progesterone does not appear to be as potent 
an anti-inflammatory as cortisol at the same concentration.  The biological likelihood 
of progesterone acting on the PSE is enhanced by evidence of the progesterone 
receptor in these cells (figure 4.12).  This finding is important from several angles.  
Firstly, it is likely that the peritoneum has the potential to be influenced by the 
fluctuations in serum progesterone that occur with the menstrual cycle.  Secondly the 
presence of progesterone in follicular fluid may be another mechanism preventing 
adhesion formation after ovulation. Thirdly progesterone is implicated in 
endometriosis where progesterone resistance may be a feature (Burney, R.O. et al. 
2007) and where exogenous progesterone itself is one of the mainstays of treatment.   
 
A complicating factor of progesterone however is that it acts through one of two 
receptor isoforms designated PR-A or PR-B, the products of a single gene.  The 
isoforms are structurally identical except that the B form has an additional 164 amino 
acids at its NH2 terminus.  This makes immunohistochemical distinction difficult and 
it is not possible to state which isoform is being demonstrated in figure 4.12.  
Functionally, the additional region on PR-B encodes a transactivation function (AF3) 
specific to PR-B.  PR-A on the other hand, suppresses PR-B function.  In the 
presence of progesterone the isoforms dimerise and the relative ratios of PR-A and 
PR-B will determine the type of dimer formed (A: A, A:B, B:B) and thus influence 
the physiological response to P4.  This may explain Syed’s finding that P4 at low 
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concentrations stimulates OSE growth but causes inhibition of proliferation at higher 
doses (Syed, V. et al. 2001).  Several polymorphisms of the PR have been sequenced 
and one, +331A, appears to protect against the development of clear cell and 
endometrioid ovarian cancers (OR 0.46, CI 0.23-0.92)(Berchuck, A. et al. 2004): the 
subtypes associated with endometriosis (Brinton, L.A. et al. 1997; Ness, R.B. 2003). 
 
Although there is still debate as to whether endometriosis is the result of explantation 
of endometrial glandular tissue from reflux menstruation or true metaplasia of the 
mesothelium, both theories implicate the PSE in the development of the disease.   
There is also evidence from subfertile women with endometriosis that an upset in the 
biochemical environment of the pelvis alone may disturb the reproductive 
physiology through ovarian and tubal mechanisms.  There are several studies 
demonstrating increased levels of inflammatory cytokines in the peritoneal fluid of 
women with endometriosis including IL-1α (Odukoya, O.A. et al. 1997), IL-1β and 
TNFα (Taketani, Y. et al. 1992), IL-4 (Hsu, C.C. et al. 1997), IL-5 and IL-6 
(Koyama, N. et al. 1993), IL-8 (Ryan, I.P. et al. 1995), IL-10 (Ho, H.N. et al. 1997) 
and VEGF (McLaren, J. et al. 1996).  The interplay of these molecules with 
11βHSD1 in the PSE would be an interesting avenue of research.   
 
Several of these cytokines were specifically investigated using a PCR-based 
microarray to compare OSE and PSE.  The advantages of such a technique were that 
it used small amounts of RNA compared to standard genome microarray, that the 
results could be generated in a shorter space of time and the costs were lower.  The 
product also allowed comparison of cell responses across a large number of chosen 
genes that would have been prohibitive to examine individually using Taqman PCR 
because of cost, time and tissue resource.  The first set of data generated compared 
basal gene expression in unstimulated OSE and PSE samples.  These data suggested 
that there were some differences in gene expression between the two cell types.  As 
the OSE and PSE samples were paired, there would be little difference expected, yet 
the analysis showed some small fold differences.  Whether these differences are 
biologically important remains to be seen.  The results of the fold changes with IL-1α 
treatment are likely to be more relevant.  The array compared gene expression in 
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control and IL-1α-treated samples in PSE and OSE from the same patient.  The 
results demonstrate that eight genes are significantly up-regulated in both OSE and 
PSE, while one gene, ERβ, is significantly up-regulated in OSE with IL-1α treatment 
and in PSE is also up-regulated although to a lesser extent (1.66-fold).  There were 
four genes where the down-regulation was significant in both PSE and OSE and in 
the four other genes where the down-regulation occurred in OSE there was also a 
down-regulation in PSE.  In all cases the fold changes were in the same direction for 
OSE and PSE.  Another reason that suggests these data are biologically significant is 
that several have been reported in the literature before.  IL-1α is known to increase 
11βHSD1, COX2 (Rae, M.T. et al. 2004; Yong, P.Y. et al. 2002),   lysyl oxidase 
(LOX), IL-6, IL-8 (Rae, M.T. et al. 2004) in the OSE so validating the results seen in 
this study.  In studies of normal OSE and malignant epithelial cells CCL2 expression 
was induced and sustained by TNF-α  (Szlosarek, P.W. et al. 2006).  Its role involves 
recruitment of macrophages to sites of inflammation which is of clinical importance 
as described below. The modest rise in LOX in both OSE and PSE may suggest that 
these cells respond to inflammation by preparing to lay down collagen given LOX’s 
main function is to catalyse the cross-linking of elastin and collagen fibrils.  Modest 
collagen synthesis may be important in basement membrane synthesis but if it goes 
unchecked could result in adhesion formation.   
 
The finding of a down-regulation in E-Cadherin with IL-1 in both OSE and PSE is 
likely to be significant.  Sundfeldt et al. first noted a difference in E-Cadherin 
expression in the normal human ovary with reduced expression in the OSE but 
greater expression within ovarian cortical inclusion cysts (Sundfeldt, K. et al. 1997) 
suggesting that increased expression might be related to the oncogenic process.  This 
increase in E-Cadherin around inclusion cysts was confirmed by Maines-Bandiera et 
al (Maines-Bandiera, S.L. et al. 1997).  Furthermore both these papers suggest that 
E-cadherin expression is more associated with OSE metaplasia. Interestingly the 
addition of IL-1α down-regulated E-cadherin in this study whereas IL-1α would be 
anticipated to induce metaplasia and morphologically cause epithelio-mesenchymal 
transition.  Therefore there may be a difference in studying OSE in vitro or the 
location of the OSE may be more relevant in E-cadherin expression by interaction 
with other cell adhesion molecules.  It is known to play a role in determination of cell 
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polarity which is important in the single layer of the mesothelium.  E-cadherin has 
multiple functions other than the formation of tight junctions.  Although it lacks 
intrinsic enzymatic activity it is able to influence cellular behaviour by interacting 
with cell signalling molecules including tyrosine kinases and tyrosine phosphatases.  
Many of its actions arise through intermediary proteins, often β-catenin.  Its 
expression appears to be increased in many epithelial tumours, not least EOC 
although this is lost in poorly differentiated tumours  (Jeanes, A. et al. 2008).  So as 
suggested by these physiological studies the response to IL-1α in normal mesothelial 
cells is a down-regulation of E-cadherin.  As E-cadherin may act as a tumour 
suppressor and inhibit mitosis, the loss of its expression could allow cellular 
proliferation in the OSE/PSE and thus resolve the cell loss caused by inflammation.  
 
The down-regulation of 3βHSD1 by IL-1α was previously demonstrated by 
microarray and confirmed on RT-PCR in OSE by Rae et al. (Rae, M.T. et al. 2004).  
This was further explored in the OSE and evidence presented that IL-1α may be 
acting via the NFκB pathway (Papacleovoulou, G. et al. 2008).  As 3βHSD1 is 
involved in the metabolism of all classes of steroid precursors, its down-regulation 
could significantly reduce steroid production in the mesothelium.  The physiological 
advantage of this is not clear but could remove the growth inhibiting effects of 
progesterone and cortisol (Ivarsson, K. et al. 2001) and allow cell proliferation and 
repair to the mesothelial wound.  Intriguingly 3βHSD2 expression is unchanged by 
IL-1α.  The expression of progesterone receptor is unchanged following IL-1α 
treatment indicating mesothelial sensitivity to progesterone is likely to be unchanged.   
 
ERβ is up-regulated 3-fold in OSE (only 1.66-fold in PSE), while ERα expression is 
unchanged by IL-1α.  What is not revealed is the relative expression of these 
receptors in the mesothelium. While Hillier et al. have previously shown that both 
isoforms are present in OSE they were also unable to determine the relative 
abundances of the ER subtypes (Hillier, S.G. et al. 1998).   There is very little in the 
literature regarding ER expression in normal human mesothelial cells but one study 
examined fibroblasts from normal and adhesion associated peritoneal tissue and 
discovered that both ERα and ERβ mRNA expression was greater in the tissue 
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derived from adhesions (Detti, L. et al. 2008).  Lau et al. identified the ERα mRNA 
but not ERβ in a mesothelial cell line while examining differences in ER and PR 
expression between OSE and EOC (Lau, K.M. et al. 1999).  
 
These data demonstrate for the first time that the PSE - like the OSE - is able to 
respond to inflammation by regenerating local cortisol by up-regulation of 
11βHSD1.  The pattern of 11βHSD1 response in both cell types is similar in dose, 
time, and exaggerated effect with cortisol.  However the enzymic activity of 
11βHSD1 in the PSE is considerably less than that of the OSE, which has important 
consequences.  In most epithelial tissues inflammation leads to influx of 
inflammatory cells including monocyte/macrophages and fibroblasts which mediate 
tissue remodelling and laying down of scar tissue.  In the peritoneum this can lead to 
the formation of intra-abdominal adhesions which under some conditions carry 
significant risks.  However an idiosyncrasy of the ovary is its ability to heal without a 
scar and this could be explained by its relatively potent ability to regenerate local 
cortisol via up-regulation of 11βHSD1 which would be expected to inhibit local 
inflammatory cytokine and eicosanoid synthesis, thus minimising attraction of 
inflammatory cells and subsequent scar tissue formation.  In contrast, while the PSE 
is able to up-regulate 11βHSD1 in response to inflammation, its ability to regenerate 
cortisol is rather more feeble, hence the brake on inflammatory cell infiltration is 
weaker and scar tissue (adhesions) more likely to result.  The difference in 11βHSD1 
enzyme activity between OSE and PSE was not replicated by relative levels of 
mRNA.  However as shown in figure 4.13, there is a trend towards higher levels in 
the OSE and use of more samples may have allowed statistical significance to be 
reached.  As 11βHSD2 expression is expressed at such low levels in the PSE and 
OSE, in addition to the fact that its levels are unchanged by any of the agents used in 
this study, any alteration in glucocorticoid shuttling is most likely to be due to swings 
in 11βHSD1 expression.  Thus although there are no changes in the type 2 enzyme it 
was nevertheless important to demonstrate its expression in this set of experiments.  
The model for prevention of scar tissue formation in the ovary is realistic as it has 
been clearly demonstrated that OSE cells are able to convert cortisone to cortisol and 
that the rate of conversion is increased by IL-1α.  However it is not clear what 
cellular component the glucocorticoid may be acting on.  Candidates include the 
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monocyte/macrophage fraction, fibroblasts and the mesothelial cells themselves.  
Bachus et al have provided evidence that proliferation of fibroblasts is inhibited by 
co-culture with macrophages which was overcome by administration of 
hydrocortisone (cortisol).  Mesothelial cells however had increased proliferation 
rates in the presence of macrophages and this was not affected by hydrocortisone or 
IL-1 (Bachus, K.E. et al. 1995).  Translation of this into the human peritoneum 
would suggest that fibroblast activation is held in check by a balance of macrophage 
and peritoneal cell populations.  Indeed macrophages appear to have an important 
role in the prevention of adhesions.  Adhesions were more common following 
chemical peritonitis in a macrophage Fas-induced apoptosis (Mafia) transgenic 
mouse model, in which macrophages are depleted, compared to the wild type 
(Burnett, S.H. et al. 2006).  It may be that macrophages prevent adhesions by 
increasing ingestion of apoptotic neutrophils facilitating resolution of inflammation 
(Liu, Y. et al. 1999).  In the mouse where 11-dehydrocorticosterone is converted to 
the active glucocorticoid corticosterone by 11βHSD1, mice deficient for the enzyme 
take longer to resolve an episode of acute inflammation (Gilmour, J.S. et al. 2006).   
 
It is likely that macrophages have an important role in the inflammatory events at 
ovulation.  These functions include secretion of proteolytic enzymes and 
phagocytosis of apoptotic cells but they may promote follicle development and 
atresia (Wu, R. et al. 2004).  Macrophage numbers correspond with the menstrual 
cycle and inhibition of macrophage function by clodidronate reduces ovulation rate 
(Van der Hoek, K.H. et al. 2000).  One reason that the ovary does not frequently 
produce adhesions with the pelvic peritoneum may be because the resolution of 
inflammation originates from the interior of the ovary and by the time ovulation 
occurs the anti-inflammatory cells and mechanisms have been primed allowing swift 
resolution and minimal scar tissue deposition.    
 
In their mildest form peritoneal adhesions may have no clinical importance however 
in the female adhesion formation from whatever cause, be it infection, surgery or 
endometriosis, is associated with infertility.  More extensive adhesions carry more 
serious and potentially life-threatening sequelae for example bowel obstruction.  
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Therefore in responding to an intra-abdominal inflammatory insult it is important 
that an organism responds to that insult appropriately allowing resolution of the 
inflammatory process but without over-reacting and creating potentially harmful 
peritoneal adhesions.   
 
The discovery of dissimilar mesothelial cells in distinct areas of the peritoneum then 
broaches the prospect that it is the underlying tissue than influences mesothelial 
phenotype.  Evidence for this concept is provided in this study by differential 
11βHSD1 enzyme activities in OSE and PSE.  What is not clear is whether the 
mesothelial cell arises from a single progenitor cell then differentiates once attached 
to the visceral surface or whether there are separate progenitor cell types for different 
organs.  Evidence for the former is supplied by Foley-Comer et al and has been 
discussed in Chapter 1 (Foley-Comer, A.J. et al. 2002) . The possibility that a defect 
in the ovarian surface could be filled by a mesothelial progenitor cell which then 
differentiates into the OSE phenotype (which is not so different from PSE) is highly 
appealing and describes an efficient and rapid mechanism for healing in a tissue 
where scar formation is often unhelpful and harmful.  The isolation and 
characterisation of the mesothelial stem cell could have important clinical 
implications.   Given that absence of mesothelial cells leads to adhesion formation, it 
is conceivable that administration of mesothelial cells, as an autologous transplant 
could be a pragmatic method for prevention of post-surgical adhesions and treatment 
of endometriosis and even ovarian cancer.   
 
While the OSE is widely held as the source of epithelial ovarian cancer (EOC) the 
reaction of the peritoneum to the disease is likely to play an important role in its 
trans-coelomic spread.  Mesothelial cells have been shown to be able to inhibit 
attachment of ovarian cancer cells to cell matrices (Kenny, H.A. et al. 2007) 
suggesting that autologous mesothelial cell transplants could also help prevent 
metastasis. Furthermore the striking similarities between EOC and primary 
peritoneal cancer (PPC) make it likely that they have a common cell of origin.  It has 
been estimated that 10% of EOCs could be classified as PPC (Chu, C.S. et al. 1999) 
– though whether this matters clinically is contentious as both conditions are 
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managed similarly with surgery and the same chemotherapeutic regimens.  Like 
EOC, BRCA1 and BRCA2 mutations increase the risk of developing the disease and 
PPC can still occur in women who have undergone prophylactic surgery.  If these 
women had had their ovaries in situ would the disease have been called EOC 
instead? 
 
In conclusion, this novel method of culturing human peritoneal surface epithelium 
has demonstrated that these cells closely resemble the cells covering the surface of 
the ovary morphologically and in their response to inflammation.  In addition both 
cell types are receptive to progesterone which appears to act as an anti-inflammatory 
agent.  However one major difference is the enhanced ability of the OSE to 
regenerate cortisol via up-regulation of 11βHSD1 which may explain the ovary’s 
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5 IgLON Expression in Primary Cultures of Human 
Ovarian Surface Epithelium 
5.1 Introduction 
In any epithelial tissue cellular proliferation is a tightly regulated process.  An excess 
of cellular material could impair tissue function while a shortage leaves the 
underlying stroma exposed and initiation of fibrosis and scarring could occur.  Tissue 
homeostasis is dependent on signals informing progenitor cells when to divide and 
when to remain in a non-proliferative state.  While there are multiple signals, many 
of these are transduced by the switching on and off of tumours suppressor genes 
(TSGs) and oncogenes.  When a TSG is permanently switched off or an oncogene 
permanently activated, uncontrolled cellular division may result leading to tumour 
formation.  One such TSG linked to ovarian cancer is opioid binding cell adhesion 
molecule-like (OPCML or OBCAM), introduced in Chapter 1 (Section 1.7.4.2).   
 
OPCML is one of a family of four proteins which appear to have similar roles as 
immunoglobulin domain containing GPI-anchored cell adhesion molecules.  The 
other molecules include limbic system associated membrane protein (LSAMP) and 
neuronal growth regulator-1 (NEGR1/Kilon), and neurotrimin (HNT).  Little is 
known about the expression of these molecules outwith the central nervous system, 
but here they appear to form hetero- and homomeric dimers and play an important 
role in neuronal growth and development (Gil, O.D. et al. 2002; Lodge, A.P. et al. 
2000; McNamee, C.J. et al. 2002; Miyata, S. et al. 2003; Reed, J. et al. 2004).   
 
Evidence for OPCML’s role in ovarian cancer arises from studies showing loss of 
heterozygosity (LOH) in EOC at 11q25 (Sellar, G.C. et al. 2003).  On further 
investigation the defining marker D11S4085 was found to lie within the second 
intron of the gene for OPCML.  Furthermore transfection of OPCML DNA into an 
ovarian cancer cell line that did not endogenously express OPCML demonstrated 
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tumour suppressor activity in both in vitro and mouse in vivo models.  In addition the 
majority of EOC tumours were found to have undergone epigenetic inactivation of 
OPCML and the discovery of only one OPCML mutation in over 200 tumours 
suggested that OPCML CpG island methylation, rather than gene mutation, was the 
most likely cause of malignant transformation.  Thus OPCML acquired the label of a 
“new-age” TSG that includes CpG island methylation as a recognised method of 
gene inactivation; an updated definition of Knudson’s two-hit hypothesis.  Having 
established this role for OPCML in malignant tissue it was important to then uncover 
its pattern of expression in normal tissue and in particular the ovarian surface 
epithelium, given its role as likely source of EOC.  Interestingly Sellar et al chose 
whole ovary rather than OSE for quantitative RT-PCR analysis so the contribution of 
the OSE to these samples is likely to have been minimal given that the predominant 
tissue in whole ovary is stroma.  Also their RT-PCR analysis included samples which 
had the OSE dissected from the ovary at surgery.  Given that the OSE is only one 
cell thick it is not possible to dissect this layer off at surgery even with the aid of a 
microscope and it is highly likely that their samples would have consisted of mainly 
stromal cells.  Thus once again the need to assess OPCML expression in pure OSE 
becomes clear.  There is a paucity of data looking at hormone response elements in 
the IgLONs. However by examining the promoter sequences of each of the genes, 












Figure 5.1  Predicted transcription factor binding sites for the IgLON 
promoter sequences (www.genecards.com).   
Evidence has been presented in Chapter 1 suggesting a link between inflammatory 
damage of the OSE and development of EOC.  Ovulation dramatically disrupts the 
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OSE at ovulation but the exact sequence of events at the OSE has never been 
definitively described, in particular how the OSE is reconstituted following wound 
formation. The author hypothesised that inflammation causes a down-regulation of 
the OPCML tumour suppressor gene, allowing proliferation of OSE surrounding the 
damaged area of the ovary and subsequent repair.  Having developed expertise in 
collection and culture of OSE the aim of this study was to establish whether OPCML 
was expressed in OSE, whether inflammation affected its expression and whether 
expression of other members of the IgLON family altered in tandem.   
 
In order to test this hypothesis, samples of OSE were collected from premenopausal 
women undergoing surgery for benign gynaecological conditions and cultured in 
vitro.  In order to recreate the inflammatory stimulus associated with inflammation 
IL-1α was used to treat the cells.  IL-1α is closely linked to inflammation in the 
ovary (Gerard, N. et al. 2004)  and its production is stimulated in the mouse by the 
luteinising hormone surge or HCG injection (Simon, C. et al. 1994).  IL-1α initiates a 
pro-inflammatory cascade including cyclo-oxygenase (COX2) production, matrix 
metalloproteinase (MMP) activity and Nitric Oxide (NO) synthesis and as such is an 
ideal agent for mimicking ovulation in vitro.  The effects of IL-1 can be abrogated by 
the potent anti-inflammatory steroid cortisol and OSE was also treated with this 
agent to identify whether OPCML and IgLON expression was controlled by pro- and 





5.2.1 OSE Collection and Culture 
Samples were collected as described in Chapter 2.  Relevant clinical details for 





Table 5.1  Relevant clinical details for patients donating OSE. TAH = 
total abdominal hysterectomy, BSO = bilateral salpingo-oophorectomy, 














































































































































































































































































































































































































































































5.2.2 Cell Experiment & RNA Extraction 
Methods were as described in Chapter 2. 
 
5.3 Results 
5.3.1 Comparison of OPCML mRNA detection by  Light Cycler and 
Taqman RT-PCR  
5.3.1.1 Rotorgene Light Cycler 
Analysis of the data from the light cycler was hampered by the low levels of OPCML 
message in the samples.  On plotting the CT fluorescence signal versus quantification 
as compared to a standardised RNA sample, the OSE sample data lay outside the 
standard curve, beyond the lowest concentration (figure 5.1). This meant that RNA 









Figure 5.2   Light cycler RNA standard curve demonstrating CT standard 
samples (blue) and OSE samples (red). 
 
Whilst these CT values lay outside the standard curve analysis of the melt curve for 
the DNA strands revealed identical features to the melt curve of the standards 
suggesting that the DNA products were due to the presence of the OPCML transcript 







Figure 5.3  Melt curve analysis of OPCML PCR products following 
quantitative RT-PCR.  Samples shown include RNA standard 
(uppermost curve) and six OSE samples. The bottom curve represents 




However if the CT values are extrapolated from the straight line obtained from 
plotting the RNA standards the results generated are shown in figure 5.3.  Analysis 
of these data demonstrate a significant increase in OPCML mRNA expression with 
IL-1α at 0.5ng/ml for 48h (P<0.01) compared to untreated cells, however there is no 
significant difference between IL-1α treatment and IL-1α in the presence of 
progesterone (at 1μM).  In contrast there is a significant difference in OPCML 
mRNA expression between IL-1α treated cells and IL-1α in the presence of cortisol 
(also at 1μM) (P<0.01).   
 
Figure 5.4  OPCML mRNA expression in OSE (n=3) using the Rotorgene 
light cycler in OSE cells treated with progesterone (P4), cortisol (F) (at 
1μM) and interleukin-1α (IL-1, 0.5ng/ml). 




Taqman RT-PCR analysis of OPCML mRNA expression using an assay-on-demand 
primer/probe assay mix gave quantifiable CT values suggesting up-regulation of 
OPCML expression in OSE with IL-1α (see figure 5.4).   
 
Figure 5.5  OPCML mRNA Expression in OSE using Taqman 
quantitative RT-PCR (n=3).  Treatments include progesterone (P4), 
cortisol (F) (both 1μM) and interleukin-1α (IL-1) (0.5ng/ml for 48h). 
 
Treatment with IL-1α caused a mean 4-fold up-regulation of OPCML expression in 
these OSE cell samples (figure 5.4).  Treatment effects failed to reach statistical 
significance.   
 
5.3.2 OPCML mRNA expression in human OSE 
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Having demonstrated that quantification of OPCML mRNA in OSE was more easily 
quantified with Taqman assay this became the method of choice for the remainder of 
the study. 
 
5.3.2.1 Effect of time on OPCML mRNA expression induced by IL-1α 
 
Four separate time course experiments were set up to investigate the profile of IL-1α 
induced OPCML expression over time (figure 5.5).  Data were analysed by paired t-



























Figure 5.6  Mean fold change in OPCML mRNA expression (compared 
to same time point control) in IL-1α treated OSE cells (0.5ng/ml) from 4 
separate individuals, as a function of length of IL-1α treatment.  Error 




The fold change in OPCML mRNA expression did not begin to rise until 24 hours 
incubation of IL-1α (2.4-fold), although this did not reach statistical significance.  
OPCML mRNA expression was significantly higher in IL-1α-treated cells at 48 
hours (2.0-fold, P<0.01). 
 



















































Figure 5.7  Dose response effect of IL-1α on OPCML mRNA expression 
by quantitative RT-PCR (n=8).  Data were analysed using repeated 
measures ANOVA. Bars represent Mean / SEM.   Asterisks indicate 




OPCML mRNA expression was significantly increased by each of the doses of IL-1α 
used, reaching a maximum fold induction of 3.1 with 0.5ng/ml.  There was no 
significant difference in OPCML expression between the IL-1α treatments. 
 
5.3.2.3 Cortisol Dose Response 
 
The effect of cortisol on IL-1α induced OPCML expression was investigated using 
ten-fold changes in cortisol concentration (figure 5.7) in OSE cells from five 
different patients.  IL-1α (at 0.5ng/ml for 48h) significantly increased the quantity of 
OPCML mRNA in the absence of cortisol (7.3-fold, P<0.001).  OPCML mRNA 





















































Figure 5.8  Effect of cortisol (F) in the presence and absence of IL-1α on 
OPCML mRNA expression by quantitative RT-PCR in OSE cells from 
five different patients.  Points represent mean fold induction and error 
bars indicate SEM.   
 
5.3.2.4 Interleukin-1α up-regulates OPCML mRNA expression 
 
The next questions to be answered were whether there was any effect of 
inflammation using interleukin-1α (IL-1α) on OPCML expression, and whether 
cortisol had any opposing effect, as would be hypothesised by its anti-inflammatory 
nature.   
 
Samples from seven different patients were used in experiments to assess the effects 
of cortisol and interleukin-1α on OSE cells.  The results demonstrate a significant up-
regulation of OPCML following treatment with IL-1α (4.7-fold, P<0.01) and a 
significant reduction in OPCML expression in IL-1α treated cells in the presence of 











































Figure 5.9 OPCML mRNA expression by Taqman quantitative RT-PCR 
(n=7).  Treatments included cortisol (F) (1μM) and interleukin-1α (IL-1) 
(0.5ng/ml).  Different superscripts indicate significant differences due to 
treatment. 
 
5.3.2.5 Cortisol, but not progesterone, abrogates IL-1α induced OPCML 
expression 
 
Given the previously demonstrated anti-inflammatory effect of progesterone on 
cyclo-oxygenase expression in OSE cells (Rae, M.T. et al. 2004), experiments using 
OSE from a further nine separate patients were undertaken to compare the effects of 
cortisol and progesterone on IL-1α-induced OPCML expression (figure 5.9).  The 
results demonstrate that neither cortisol nor progesterone have any effect on OPCML 
mRNA expression alone.  There is a significant increase in OPCML expression with 
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addition of IL-1α (at0.5ng/ml for 48h) (3.8-fold, P<0.01).  Compared to IL-1α alone, 
OPCML mRNA expression is significantly lower in IL-1α plus 1μM cortisol treated 















































Figure 5.10  OPCML mRNA expression by Taqman quantitative RT-PCR 
(n=9).  Bars represent Mean/SEM.  Differing superscripts indicate 
significant differences due to treatment. 
 
5.3.2.6 A Comparative study of OPCML mRNA expression in EOC, OSE 
and PSE. 
 
Control RNA samples from thirteen EOC, three OSE and four PSE cell cultures were 
analysed on the same Taqman plate in duplicate.  RNA quantity was expressed 
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relative to a standard quantity of Fallopian tube RNA (discovered to contain high 
levels of OPCML mRNA).  The relative quantities are shown in figure 5.10.  As 
OPCML level was not normally distributed, non-parametric statistical testing was 
























































































Figure 5.11  OPCML mRNA expression in EOC , OSE (open) and PSE 
(hatched).  EOC sample number refers to table 3.1, A indicates ascites, 
T primary tumour and M metastatic tumour sources of cell culture. 
 
There was no statistical difference in OPCML mRNA expression between the cell 



































Figure 5.12 OPCML mRNA expression in EOC (squares; n=13), OSE 
(triangles; n=3) and PSE (inverted triangles; n=4).  Horizontal bars 
represent median values. 
 
5.3.3 OPCML Protein expression in human OSE 
 
Western blotting, using protein lysates of cultured OSE, was used to assess presence 
of OPCML in normal human OSE (figure 5.12).  Despite several attempts, no band 
was seen corresponding to OPCML in the OSE samples, yet the positive control 
sample of an OPCML over-expressing SKOV-3 cell line BKS2.1 confirmed antibody 
binding at correct molecular weight corresponding to OPCML.  Subsequent staining 





Figure 5.13 Western blot of OPCML and β-actin expression in human 
OSE by. SKNV3.3 cells were used as a negative control and the SKOV-3 




5.3.4 IgLON mRNA expression in human OSE 
 
Previous studies have suggested correlations between expression of OPCML and the 
other IgLON proteins.  In order to examine whether such a relationship existed 
Taqman quantitative RT-PCR was used to analyze mRNA expression of other 






5.3.4.1.1 IL-1α Effects on NEGR1 expression 
OSE samples from four separate patients were analysed to investigate the effect of 
five-fold increments in IL-1α dose on NEGR1 expression.  While there was a 
statistically significant increase in NEGR1 mRNA expression observed at each IL-1α 
concentration (1.6, 1.8 and 1.6-fold for 0.02, 0.1 and 0.5ng/ml respectively, figure 















































Figure 5.14  Histogram showing the effect of IL-1α (over 48h) on NEGR1 
mRNA expression by quantitative RT-PCR (n=4).  Bars represent Mean / 





5.3.4.1.2 Effect of time on NEGR1 expression 
 
To investigate whether IL-1α might have an effect on NEGR1 mRNA expression at 
time point other than 48hours, Taqman quantitative RT-PCR was used to analyse 
OSE samples from four different patients after 6, 12, 24 and 48 hour exposures to IL-
1α.  The only significant effect of IL-1α over untreated control occurred at 12 hours 


























Figure 5.15  Fold change in NEGR1 mRNA expression compared to 
untreated control after different lengths of exposure to IL-1α 





5.3.4.1.3 IL-1α in the presence of cortisol down-regulates NEGR1 mRNA 
expression 
 
Taqman quantitative RT-PCR was used to investigate NEGR1 expression in OSE 
from six separate patients treated with cortisol, IL-1α and both together (figure 5.15).  
Cortisol treatment alone caused a small but significant rise in NEGR1 expression 
(1.3-fold, P<0.05) but IL-1α alone caused a similar size of mean rise in NEGR1 
mRNA that failed to reach statistical significance (1.3-fold, P>0.05).  The 
combination of IL-1α and cortisol however caused a significant down-regulation of 


















































Figure 5.16 Histogram of NEGR1 mRNA expression in OSE (n=6) treated 
with cortisol (F) (1μM) and interleukin-1α (IL-1) (0.5ng/ml) over 48h.  




5.3.4.1.4 Progesterone does not significantly influence NEGR1 mRNA 
expression 
 
A comparison of the effects of cortisol and progesterone was undertaken using OSE 
samples from five separate patients (figure 5.16).  Neither cortisol nor progesterone 
had any significant effect on NEGR1 mRNA expression, nor did IL-1α alone.  In the 
presence of IL-1α, progesterone had no significant effect but cortisol caused a 













































Figure 5.17  Histogram of NEGR1 mRNA expression in OSE (n=5) 
treated with cortisol (F) (1μM), progesterone (P4) (1μM) and interleukin-
1α (IL-1) (0.5ng/ml, over 48h). Asterisk indicates significant difference 




5.3.4.1.5 NEGR1 Cortisol Dose Response 
 
Experimental culture media with ten-fold differences in cortisol concentration were 
used to investigate the effect on NEGR1 mRNA expression (figure 5.17).  
Experimental data were obtained from two experiments therefore statistical analysis 
could not be undertaken.  However in the absence of cortisol, mean NEGR1 
expression was increased by IL-1α (to 1.6-fold).  On addition of cortisol there was a 
down regulation of NEGR1 expression when concentrations of 10-7M and 10-6M 

















































Figure 5.18  Effect of increasing cortisol concentration on NEGR1 




5.3.4.2  LSAMP 
 
5.3.4.2.1 LSAMP levels are unchanged by IL-1α 
 
LSAMP mRNA levels are static in OSE cells when challenged by increasing doses 
































































































Figure 5.19  LSAMP mRNA expression in OSE cells with increasing 
concentration of IL-1α (ng/ml)(n=8) (upper figure) and with IL-1α at 
0.5ng/ml at different time points (n=5)(lower figure). 
5.3.4.2.2 In the presence of cortisol, IL-1α down-regulates LSAMP 
 
While neither cortisol nor IL-1α have any independent effect on LSAMP mRNA 
expression they appear to act together and significantly down-regulate LSAMP (0.25 
compared to untreated control, p<0.001, n=7).  In contrast progesterone does not 
have significant effect on LSAMP on its own or in combination with IL-1α (n=5) 































































































Figure 5.20  Histograms showing LSAMP mRNA expression after 
treatment with progesterone (P4), cortisol (F) and Interleukin-1α (IL-1α).  
Bars represent mean / SEM.  Asterisks indicate significant differences 
due to treatment (**= P<0.01, ***=P<0.001). 
5.3.4.2.3 Dose dependent effects of cortisol on LSAMP mRNA expression 
 
While the mean fold change in LSAMP with cortisol was lower than the untreated 
control values this did not reach statistical significance (figure 5.20).  However 
paired t-tests indicated that cortisol at 1μM in the presence of IL-1α significantly 




























Figure 5.21  LSAMP mRNA expression in OSE cells (n=5) with ten-fold 
changes of cortisol (F) concentration, in the presence and absence of 
IL-1α (0.5ng/ml, over 48h).  Points indicate mean expression compared 




5.3.4.3 Neurotrimin (HNT) 
5.3.4.3.1 IL-1α up-regulates HNT – an effect obliterated by cortisol 
Seven separate OSE samples were analysed to assess the effect of cortisol and IL-1α 
on HNT expression.  Cortisol and IL-1α were both found to up-regulate HNT mRNA 
expression (1.4 fold, P<0.01 and 3.3-fold, P<0.05, respectively).  HNT mRNA 
expression following treatment with the combination of cortisol and IL-1α was not 

















































Figure 5.22  HNT mRNA expression in OSE treated with cortisol (F), IL-
1α or both F and IL-1α over 48h(n=7).  Bars represent mean/SEM.  





5.3.4.3.2 Absence of Progesterone effect on IL-1α induced HNT expression 
Analysis of OSE samples from four experiments revealed a non-significant increase 
in HNT mRNA expression following IL-1α treatment (4.1 mean fold change).  
Although no treatment achieved a statistically significant effect, IL-1α induced HNT 












































Figure 5.23  HNT mRNA expression in OSE cells (n=4) following 
treatment with progesterone (P4) (1μM), cortisol (F) (1μm), IL-1α 
(0.5ng/ml) or in combination over 48h.  Bars represent mean/SEM.    
5.3.4.3.3 Absence of IL-1α Dose Response Effect 
Analysis of three OSE specimens where the concentration of IL-1α had been 
escalated in a five-fold manner did not demonstrate any significant corresponding 






























Figure 5.24 HNT mRNA expression with increasing concentration of IL-
1α at 48h(n=3).  Bars represent mean/SEM.   
 
5.3.4.3.4 Cortisol Dose Response 
Taqman quantitative RT-PCR analysis was used to define HNT mRNA expression in 
two separate OSE experiments where there was a ten-fold difference in cortisol 
concentrations.  In the absence of cortisol but presence of IL-1α, the HNT mRNA 
level was nearly three times that of the control sample.  However even at low cortisol 
















































Figure 5.25  HNT mRNA expression in the presence and absence of IL-
1α (0.5ng/ml) after 48h with increasing cortisol concentration (µM) 
(n=2).  Closed squares indicate HNT expression with IL-1α absent and 
open squares with IL-1α present. 
 
5.3.4.3.5 Time course of IL-1α treatment on HNT expression 
Quantitative RT-PCR analysis of four separate OSE experiments did not show any 
significant difference in HNT expression with IL-1α treatment (0.5ng/ml) over time 


























Figure 5.26  HNT mRNA expression following IL-1α treatment relative to 
same time point control in OSE (n=4).  Bars indicate SEM. 
 
5.3.4.4 Cyclo-oxygenase 2 mRNA expression 
The OSE samples were used to determine COX2 mRNA expression also.  As COX2 
mRNA expression data in OSE have been previously published in the literature and 
its behaviour more predictable, it is a good candidate for reflecting the inflammatory 
status in this tissue, with high COX2 indicating an inflammatory response. 
5.3.4.4.1 Dose dependent effect of IL-1α  
Data were obtained from two experiments confirming a dose dependent effect of IL-













































Figure 5.27  Dose dependent effect of IL-1α on COX2 mRNA expression 
(n=2).  Bars represent mean. 
 
5.3.4.4.2 Cortisol Inhibits IL-1α induction of COX2 mRNA in normal human 
OSE 
 
In five separate experiments OSE cells were treated with IL-1α (0.5ng/ml), cortisol 
(1μM) and a combination of both (figure 5.27).  IL-1α alone caused a significant up-
regulation of COX2 mRNA expression (mean 45.2-fold, P<0.001).  COX2 mRNA 
expression after treatment with cortisol and IL-1α together was not significantly 
















































Figure 5.28   COX2 mRNA expression in OSE cells (n=5) after treatment 
with cortisol (F)(1μM), IL-1α (0.5ng/ml) and in combination over 48h.  
Bars represent mean/SEM.  Asterisks indicate significant difference due 
to treatment (***=P<0.001). 
 
5.3.4.4.3 Progesterone does not show any anti-inflammatory effect in OSE 
 
In a further five different experiments, OSE cells were treated with progesterone 
(1μM), cortisol (1μM), IL-1α (0.5ng/ml) or a combination of IL-1α plus steroid 
(figure 5.28).  These data demonstrated that steroid alone had no effect on COX2 
mRNA expression.  However IL-1α caused a significant up-regulation of COX2 
mRNA expression (mean 14.4-fold induction, P<0.01).  The presence of cortisol (2.1 
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mean fold change over untreated control) but not progesterone (mean fold change 
















































Figure 5.29  COX2 mRNA expression in OSE cells (n=5) following 
treatment with progesterone (P4) (1μM), cortisol (F) (1μm) and IL-1α 
(0.5ng/ml).  Bars represent mean/SEM.  Dissimilar superscripts indicate 
significant difference due to treatment.   
  
Data from two separate experiments indicate that COX2 mRNA rises from 6 hours 
following treatment (mean fold induction 5.5) and remains persistently elevated for 
48 hours (mean fold induction 6.9) (figure 5.29).   
























































Scientific advances in ovarian cancer research have not yielded significant 
improvements in clinical outcomes and the disease is still associated with a poor 
prognosis for most patients.  Thus identification of novel genes that could influence 
EOC development is often accompanied by much enthusiasm, optimism and 
expectation.  The discovery of OPCML as a potential tumour suppressor gene for 
epithelial ovarian cancer in 2003 was no different with national and international 
scientific and lay press interest.  While Sellar’s paper identified epigenetic 
inactivation of OPCML as a mechanism for development of ovarian pathology 
(Sellar, G.C. et al. 2003), there are no publications highlighting a role for OPCML in 
normal ovarian physiology.  Indeed, until 2003 there was no evidence for a role for 
OPCML outside the nervous system.  The data presented in this chapter are the first 
to evaluate OPCML’s role in the normal human ovarian surface epithelium. 
 
Using previously described methods for OSE culture and collection (Hillier, S.G. et 
al. 1998; Rae, M.T. et al. 2004; Rae, M.T. et al. 2004; Yong, P.Y. et al. 2002), 
experiments were initiated where the effects of inflammation on OPCML and IgLON 
expression could be studied.  While it is likely that during ovulation the OSE is 
exposed to a variety of inflammatory mediators, in these experiments IL-1α alone 
was used.  The rationale for this was firstly to minimise the number of variables in 
any experiment.  Secondly, IL-1 is likely to have a dominant role in ovulation 
induced inflammation; IL-1 activity has been identified in human follicular fluid 
(Barak, V. et al. 1992) and influences key components of the inflammatory cascade 
including prostaglandin, nitric oxide and steroid hormone production as reviewed by 
Gerard  (Gerard, N. et al. 2004).  Thirdly there was extensive local experience of IL-





Initially work was carried out in two separate laboratories.  OSE cell culture 
experiments were undertaken in the laboratory of Professor Hillier, Centre for 
Reproductive Biology, university of Edinburgh.  The RNA from these experiments 
was extracted, quantified and quality assessed then transferred to the University of 
Edinburgh Cancer Research Centre where RNA quantities were assessed using 
Rotorgene light-cycler quantitative RT-PCR technology.  As highlighted in 5.3.1.1 
this system was unable to provide meaningful values for OPCML mRNA due to the 
low quantities of this messenger RNA in the sample, with OPCML signal only 
appearing late in the reaction and almost always after the most dilute standard.  
Attempts were made to improve detection of OPCML in OSE samples by increasing 
the number of cycles, increasing the extension time in the PCR reaction, doubling the 
quantity of RNA used per reaction to 20ng/μl and finally using a sixth and seventh 
RNA standard.  None of these alterations had a significant impact on the ability to 
detect OPCML in these specimens and drawing the conclusion that OPCML mRNA 
levels in cultured human OSE was nearly undetectable using this technique.  Because 
the primers and RNA standards were being used extensively in cell line work from 
the same laboratory group that first published data on OPCML in ovarian cancer it 
was likely that OPCML RNA levels were extremely low in normal OSE, rather than 
there being an inability to quantify the RNA.  Indeed melt curve analysis of the DNA 
products from OSE samples demonstrated an identical profile to the OPCML 
standard (figure 5.2), suggesting that the signal that was obtained was a true 
representation of OPCML DNA and not due to primer dimer formation. It could be 
argued that cultured OSE was not a true representation of OSE in vivo but the time 
spent in culture was relatively short (certainly compared to cell lines) and other 
mRNAs are not lost following culture (e.g. 11βHSD1).   
 
The mechanism of fluorescence in the Rotorgene light-cycler is via SYBR green dye 
which selectively binds double stranded DNA(dsDNA) (Zipper, H. et al. 2004).  An 
alternative method of RNA/DNA quantification is Taqman quantitative RT-PCR 
(Applied Biosystems).  Here fluorescence remains the method of DNA quantification 
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but rather than indiscriminate binding of dye to dsDNA, fluorescent “reporter” dye is 
released from a “quencher” when DNA polymerisation occurs at the site of the probe 
for the gene of interest.  Thus specific probe binding is required before a fluorescent 
signal can be generated.  This enabled detection of OPCML at a level that could be 
quantified and as the primer/probe assay was commercially generated quality control 
was guaranteed.  Hence the Taqman assay being the preferred method of RNA 
quantification in this study.   
The discovery of a rise in OPCML mRNA in response to IL-1α was contrary to the 
initial hypothesis.  It was predicted that in order for OSE cells to recover from the 
inflammatory damage caused by ovulation, the OPCML TSG would require to be 
switched off, thus allowing cellular proliferation.  Furthermore, the only previously 
published study describing a change in OPCML following IL-1 treatment reported a 
4-fold reduction in OPCML(OBCAM) in a microarray study of IL-1 on a 
chondrocyte cell line (SW1353) (Vincenti, M.P. et al. 2001).  In Vincenti’s study IL-
1 exposure was only two hours but 48hour exposure used for the OSE study is 
considerably longer than would be encountered in vivo.  Indeed activation and 
phosphorylation of transcription factors may occur within minutes of IL-1 
administration but this was not a primary endpoint of this study.  The dose that was 
used for experiments in this thesis (0.5ng/ml) was 20 times less concentrated than in 
Vincenti’s study (10ng/ml).  The decision to use 0.5ng/ml and for 48 hours was 
borne out by the finding that OPCML mRNA only reached significant up-regulation 
at 48 hours (like 11βHSD1).  Moreover the minimal concentration of IL-1α required 
to up-regulate OPCML was 0.02ng/ml and thus could have been lowered further.  
The endogenous IL-1 receptor (IL1R) and IL-1 receptor antagonist (IL1RA) were not 
measured in this study but using lower dose IL-1 and more prolonged incubation 
times would increase the likelihood of their levels being important.  A short exposure 
of high dose IL-1 such as in Vincenti’s study would likely be so overwhelming as to 
negate the importance of these mediators of IL-1 bioactivity and therefore be less 
physiological in the context of chronic inflammation.  Conversely it could be argued 
that as ovulation is a rapidly resolving episode of acute inflammation, perhaps 
Vincenti’s model is a rather good model of the inflammatory events surrounding 
ovulation.  Furthermore a chondrosarcoma cell line is likely to behave quite 
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differently to a primary cell culture of normal untransformed cells.  Nevertheless any 
extension of this thesis’ work should include an investigation of higher dose IL-1 
over shorter time periods. 
 
With regard to IL-1 responsiveness it was noted that for individual OSE experiments 
there was an all or nothing effect where some individuals failed to mount an IL-1 
induced rise in OPCML mRNA.  In 7 of the 17 patient samples the OPCML fold 
change following IL-1 treatment was less than 2.  This may indicate that OPCML is 
non-functional in these individuals.  What it also suggests is that OPCML is not a 
necessary mediator in the response to IL-1α.  However in those women whose OSE 
cells did respond to IL-1 by up-regulating OPCML there was a consistent abrogation 
of this effect by cortisol (section 5.3.2.5).  Whether OPCML responsivity could be 
utilised as a marker for disease development remains to be elucidated but the cohort 
of patients here could be used for such a prospective study if ethical approval was 
obtained.  It can be concluded that in the OSE of most women OPCML shows 
characteristics typical of an inflammation-associated gene.   
 
Studies by Rae et al have indicated that progesterone may have an anti-inflammatory 
role in the OSE (Rae, M.T. et al. 2004).  These findings were not replicated in this 
study and the addition of progesterone to IL-1-containing media appeared to have 
little effect on IL-1 induced up-regulation of both OPCML and COX2 (sections 
5.3.2.5 and 5.3.4.5.3 respectively).  Reasons for this disparity were not investigated 
in the interests of time and resources but the progesterone used came from a 
laboratory stock solution and was biologically active in other experiments. 
 
Quantitative RT-PCR had indicated that levels of OPCML mRNA were low in 
samples of cultured OSE.  An investigation of OPCML protein expression failed to 
demonstrate its presence in OSE.  While OPCML protein was readily identifiable in 
the positive control sample, it was not detectable in any of the OSE samples.  
Adequate protein loading of the OSE wells was demonstrated by bands for β-actin, 
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suggesting that OPCML protein is not likely to be present in OSE in significant 
amounts.  The fact that even in the IL-1 treated samples (where OPCML levels 
would be anticipated to be higher) OPCML was not present suggests that either 
OPCML protein detection was not sensitive enough or OPCML is absent in the 
human OSE. Another explanation could be that the OPCML antigen in the OSE is 
altered by IgLON dimerization (discussed later in this chapter) and thus not “visible” 
to the antibody.  Western blotting was attempted from two different patients 
therefore it may be that OPCML expression varies between individuals and that the 
two chosen were simply low expressors of OPCML.  A large proteomic study could 
be used to demonstrate OPCML expression in the general population. 
 
Quantitative RT-PCR was also used to determine the quantity of OPCML mRNA 
amongst samples of EOC primary culture, OSE and peritoneal surface epithelium 
(PSE).  The number of samples was limited by the number of wells on the PCR plate.  
However for the panel of samples selected there was no difference in mean OPCML 
level between the samples.  For such a small number of samples however it is 
possible that statistical testing would not be able to distinguish a significant 
difference hence the need to expand the number of samples in each group for a 
definitive answer. However in Sellar’s original paper OPCML mRNA was present in 
normal ovary but absent in a panel of ovarian cancer cell lines.  Here the primary 
EOC cell cultures had some of the highest levels of OPCML.  This could be 
explained by cellular contamination of primary EOC cultures by cells other than 
malignant tumour cells. Alternatively the OSE sample in the published paper may 
not contain pure OSE.  The only other study examining OPCML in normal ovary and 
EOC also demonstrated significant overlap of OPCML quantity in the two tissue 
types (Ntougkos, E. et al. 2005). Finally as already highlighted the quantity of 
OPCML in OSE appears to be very low overall so the quantities may be extremely 
low compared to other tissues.  Indeed evidence for this arises from the comparison 
with Fallopian tube RNA that was used as the standard.  While the same quantity of 
total RNA per sample was used to make cDNA, values for the test samples are 105 




The discovery of high levels of OPCML mRNA in Fallopian tube may provide an 
avenue for further research.  OPCML protein has been discovered in murine and 
human Fallopian tube (Dr G Sellar, personal communication).  Given OPCML’s 
likely extracellular domain and role in directing neuronal growth, it is highly 
probable that it plays an important role in cell to cell signalling.  The oviduct’s 
ability to identify and transport ova following ovulation is poorly understood, but is 
an area which has significant implications for understanding human reproductive 
physiology and pathology.  It has been suggested that dysfunction of the fimbrio-
ovarian relationship could be the cause of some cases of unexplained infertility (Roy, 
K.K. et al. 2005).  With regard to ovarian cancer, there is increasing evidence for the 
Fallopian tube being the source of some cases of EOC, discussed in Chapter 1 and 
reviewed by Piek (Piek, J.M. et al. 2008).  In summary while a role for OPCML in 
the OSE has yet to be fully defined, the role of OPCML in tubal function and disease 




Figure 5.31. All IgLONs are expressed in human Fallopian tube (pictures 
courtesy of Dr Grant Sellar). 
 
 
The current state of knowledge of OPCML function suggests that in the central 
nervous system it forms dimers with itself and other members of the IgLON family 
(Reed, J. et al. 2004).  With regard to the IgLONs other than OPCML, Ntougkos’ 
paper suggested that HNT was increased in ovarian cancer compared to normal 
ovary, while LSAMP and NEGR1 were lower.  The data presented in this thesis are 
the first to describe the effect of IL-1 on the other IgLON family members in human 
OSE. 
 
The emerging theme from these studies is that IL-1α alone has no effect on 
expression of NEGR1 and LSAMP, but that there is a significant down-regulation of 
both when IL-1α and cortisol are used in combination (sections 5.3.4.1.3 and 
5.3.4.2.2).  This down-regulation is not seen when IL-1α is used in the presence of 
progesterone.  The mechanism behind this synergistic effect requires further study 
but it is possible that the pro-inflammatory effect of IL-1α primes the cells thus 
enhancing the effect of cortisol.  In contrast both OPCML and HNT are up-regulated 
by IL-1α, an effect that is lost when cortisol is added.  The configuration of IgLON 
expression in OSE places the individual members in quite separate categories and the 
data suggest similarities between OPCML and HNT, and the other pairing of NEGR1 
and LSAMP.  It seems likely that NEGR1 and LSAMP are constitutionally expressed 
while OPCML and HNT are more dynamic members of the IgLON family.  The 
concern raised earlier of OPCML levels being so low to suggest lack of function may 
be countered by considering that small changes in OPCML levels might have 
amplified effects on dimer function and thus enhancing cell-cell adhesion or 
communication.  The functional relevance of these IgLON expression patterns in 












6 General Discussion and Future Directions 
 
 
The underlying theme of this thesis is the exploration of mechanisms in primary cell 
cultures that may be relevant to the origin of epithelial ovarian cancer (EOC). For a 
relatively prevalent disease about which so much is known, it is remarkable how 
little is known about its natural history.  While much epidemiological evidence 
supports the incessant ovulation theory of damage to the ovarian surface epithelium 
(OSE) as the initiating event, the direct evidence for this is lacking.  There is much 
debate even about the tissue from which EOC originates, with several groups 
favouring the Fallopian tube over the OSE, with further evidence that endometrioid 
histiotypes may arise within endometriosis.  Nevertheless the OSE remains a likely 
candidate for some, if not all, types of EOC and worthy of research.   
 
While there is extensive knowledge of glucocorticoid metabolism in the OSE, there 
is little published literature regarding glucocorticoid metabolism in EOC.  It was this 
deficiency that stimulated the work presented in Chapter 3, where it was 
hypothesised that 11βHSD1 expression is deregulated in cancer and that an 
imbalance in 11βHSD1 and 11βHSD2 isozymes alters generation of local cortisol, 
favouring proliferation of malignant cells.  Previous published work had suggested 
this to be the case in ovarian cancer cell lines (Gubbay, O. et al. 2005) and a group 
from Birmingham, UK had reviewed evidence for a predominance of 11βHSD2 in 
some cancers (Rabbitt, E.H. et al. 2003).  The mRNA studies described in Chapter 3 
would appear to agree with Gubbay’s data and suggest an abrogation of the 
11βHSD1 mRNA response to inflammatory stimulation by IL-1α in EOC.  However 
on reviewing the basal unstimulated mRNA levels in OSE and EOC primary 
cultures, there was no discernible difference.  Furthermore using radio-labelled 
cortisone there was no significant difference in 11βHSD1 enzyme activity between 
normal OSE and EOC primary cultures. Yet these metabolism assays were missing 
from Gubbay’s paper. For comparison it would perhaps have been useful to have 
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included some EOC cell lines in the metabolism assays here.   The biologically 
significant finding is that levels of type 2 11βHSD mRNA appear to be higher within 
the malignant cultures compared to normal.  These findings suggest that within 
malignant tissue not only is there a deficiency in production of cortisol (by 
dysfunction of 11βHSD1) but there is also a shift in glucocorticoid metabolism 
towards dehydrogenation of cortisol by higher levels of type 2 11βHSD.  As target 
tissue effects of cortisol include a drive towards cell differentiation and less 
proliferation, it would be reasonable to assume that within the malignant tissue cells 
are more likely to proliferate and less likely to differentiate.  It is therefore possible 
that these changes in 11βHSD dynamics could form an important step in the genesis 
of ovarian cancer.  
 
There are many advantages of working with primary cell cultures over cell lines 
however.  The first is that it is likely that the primary culture reflects the original 
tumour much more realistically than a cell line as it is derived directly from the 
patient and as such makes the research more clinically relevant.  Secondly cell lines 
have been selected for their ability to persist in culture and as such may have lost 
many features relating to the original tumour.  Thus the endurance of cells over many 
years and passages promotes further genetic mutation and divergence from the 
original cell line isolated. The assertion that the cell line behaves just like a cancer is 
potentially misleading.  In contrast the cell line does offer more reproducibility than 
the primary cell culture which not only carries the inter-patient genetic and 
histological differences, but which may contain more than one cell type.  Timing of 
experiments can be much more closely controlled with cell line work whereas 
primary cell culture is dependent on clinical cases presenting and being recruited.  
There are obvious ethical and bureaucratic constraints with primary cell culture, 
where ethical approval and compliance with good practice guidelines is essential; an 
aspect of research which plays much less heavily in cell line experimentation.  In the 
work presented here the comparison of like with like was felt to be important and 
thus normal OSE was collected from patients and compared directly with EOC 
primary cultures rather than cell lines.  A further advantage of the prospective 
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method of primary cell culture used here was that each sample could be considered a 
case study and indeed there were some interesting findings at individual sample 
levels such as the switch in 11βHSD1 and 11βHSD2 isozymes seen in a patient with 
highly proliferative undifferentiated cells (patient 13, figure 3.8).   
 
With regard to future directions for the EOC primary cultures, it is important to 
establish the complement of cells within these cultures, and if possible encourage 
growth of malignant cells only. However this may further remove the culture from its 
original primary nature, where the malignant cell component may be dependent on 
the supporting stromal cell network.  Taking this further it may be more clinically 
relevant to assess growth of clumps of malignant cells (spheroids) seen in ascites, or 
tumour explants, in three dimensional culture, than dispersed monolayers of cells.  
Another aspect of primary cell culture that warrants investigation is cell co-culture 
where normal mesothelial cells could be cultured in the same medium but in a 
separate chamber from malignant cells.  The signalling between the cell types could 
be investigated by analysis of culture medium or treatments added to the culture 
medium and responses in the primary cells investigated.  The response of the 
peritoneum to malignant cells is an important step in dissemination of ovarian cancer 
and inhibition of this process could lead to improvements in the clinical course.   
 
The search for a cell of origin of EOC may ultimately turn out to be fruitless as the 
cancer could arising from a stem cell, which may have potential for differentiation 
into different histological subtypes of EOC.    Evidence for the concept of cancer 
stem cells (CSC) in EOC is accumulating.  One study from India suggested that 
CSCs can be derived from EOC ascitic spheroids (Bapat, S.A. et al. 2005).  Their 
reasons for concluding that there were stem cells present were that:  
 
“(a) they self-renew and are clonogenic, (b) differentiate in vitro to form organized 
spheroids in suspension, (c) express multipotency and tissue-specific differentiation 
markers, (d) express self-renewal mechanisms in vivo (sequential tumorigenicity), 
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and (e) undergo in vivo differentiation to produce a disease similar to that in the 
patient”. 
  
The evidence for CSCs is drawn from clinical observations that not all malignant 
cells need to be destroyed by chemo or radiotherapy for a cancer to be cured, and 
even if some malignant cells remain they do not proceed to clinical disease 
recurrence. In development of serial tumour transplantation whereas inoculation of 
mice requires large numbers of cells initially, fewer numbers are needed for 
transplant with each passage suggesting selection of a self renewing stem cell.  In 
addition the frequent relapse seen in EOC following treatment might suggest a 
quiescent group of stem cells, that may have elevated multi-drug resistance (MDR) 
pump activity (a feature of stem cells) that undergo renewal once the chemotherapy 
has finished.  However there remains some debate as to the existence of CSCs 
reviewed by (Hill, R.P. 2006) and further analysis of primary tumours and ascites 
looking for stem cell markers would be useful.  
 
The concept of a mesothelial stem has already been discussed but the similarities 
between the OSE and PSE revealed in Chapter 4 would support a common cell of 
origin.  The OSE has long been heralded as a unique type of cell capable of 
differentiation into multiple histological subtypes when it undergoes malignant 
transformation.  However if a disease indistinguishable from EOC (i.e. primary 
peritoneal carcinoma) can arise in women whose ovaries and tubes have been 
removed, the PSE deserves attention as a possible source of malignancy.  In the 
studies described in Chapter 4, evidence is presented that the OSE and PSE may be 
more alike than has previously been acknowledged. Certainly both are able to up-
regulate 11βHSD1 mRNA and enzyme activity in response to IL-1α-induced 
inflammation.  However the only distinction is that the degree of enzyme response is 
greater in the OSE.  While it could be conceded that the metabolism assays might 
have benefited from a larger number of samples to provide greater statistical 
confidence, the result appears to demonstrate a difference in cortisol generation 
according to site of mesothelial cell sampling.  This may explain why the ovary heals 
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without adhesion formation following ovulation, whereas the peritoneum, which has 
less 11βHSD1 activity, is more prone to adhesion formation.  Unanswered questions 
are: where do the cells that repopulate the OSE following ovulation arise from, is 
there a free-floating circulating population of mesothelial progenitor cells that are 
able to quickly repair damaged mesothelium, and do the OSE and PSE share a 
common stem cell?  The successful primary culture of PSE demonstrated here will 
allow further comparison of the cell types. One relevant experiment would be to 
assess whether there is a difference in would healing between the cell types, and 
whether this process is dependent on induction of 11βHSD1 expression or affected 
by glucocorticoids.  These types of study could open the door to investigation of 
putative anti-adhesion products and mechanisms e.g. inhibitors of collagen 
deposition.   
 
The PCR array study raises several candidate genes for further research.  CCL2 is up-
regulated by IL-1α in both cell types and may play an important role in the initiation 
of adhesion formation and the response to inflammation and cancer by drawing in 
macrophages from the circulation and surrounding tissues.  The initial host-tissue 
reaction is a potential target for inhibition of EOC metastasis and elucidation of the 
role of macrophages is an important goal.  The interaction of this protein with other 
cytokines also needs further attention in particular as the array demonstrated 
significant increases in IL-6 and IL-8 in both mesothelial cell types.  A relevant study 
demonstrated that chemo-attraction of neutrophils by female reproductive tract cells 
(but not OSE) was dependent on synergy between IL-8 and granulocyte / monocyte 
colony stimulating factor (GM-CSF), coded by the gene CSF2 (Shen, L. et al. 2004).  
In the PCR microarray CSF2 mRNA was significantly elevated in both OSE and PSE 
by IL-1α treatment suggesting that such a mechanism may be important in the 
mesothelium also.  The demonstration of these inflammation associated genes 
changing in the OSE may suggest that the OSE participates in the process of 
ovulation while the delayed up-regulation of 11βHSD1 as well as the rise in collagen 
synthesising elements such as lysyl oxidase indicates that the OSE may also play a 
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role in resolution of the injury caused by ovulation.  These repair mechanisms are 
also potential targets for prevention of pelvic adhesions.   
 
The second group of genes highlighted by the microarray are those involved with 
reproductive endocrinology.  Further examination of ER would be of value 
particularly as its expression has not been examined in human primary mesothelial 
cells and it may have an important role in the development of endometriosis where 
ERα appears to predominate (Matsuzaki, S. et al. 2000).  The FSH receptor is also a 
candidate gene of potential interest as gonadotrophins are elevated following the 
menopause and the effect of high gonadotrophins has been hypothesised to 
predispose to EOC development (Choi, J.H. et al. 2007).   
 
The final group of genes raised by the microarray are the IgLONs.  The discovery of 
OPCML as a potential tumour suppressor gene in EOC led to interest in this gene and 
its family of immunoglobulin like proteins (Sellar, G.C. et al. 2003).  The PCR array 
demonstrated a significant rise in OPCML mRNA expression with IL-1α in both 
OSE and PSE, but no change in the mRNA levels of LSAMP, NEGR1 and HNT.  
The effect of IL-1α on all of these genes was examined in Chapter 5 and confirms 
these findings, although there appeared to be a significant effect of IL-1α on HNT 
mRNA expression by Taqman analysis.  There is scope for further exploration of 
these genes within the female reproductive tract and further functional studies in the 
OSE by interference with gene expression using transfection techniques.  To date, 
there have been no data published describing IgLON expression in the OSE.  The 
results presented here indicate that OPCML expression is related to inflammation 
and as such strengthens its position as a player in the origin of some ovarian cancers.   
 
In summary, this thesis examines diverse aspects of EOC origins through 
establishment of and experimentation on primary cultures of EOC, OSE, and PSE.  It 
has revealed that 11βHSD1 expression may not be so different in normal OSE and 
malignant EOC tissue while 11βHSD2 is higher in ovarian cancers.  The OSE, from 
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which EOC may derive, resembles the peritoneal surface epithelium, but has higher 
11βHSD1 activity.  The mRNA signature of both OSE and PSE in response to IL-1α 
is almost identical in a panel of 48 selected genes.  One of these genes, OPCML is a 
candidate for a tumour suppressor gene in EOC and appears to be physiologically 










Ali-Fehmi, R., R. T. Morris, S. Bandyopadhyay, M. Che, V. Schimp, J. J. M. Malone 
and A. R. Munkarah (2005). "Expression of cyclooxygenase-2 in advanced 
stage ovarian serous carcinoma: Correlation with tumor cell proliferation, 
apoptosis, angiogenesis, and survival." American Journal of Obstetrics and 
Gynecology 192(3): 819. 
Andersen, C. Y. (1991). "Concentrations of free oestradiol and progesterone in 
human preovulatory follicular fluid." Hum Reprod 6(3): 359-64. 
Andersen, C. Y. and P. Hornnes (1994). "Intrafollicular concentrations of free 
cortisol close to follicular rupture." Hum Reprod 9(10): 1944-9. 
Andersen, C. Y. (2002). "Possible new mechanism of cortisol action in female 
reproductive organs: physiological implications of the free hormone 
hypothesis." J Endocrinol 173(2): 211-7. 
Anderson, R. A., L. L. Robinson, J. Brooks and N. Spears (2002). "Neurotropins and 
their receptors are expressed in the human fetal ovary." J Clin Endocrinol 
Metab 87(2): 890-7. 
Andrew, R., K. Smith, G. C. Jones and B. R. Walker (2002). "Distinguishing the 
activities of 11beta-hydroxysteroid dehydrogenases in vivo using isotopically 
labeled cortisol." J Clin Endocrinol Metab 87(1): 277-85. 
Ann, D. K., J. Hasegawa, J. L. Ko, S. T. Chen, N. M. Lee and H. H. Loh (1992). 
"Specific reduction of ?-opioid receptor binding in transfected NG108-15 
cells." Journal of Biological Chemistry 267(11): 7921-7926. 
Aoki, Y., N. Kawada and K. Tanaka (2000). "Early form of ovarian cancer 
originating in inclusion cysts. A case report." J Reprod Med 45(2): 159-61. 
Armstrong, D. K., B. Bundy, L. Wenzel, H. Q. Huang, R. Baergen, S. Lele, L. J. 
Copeland, J. L. Walker and R. A. Burger (2006). "Intraperitoneal cisplatin 
and paclitaxel in ovarian cancer." N Engl J Med 354(1): 34-43. 
ATAC Trialists' Group (2005). "Results of the ATAC (Arimidex, Tamoxifen, Alone 
or in Combination) trial after completion of 5 years' adjuvant treatment for 
breast cancer." The Lancet 365(9453): 60-62. 
Auersperg, N., A. S. Wong, K. C. Choi, S. K. Kang and P. C. Leung (2001). 
"Ovarian surface epithelium: biology, endocrinology, and pathology." Endocr 
Rev 22(2): 255-88. 
Bachus, K. E., E. Doty, A. F. Haney and J. B. Weinberg (1995). "Differential effects 
of interleukin- I [alpha], tumor necrosis factor-[alpha], indomethacin, 
hydrocortisone, and macrophage co-culture on the proliferation of human 
fibroblasts and peritoneal mesothelial cells." Journal of the Society for 
Gynecologic Investigation 2(4): 636. 
 
 240
Bailey, C. L., F. R. Ueland, G. L. Land, P. D. DePriest, H. H. Gallion, R. J. Kryscio 
and J. R. van Nagell (1998). "The Malignant Potential of Small Cystic 
Ovarian Tumors in Women over 50 Years of Age." Gynecologic Oncology 
69(1): 3-7. 
Bapat, S. A., A. M. Mali, C. B. Koppikar and N. K. Kurrey (2005). "Stem and 
progenitor-like cells contribute to the aggressive behavior of human epithelial 
ovarian cancer." Cancer Res 65(8): 3025-9. 
Barak, V., P. Yanai, A. J. Treves, I. Roisman, A. Simon and N. Laufer (1992). 
"Interleukin-1: local production and modulation of human granulosa luteal 
cells steroidogenesis." Fertil Steril 58(4): 719-25. 
Baron, A. T., C. H. Boardman, J. M. Lafky, A. Rademaker, D. Liu, D. A. Fishman, 
K. C. Podratz and N. J. Maihle (2005). "Soluble Epidermal Growth Factor 
Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and 
Diagnostic Tests for Epithelial Ovarian Cancer." Cancer Epidemiol 
Biomarkers Prev 14(2): 306-318. 
Bast, R. C., T. L. Klug, E. St John, E. Jenison, J. M. Niloff, H. Lazarus, R. S. 
Berkowitz, T. Leavitt, C. T. Griffiths, L. Parker, V. R. Zurawski and R. C. 
Knapp (1983). "A radioimmunoassay using a monoclonal antibody to 
monitor the course of epithelial ovarian cancer." N Engl J Med 309(15): 883-
887. 
Baylin, S. B. and J. E. Ohm (2006). "Epigenetic gene silencing in cancer - a 
mechanism for early oncogenic pathway addiction?" Nat Rev Cancer 6(2): 
107-116. 
Beger, C., K. Gerdes, M. Lauten, W. J. E. Tissing, I. Fernandez-Munoz, M. Schrappe 
and K. Welte (2003). "Expression and structural analysis of glucocorticoid 
receptor isoform gamma in human leukaemia cells using an isoform-specific 
real-time polymerase chain reaction approach." British Journal of 
Haematology 122(2): 245-252. 
Benedet, J. L., H. Bender, H. Jones, 3rd, H. Y. Ngan and S. Pecorelli (2000). "FIGO 
staging classifications and clinical practice guidelines in the management of 
gynecologic cancers. FIGO Committee on Gynecologic Oncology." Int J 
Gynaecol Obstet 70(2): 209-62. 
Beral, V. (2007). "Ovarian cancer and hormone replacement therapy in the Million 
Women Study." The Lancet 369(9574): 1703-1710. 
Berchuck, A., E. S. Iversen, J. M. Lancaster, H. K. Dressman, M. West, J. R. Nevins 
and J. R. Marks (2004). "Prediction of optimal versus suboptimal 
cytoreduction of advanced-stage serous ovarian cancer with the use of 
microarrays." Am J Obstet Gynecol 190(4): 910-25. 
Berchuck, A., J. M. Schildkraut, R. M. Wenham, B. Calingaert, S. Ali, A. Henriott, 
S. Halabi, G. C. Rodriguez, D. Gertig, D. M. Purdie, L. Kelemen, A. B. 
Spurdle, J. Marks and G. Chenevix-Trench (2004). "Progesterone receptor 
promoter +331A polymorphism is associated with a reduced risk of 
 
 241
endometrioid and clear cell ovarian cancers." Cancer Epidemiol Biomarkers 
Prev 13(12): 2141-7. 
Blaustein, A. (1984). "Peritoneal mesothelium and ovarian surface cells--shared 
characteristics." Int J Gynecol Pathol 3(4): 361-75. 
Bookman, M. A., K. M. Darcy, D. Clarke-Pearson, R. A. Boothby and I. R. Horowitz 
(2003). "Evaluation of Monoclonal Humanized Anti-HER2 Antibody, 
Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary 
Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the 
Gynecologic Oncology Group." J Clin Oncol 21(2): 283-290. 
Bowman, A., H. Gabra, S. P. Langdon, A. Lessells, M. Stewart, A. Young and J. F. 
Smyth (2002). "CA125 Response Is Associated with Estrogen Receptor 
Expression in a Phase II Trial of Letrozole in Ovarian Cancer: Identification 
of an Endocrine-sensitive Subgroup." Clin Cancer Res 8(7): 2233-2239. 
Brewer, M. A., J. Ranger-Moore, M. H. Greene, D. S. Alberts, Y. Liu, H. G. Bartels, 
A. C. Baruch and P. H. Bartels (2004). "Preneoplastic changes in ovarian 
tissues." Anal Quant Cytol Histol 26(4): 207-16. 
Brinton, L. A., G. Gridley, I. Persson, J. Baron and A. Bergqvist (1997). "Cancer risk 
after a hospital discharge diagnosis of endometriosis." American Journal of 
Obstetrics and Gynecology 176(3): 572-579. 
Bristow, R. E., D. R. Gossett, D. R. Shook, M. L. Zahurak, R. S. Tomacruz, D. K. 
Armstrong and F. J. Montz (2002). "Micropapillary serous ovarian 
carcinoma: surgical management and clinical outcome." Gynecol Oncol 
86(2): 163-70. 
Bristow, R. E., R. S. Tomacruz, D. K. Armstrong, E. L. Trimble and F. J. Montz 
(2002). "Survival effect of maximal cytoreductive surgery for advanced 
ovarian carcinoma during the platinum era: a meta-analysis." J Clin Oncol 
20(5): 1248-59. 
Brummendorf, T. and V. Lemmon (2001). "Immunoglobulin superfamily receptors: 
cis-interactions, intracellular adapters and alternative splicing regulate 
adhesion." Current Opinion in Cell Biology 13(5): 611-618. 
Bublitz, C., C. A. Lawler and S. Steavenson (1987). "The topology of 
phosphogluconate dehydrogenases in rat liver microsomes." Arch Biochem 
Biophys 259(1): 22-8. 
Bujalska, I. J., E. A. Walker, J. W. Tomlinson, M. Hewison and P. M. Stewart 
(2002). "11Beta-hydroxysteroid dehydrogenase type 1 in differentiating 
omental human preadipocytes: from de-activation to generation of cortisol." 
Endocr Res 28(4): 449-61. 
Burnett, S. H., B. J. Beus, R. Avdiushko, J. Qualls, A. M. Kaplan and D. A. Cohen 
(2006). "Development of peritoneal adhesions in macrophage depleted mice." 
J Surg Res 131(2): 296-301. 
Burney, R. O., S. Talbi, A. E. Hamilton, K. C. Vo, M. Nyegaard, C. R. Nezhat, B. A. 
Lessey and L. C. Giudice (2007). "Gene expression analysis of endometrium 
 
 242
reveals progesterone resistance and candidate susceptibility genes in women 
with endometriosis." Endocrinology 148(8): 3814-26. 
Buys, S. S., E. Partridge, M. H. Greene, P. C. Prorok, D. Reding, T. L. Riley, P. 
Hartge, R. M. Fagerstrom, L. R. Ragard, D. Chia, G. Izmirlian, M. Fouad, C. 
C. Johnson and J. K. Gohagan (2005). "Ovarian cancer screening in the 
Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: 
findings from the initial screen of a randomized trial." Am J Obstet Gynecol 
193(5): 1630-9. 
Cai, T.-Q., B. Wong, S. S. Mundt, R. Thieringer, S. D. Wright and A. Hermanowski-
Vosatka (2001). "Induction of 11[beta]-hydroxysteroid dehydrogenase type 1 
but not -2 in human aortic smooth muscle cells by inflammatory stimuli." The 
Journal of Steroid Biochemistry and Molecular Biology 77(2-3): 117. 
Castillo, G., J. L. Alcazar and M. Jurado (2004). "Natural history of sonographically 
detected simple unilocular adnexal cysts in asymptomatic postmenopausal 
women." Gynecologic Oncology 92(3): 965-969. 
Chan, J. K., C. A. Hamilton, E. M. Anderson, M. K. Cheung, J. Baker, A. Husain, N. 
N. Teng, C. S. Kong and R. S. Negrin (2007). "A novel technique for the 
enrichment of primary ovarian cancer cells." American Journal of Obstetrics 
and Gynecology 197(5): 507.e1-507.e5. 
Chen, J., W. O. Lui, M. D. Vos, G. J. Clark, M. Takahashi, J. Schoumans, S. K. 
Khoo, D. Petillo, T. Lavery, J. Sugimura, D. Astuti, C. Zhang, S. Kagawa, E. 
R. Maher, C. Larsson, A. S. Alberts, H. O. Kanayama and B. T. Teh (2003). 
"The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in 
clear cell renal cell carcinomas." Cancer Cell 4(5): 405-13. 
Cheng, W., J. Liu, H. Yoshida, D. Rosen and H. Naora (2005). "Lineage infidelity of 
epithelial ovarian cancers is controlled by HOX genes that specify regional 
identity in the reproductive tract." Nat Med 11(5): 531-7. 
Cho, T. M., J. Hasegawa, B. L. Ge and H. H. Loh (1986). "Purification to apparent 
homogeneity of a mu-type opioid receptor from rat brain." Proc Natl Acad 
Sci U S A 83(12): 4138-42. 
Choi, J.-H., K.-C. Choi, N. Auersperg and P. C. K. Leung (2005). "Gonadotropins 
upregulate the epidermal growth factor receptor through activation of 
mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in 
human ovarian surface epithelial cells." Endocr Relat Cancer 12(2): 407-421. 
Choi, J. H., A. S. Wong, H. F. Huang and P. C. Leung (2007). "Gonadotropins and 
ovarian cancer." Endocr Rev 28(4): 440-61. 
Chu, C. S., A. W. Menzin, D. G. Leonard, S. C. Rubin and J. E. Wheeler (1999). 
"Primary peritoneal carcinoma: a review of the literature." Obstet Gynecol 
Surv 54(5): 323-35. 
Clarke, J. L. and P. J. Mason (2003). "Murine hexose-6-phosphate dehydrogenase: a 
bifunctional enzyme with broad substrate specificity and 6-
phosphogluconolactonase activity." Arch Biochem Biophys 415(2): 229-34. 
 
 243
Clow, O. L., P. R. Hurst and J. S. Fleming (2002). "Changes in the mouse ovarian 
surface epithelium with age and ovulation number." Mol Cell Endocrinol 
191(1): 105-11. 
Collaborative Group on Epidemiological Studies of Ovarian, C. "Ovarian cancer and 
oral contraceptives: collaborative reanalysis of data from 45 epidemiological 
studies including 23[punctuation space]257 women with ovarian cancer and 
87[punctuation space]303 controls." The Lancet 371(9609): 303-314. 
Comoglio, P. M. (2001). "Pathway specificity for Met signalling." Nat Cell Biol 
3(7): E161-E162. 
Cooper, M. S., I. Bujalska, E. Rabbitt, E. A. Walker, R. Bland, M. C. Sheppard, M. 
Hewison and P. M. Stewart (2001). "Modulation of 11beta-hydroxysteroid 
dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an 
autocrine switch from glucocorticoid inactivation to activation." J Bone 
Miner Res 16(6): 1037-44. 
Cormio, G., G. Di Vagno, G. Di Gesu, M. Mastroianni, G. A. Melilli, A. Vimercati, 
G. Putignano, G. Loverro and L. Selvaggi (2000). "Primary peritoneal 
carcinoma: a report of twelve cases and a review of the literature." Gynecol 
Obstet Invest 50(3): 203-6. 
Corps, A. N., H. M. Sowter and S. K. Smith (1997). "Hepatocyte growth factor 
stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells 
expressing high levels of c-MET." International Journal of Cancer 73(1): 
151-155. 
Coussens, L. M. and Z. Werb (2002). "Inflammation and cancer." Nature 420(6917): 
860-867. 
Cramer, D. W. and W. R. Welch (1983). "Determinants of ovarian cancer risk. II. 
Inferences regarding pathogenesis." J Natl Cancer Inst 71(4): 717-21. 
Crouch, E. C. (1998). "Collectins and Pulmonary Host Defense." Am. J. Respir. Cell 
Mol. Biol. 19(2): 177-201. 
Crum, C. P., R. Drapkin, A. Miron, T. A. Ince, M. Muto, D. W. Kindelberger and Y. 
Lee (2007). "The distal fallopian tube: a new model for pelvic serous 
carcinogenesis." Curr Opin Obstet Gynecol 19(1): 3-9. 
Cunat, S., F. Rabenoelina, J. P. Daures, D. Katsaros, H. Sasano, W. R. Miller, T. 
Maudelonde and P. Pujol (2005). "Aromatase expression in ovarian epithelial 
cancers." J Steroid Biochem Mol Biol 93(1): 15-24. 
Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-
Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. 
Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M. L. Disis, K. L. 
Knutson, L. Chen and W. Zou (2004). "Specific recruitment of regulatory T 
cells in ovarian carcinoma fosters immune privilege and predicts reduced 
survival." Nat Med 10(9): 942-9. 
Czegle, I., S. Piccirella, et al. (2006). "Cooperativity between 11beta-hydroxysteroid 
dehydrogenase type 1 and hexose-6-phosphate dehydrogenase is based on a 
 
 244
common pyridine nucleotide pool in the lumen of the endoplasmic 
reticulum." Mol Cell Endocrinol 248(1-2): 24-5. 
Davis, M., A. Hitchcock, W. D. Foulkes and I. G. Campbell (1996). "Refinement of 
two chromosome 11q regions of loss of heterozygosity in ovarian cancer." 
Cancer Res 56(4): 741-4. 
Dees, W. L., J. K. Hiney, N. H. McArthur, G. A. Johnson, G. A. Dissen and S. R. 
Ojeda (2006). "Origin and ontogeny of mammalian ovarian neurons." 
Endocrinology 147(8): 3789-96. 
Detti, L., G. M. Saed, Z. L. Jiang, M. L. Kruger and M. P. Diamond (2008). "The 
effect of estradiol on the expression of estrogen, progesterone, androgen, and 
prolactin receptors in human peritoneal fibroblasts." J Assist Reprod Genet 
25(6): 245-50. 
Di Renzo, M. F., M. Olivero, D. Katsaros, T. Crepaldi, P. Gaglia, P. Zola, P. 
Sismondi and P. M. Comoglio (1994). "Overexpression of the Met/HGF 
receptor in ovarian cancer." Int J Cancer 58(5): 658-62. 
DiFeo, A., G. Narla, J. Hirshfeld, O. Camacho-Vanegas, J. Narla, S. L. Rose, T. 
Kalir, S. Yao, A. Levine, M. J. Birrer, T. Bonome, S. L. Friedman, R. E. 
Buller and J. A. Martignetti (2006). "Roles of KLF6 and KLF6-SV1 in 
Ovarian Cancer Progression and Intraperitoneal Dissemination." Clin Cancer 
Res 12(12): 3730-3739. 
Dinulescu, D. M., T. A. Ince, B. J. Quade, S. A. Shafer, D. Crowley and T. Jacks 
(2005). "Role of K-ras and Pten in the development of mouse models of 
endometriosis and endometrioid ovarian cancer." Nat Med 11(1): 63-70. 
Dobbie, J. W. (1996). "Surfactant protein A and lamellar bodies: a homologous 
secretory function of peritoneum, synovium, and lung." Perit Dial Int 16(6): 
574-81. 
Dobbie, J. W. and J. K. Lloyd (1989). "Mesothelium secretes lamellar bodies in a 
similar manner to type II pneumocyte secretion of surfactant." Perit Dial Int 
9(3): 215-9. 
Dobbie, J. W., T. Pavlina, J. Lloyd and R. C. Johnson (1988). "Phosphatidylcholine 
synthesis by peritoneal mesothelium: its implications for peritoneal dialysis." 
Am J Kidney Dis 12(1): 31-6. 
Douglas, J. (1730). A description of the peritonaeum, and of that part of the 
membrana cellularis which lies on its outside : with an account of the true 
situation of all the abdominal viscera, in respect of these two membranes /, 
Warwick Lane, London. 
Draper, N. and P. M. Stewart (2005). "11{beta}-Hydroxysteroid dehydrogenase and 
the pre-receptor regulation of corticosteroid hormone action." J Endocrinol 
186(2): 251-271. 
Draper, N., E. A. Walker, I. J. Bujalska, J. W. Tomlinson, S. M. Chalder, W. Arlt, G. 
G. Lavery, O. Bedendo, D. W. Ray, I. Laing, E. Malunowicz, P. C. White, M. 
Hewison, P. J. Mason, J. M. Connell, C. H. Shackleton and P. M. Stewart 
(2003). "Mutations in the genes encoding 11beta-hydroxysteroid 
 
 245
dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to 
cause cortisone reductase deficiency." Nat Genet 34(4): 434-9. 
Dubeau, L. (1999). "The cell of origin of ovarian epithelial tumors and the ovarian 
surface epithelium dogma: does the emperor have no clothes?" Gynecol 
Oncol 72(3): 437-42. 
Duma, D., C. M. Jewell and J. A. Cidlowski (2006). "Multiple glucocorticoid 
receptor isoforms and mechanisms of post-translational modification." The 
Journal of Steroid Biochemistry and Molecular Biology 102(1-5): 11-21. 
Dunfield, L. D., T. G. Shepherd and M. W. Nachtigal (2002). "Primary culture and 
mRNA analysis of human ovarian cells." Biol Proced Online 4: 55-61. 
ElShamy, W. M. and D. M. Livingston (2004). "Identification of BRCA1-IRIS, a 
BRCA1 locus product." Nat Cell Biol 6(10): 954-967. 
Enomoto, T., C. M. Weghorst, M. Inoue, O. Tanizawa and J. M. Rice (1991). "K-ras 
activation occurs frequently in mucinous adenocarcinomas and rarely in other 
common epithelial tumors of the human ovary." Am J Pathol 139(4): 777-85. 
Epiney, M., C. Bertossa, A. Weil, A. Campana and P. Bischof (2000). "CA125 
production by the peritoneum: in-vitro and in-vivo studies." Hum. Reprod. 
15(6): 1261-1265. 
Escher, G., I. Galli, B. S. Vishwanath, B. M. Frey and F. J. Frey (1997). "Tumor 
necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol 
shuttle." J Exp Med 186(2): 189-98. 
Espey, L. L. (1980). "Ovulation as an inflammatory reaction--a hypothesis." Biol 
Reprod 22(1): 73-106. 
Espey, L. L. (1994). "Current status of the hypothesis that mammalian ovulation is 
comparable to an inflammatory reaction." Biol Reprod 50(2): 233-8. 
Evers, J. L. H. (1994). "Endometriosis does not exist; All women have 
endometriosis." Human Reproduction 9(12): 2206-2209. 
Fathalla, M. F. (1971). "Incessant ovulation--a factor in ovarian neoplasia?" Lancet 
2(7716): 163. 
Ferguson, S. E., Z. Pallikaros, et al. (1999). "The effects of different culture media, 
glucose, pyridine nucleotides and adenosine on the activity of 11beta-
hydroxysteroid dehydrogenase in rat Leydig cells." Mol Cell Endocrinol 
158(1-2): 37-44. 
Finch, A., M. Beiner, J. Lubinski, H. T. Lynch, P. Moller, B. Rosen, J. Murphy, P. 
Ghadirian, E. Friedman, W. D. Foulkes, C. Kim-Sing, T. Wagner, N. Tung, 
F. Couch, D. Stoppa-Lyonnet, P. Ainsworth, M. Daly, B. Pasini, R. Gershoni-
Baruch, C. Eng, O. I. Olopade, J. McLennan, B. Karlan, J. Weitzel, P. Sun 
and S. A. Narod (2006). "Salpingo-oophorectomy and the risk of ovarian, 
fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 
Mutation." Jama 296(2): 185-92. 
 
 246
Finch, A., P. Shaw, B. Rosen, J. Murphy, S. A. Narod and T. J. Colgan (2006). 
"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 
159 BRCA1 and BRCA2 carriers." Gynecol Oncol 100(1): 58-64. 
Fleming, J. S., C. R. Beaugie, I. Haviv, G. Chenevix-Trench and O. L. Tan (2006). 
"Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: 
Revisiting old hypotheses." Molecular and Cellular Endocrinology 247(1-2): 
4. 
Foley-Comer, A. J., S. E. Herrick, T. Al-Mishlab, C. M. Prele, G. J. Laurent and S. 
E. Mutsaers (2002). "Evidence for incorporation of free-floating mesothelial 
cells as a mechanism of serosal healing." J Cell Sci 115(7): 1383-1389. 
Foulkes, W. D., I. G. Campbell, G. W. Stamp and J. Trowsdale (1993). "Loss of 
heterozygosity and amplification on chromosome 11q in human ovarian 
cancer." Br J Cancer 67(2): 268-73. 
Fromm, G. L., D. M. Gershenson and E. G. Silva (1990). "Papillary serous 
carcinoma of the peritoneum." Obstet Gynecol 75(1): 89-95. 
Fujii, S., I. Konishi, H. Okamura and T. Mori (1986). "Mucinous 
cystadenocarcinoma of the retroperitoneum: a light and electron microscopic 
study." Gynecol Oncol 24(1): 103-12. 
Fukunaga, M., K. Nomura, E. Ishikawa and S. Ushigome (1997). "Ovarian atypical 
endometriosis: its close association with malignant epithelial tumours." 
Histopathology 30(3): 249-55. 
Funatsu, N., S. Miyata, H. Kumanogoh, M. Shigeta, K. Hamada, Y. Endo, Y. 
Sokawa and S. Maekawa (1999). "Characterization of a novel rat brain 
glycosylphosphatidylinositol-anchored protein (Kilon), a member of the 
IgLON cell adhesion molecule family." J Biol Chem 274(12): 8224-30. 
Furlong, M. T., C. D. Hough, C. A. Sherman-Baust, E. S. Pizer and P. J. Morin 
(1999). "Evidence for the colonic origin of ovarian cancer cell line SW626." J 
Natl Cancer Inst 91(15): 1327-8. 
Futreal, P. A., L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, N. Rahman 
and M. R. Stratton (2004). "A CENSUS OF HUMAN CANCER GENES." 
Nature Reviews Cancer 4(3): 177-183. 
Gabra, H., S. Langdon, J. Watson, R. Hawkins, B. Cohen, L. Taylor, J. Mackay, C. 
Steel, R. Leonard and J. Smyth (1995). "Loss of heterozygosity at 11q22 
correlates with low progesterone receptor content in epithelial ovarian 
cancer." Clin Cancer Res 1(9): 945-953. 
Ganesan, S., D. P. Silver, R. A. Greenberg, D. Avni, R. Drapkin, A. Miron, S. C. 
Mok, V. Randrianarison, S. Brodie, J. Salstrom, T. P. Rasmussen, A. Klimke, 
C. Marrese, Y. Marahrens, C.-X. Deng, J. Feunteun and D. M. Livingston 
(2002). "BRCA1 Supports XIST RNA Concentration on the Inactive X 
Chromosome." Cell 111(3): 393-405. 
Gemignani, M. L., A. C. Schlaerth, F. Bogomolniy, R. R. Barakat, O. Lin, R. 
Soslow, E. Venkatraman and J. Boyd (2003). "Role of KRAS and BRAF 
 
 247
gene mutations in mucinous ovarian carcinoma." Gynecologic Oncology 
90(2): 378-381. 
Gerard, N., M. Caillaud, A. Martoriati, G. Goudet and A. C. Lalmanach (2004). "The 
interleukin-1 system and female reproduction." J Endocrinol 180(2): 203-12. 
Gil, O. D., L. Zhang, S. Chen, Y. Q. Ren, A. Pimenta, G. Zanazzi, D. Hillman, P. 
Levitt and J. L. Salzer (2002). "Complementary expression and heterophilic 
interactions between IgLON family members neurotrimin and LAMP." J 
Neurobiol 51(3): 190-204. 
Gillett, W. R., A. Mitchell and P. R. Hurst (1991). "A scanning electron microscopic 
study of the human ovarian surface epithelium: characterization of two cell 
types." Hum Reprod 6(5): 645-50. 
Gilmour, J. S., A. E. Coutinho, J. F. Cailhier, T. Y. Man, M. Clay, G. Thomas, H. J. 
Harris, J. J. Mullins, J. R. Seckl, J. S. Savill and K. E. Chapman (2006). 
"Local amplification of glucocorticoids by 11 beta-hydroxysteroid 
dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic 
leukocytes." J Immunol 176(12): 7605-11. 
Gordon, I. O. and R. S. Freedman (2006). "Defective antitumor function of 
monocyte-derived macrophages from epithelial ovarian cancer patients." Clin 
Cancer Res 12(5): 1515-24. 
Gotfredson, G. S. and W. J. Murdoch (2007). "A BRIEF COMMUNICATION: 
Morphologic Responses of the Mouse Ovarian Surface Epithelium to 
Ovulation and Steroid Hormonal Milieu." Experimental Biology and 
Medicine 232(2): 277-280. 
Grahame, G. R., M. G. Torchia, K. Dankewich and I. A. Ferguson (1985). "Surface-
active material in peritoneal effluent of CAPD patients." Peritoneal Dialysis 
Bulletin 5(2): 109-111. 
Greer, J. B., F. Modugno, G. O. Allen and R. B. Ness (2005). "Short-Term Oral 
Contraceptive Use and the Risk of Epithelial Ovarian Cancer." Am. J. 
Epidemiol. 162(1): 66-72. 
Gubbay, O., W. Guo, M. T. Rae, D. Niven, S. P. Langdon and S. G. Hillier (2005). 
"Inflammation-associated gene expression is altered between normal human 
ovarian surface epithelial cells and cell lines derived from ovarian 
adenocarcinomas." Br J Cancer 92(10): 1927-33. 
Gullick, W. J., J. J. Marsden, N. Whittle, B. Ward, L. Bobrow and M. D. Waterfield 
(1986). "Expression of Epidermal Growth Factor Receptors on Human 
Cervical, Ovarian, and Vulval Carcinomas." Cancer Res 46(1): 285-292. 
Gwinn, M. L., N. C. Lee, P. H. Rhodes, P. M. Layde and G. L. Rubin (1990). 
"Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial 
ovarian cancer." J Clin Epidemiol 43(6): 559-68. 
Hachisuka, A., T. Yamazaki, J. Sawada and T. Terao (1996). "Characterization and 
tissue distribution of opioid-binding cell adhesion molecule (OBCAM) using 
monoclonal antibodies." Neurochem Int 28(4): 373-9. 
 
 248
Hagemann, T., J. Wilson, F. Burke, H. Kulbe, N. F. Li, A. Pluddemann, K. Charles, 
S. Gordon and F. R. Balkwill (2006). "Ovarian cancer cells polarize 
macrophages toward a tumor-associated phenotype." J Immunol 176(8): 
5023-32. 
Hamid, Q. A., S. E. Wenzel, P. J. Hauk, A. Tsicopoulos, B. Wallaert, J. J. Lafitte, G. 
P. Chrousos, S. J. Szefler and D. Y. Leung (1999). "Increased glucocorticoid 
receptor beta in airway cells of glucocorticoid-insensitive asthma." Am J 
Respir Crit Care Med 159(5 Pt 1): 1600-4. 
Han, E. S. and B. J. Monk (2007). "What is the risk of bowel perforation associated 
with bevacizumab therapy in ovarian cancer?" Gynecologic Oncology 
105(1): 3-6. 
Hancox, K. A., A. A. Gooley and P. L. Jeffrey (1997). "AvGp50, a predominantly 
axonally expressed glycoprotein, is a member of the IgLON's subfamily of 
cell adhesion molecules (CAMs)." Brain Res Mol Brain Res 44(2): 273-85. 
Haning, R. V., A. J. Kiggens and T. L. Leiheit (1985). "Maternal serum 
progesterone, 17[beta]-Estradiol and estriol are increased in pregnancies 
which follow treatment with human menopausal gonadotropins: Effects of 
multiple gestation and maternal endocrine status." Journal of Steroid 
Biochemistry 22(6): 823-829. 
Heintz, A. P., F. Odicino, P. Maisonneuve, U. Beller, J. L. Benedet, W. T. Creasman, 
H. Y. Ngan and S. Pecorelli (2003). "Carcinoma of the ovary." Int J Gynaecol 
Obstet 83 Suppl 1: 135-66. 
Heller, D. S., P. Murphy and C. Westhoff (2005). "Are germinal inclusion cysts 
markers of ovulation?" Gynecol Oncol 96(2): 496-9. 
Hempling, R. E., M. S. Piver, G. H. Eltabbakh and F. O. Recio (1998). "Progesterone 
receptor status is a significant prognostic variable of progression-free survival 
in advanced epithelial ovarian cancer." Am J Clin Oncol 21(5): 447-51. 
Hill, R. P. (2006). "Identifying cancer stem cells in solid tumors: case not proven." 
Cancer Res 66(4): 1891-5; discussion 1890. 
Hillier, S. G., R. A. Anderson, A. R. Williams and M. Tetsuka (1998). "Expression 
of oestrogen receptor alpha and beta in cultured human ovarian surface 
epithelial cells." Mol Hum Reprod 4(8): 811-5. 
Ho, H. N., M. Y. Wu, K. H. Chao, C. D. Chen, S. U. Chen and Y. S. Yang (1997). 
"Peritoneal interleukin-10 increases with decrease in activated CD4+ T 
lymphocytes in women with endometriosis." Hum Reprod 12(11): 2528-33. 
Holmdahl, L. (1997). "The role of fibrinolysis in adhesion formation." The European 
journal of surgery. Supplement. : = Acta chirurgica. Supplement(577): 24-31. 
Hough, C. D., C. A. Sherman-Baust, E. S. Pizer, F. J. Montz, D. D. Im, N. B. 
Rosenshein, K. R. Cho, G. J. Riggins and P. J. Morin (2000). "Large-scale 
serial analysis of gene expression reveals genes differentially expressed in 
ovarian cancer." Cancer Res 60(22): 6281-7. 
 
 249
Hsu, C. C., B. C. Yang, M. H. Wu and K. E. Huang (1997). "Enhanced interleukin-4 
expression in patients with endometriosis." Fertil Steril 67(6): 1059-64. 
Hu, Y., S. Ghosh, A. Amleh, W. Yue, Y. Lu, A. Katz and R. Li (2005). "Modulation 
of aromatase expression by BRCA1: a possible link to tissue-specific tumor 
suppression." Oncogene 24(56): 8343-8348. 
Huber, C., J. R. Batchelor, D. Fuchs, A. Hausen, A. Lang, D. Niederwieser, G. 
Reibnegger, P. Swetly, J. Troppmair and H. Wachter (1984). "Immune 
response-associated production of neopterin. Release from macrophages 
primarily under control of interferon-gamma." J Exp Med 160(1): 310-6. 
Ivarsson, K., K. Sundfeldt, M. Brannstrom, P. Hellberg and P. O. Janson (2001). 
"Diverse effects of FSH and LH on proliferation of human ovarian surface 
epithelial cells." Hum Reprod 16(1): 18-23. 
Ivarsson, K., K. Sundfeldt, M. Brannstrom and P. O. Janson (2001). "Production of 
steroids by human ovarian surface epithelial cells in culture: possible role of 
progesterone as growth inhibitor." Gynecol Oncol 82(1): 116-21. 
Iwanoff, N. (1898). "Drüsiges cystenhaltiges Uterusfibromyom compliciert durch 
Sarcom und Carcinom. (Adenofibromyoma cysticum sarcomatodes 
carcinomatosum). ." Monatschr Geburtshilfe Gynäkol 7 295–300. 
Jaaback, K. S., L. Ludeman, N. L. Clayton and L. Hirschowitz (2006). "Primary 
peritoneal carcinoma in a UK cancer center: comparison with advanced 
ovarian carcinoma over a 5-year period." International Journal of 
Gynecological Cancer 16(s1): 123-128. 
Jeanes, A., C. J. Gottardi and A. S. Yap (2008). "Cadherins and cancer: how does 
cadherin dysfunction promote tumor progression?" Oncogene 27(55): 6920-9. 
Jimbo, H., H. Yoshikawa, T. Onda, T. Yasugi, A. Sakamoto and Y. Taketani (1997). 
"Prevalence of ovarian endometriosis in epithelial ovarian cancer." Int J 
Gynaecol Obstet 59(3): 245-50. 
Jonas, K. C., C. Chandras, D. R. Abayasekara and A. E. Michael (2006). "Role for 
prostaglandins in the regulation of type 1 11beta-hydroxysteroid 
dehydrogenase in human granulosa-lutein cells." Endocrinology 147(12): 
5865-72. 
Jones, L. M. H., M. J. Gardner, J. B. Catterall and G. A. Turner (1995). "Hyaluronic 
acid secreted by mesothelial cells: A natural barrier to ovarian cancer cell 
adhesion." Clinical and Experimental Metastasis 13(5): 373-380. 
Kabawat, S. E., R. C. Bast, Jr., A. K. Bhan, W. R. Welch, R. C. Knapp and R. B. 
Colvin (1983). "Tissue distribution of a coelomic-epithelium-related antigen 
recognized by the monoclonal antibody OC125." Int J Gynecol Pathol 2(3): 
275-85. 
Karlan, B. Y., J. Jones, M. Greenwald and L. D. Lagasse (1995). "Steroid hormone 
effects on the proliferation of human ovarian surface epithelium in vitro." Am 
J Obstet Gynecol 173(1): 97-104. 
 
 250
Kataoka, S., A. Kudo, H. Hirano, H. Kawakami, T. Kawano, E. Higashihara, H. 
Tanaka, F. Delarue, J. D. Sraer, T. Mune, Z. S. Krozowski and K. Yan 
(2002). "11beta-hydroxysteroid dehydrogenase type 2 is expressed in the 
human kidney glomerulus." J Clin Endocrinol Metab 87(2): 877-82. 
Kenny, H. A., T. Krausz, S. D. Yamada and E. Lengyel (2007). "Use of a novel 3D 
culture model to elucidate the role of mesothelial cells, fibroblasts and extra-
cellular matrices on adhesion and invasion of ovarian cancer cells to the 
omentum." Int J Cancer. 
Khalique, L., A. Ayhan, M. E. Weale, I. J. Jacobs, S. J. Ramus and S. A. Gayther 
(2007). "Genetic intra-tumour heterogeneity in epithelial ovarian cancer and 
its implications for molecular diagnosis of tumours." J Pathol 211(3): 286-95. 
Kindelberger, D. W., Y. Lee, A. Miron, M. S. Hirsch, C. Feltmate, F. Medeiros, M. 
J. Callahan, E. O. Garner, R. W. Gordon, C. Birch, R. S. Berkowitz, M. G. 
Muto and C. P. Crum (2007). "Intraepithelial carcinoma of the fimbria and 
pelvic serous carcinoma: Evidence for a causal relationship." Am J Surg 
Pathol 31(2): 161-9. 
Kmet, L. M., L. S. Cook and A. M. Magliocco (2003). "A review of p53 expression 
and mutation in human benign, low malignant potential, and invasive 
epithelial ovarian tumors." Cancer 97(2): 389-404. 
Knudson, A. G. (2000). "Chasing the cancer demon." Annu Rev Genet 34: 1-19. 
Korbonits, M., I. Bujalska, M. Shimojo, J. Nobes, S. Jordan, A. B. Grossman and P. 
M. Stewart (2001). "Expression of 11 beta-hydroxysteroid dehydrogenase 
isoenzymes in the human pituitary: induction of the type 2 enzyme in 
corticotropinomas and other pituitary tumors." J Clin Endocrinol Metab 
86(6): 2728-33. 
Koyama, N., K. Matsuura and H. Okamura (1993). "Cytokines in the peritoneal fluid 
of patients with endometriosis." Int J Gynaecol Obstet 43(1): 45-50. 
Kroon, E. and E. Andolf (1995). "Diagnosis and follow-up of simple ovarian cysts 
detected by ultrasound in postmenopausal women." Obstetrics & Gynecology 
85(2): 211-214. 
Kupryjanczyk, J., D. A. Bell, D. Dimeo, R. Beauchamp, A. D. Thor and D. W. 
Yandell (1995). "p53 gene analysis of ovarian borderline tumors and stage I 
carcinomas." Human Pathology 26(4): 387-392. 
Kuwano, T., S. Nakao, H. Yamamoto, M. Tsuneyoshi, T. Yamamoto, M. Kuwano 
and M. Ono (2004). "Cyclooxygenase 2 is a key enzyme for inflammatory 
cytokine-induced angiogenesis." Faseb J 18(2): 300-10. 
Lacey, J. V., Jr., P. J. Mink, J. H. Lubin, M. E. Sherman, R. Troisi, P. Hartge, A. 
Schatzkin and C. Schairer (2002). "Menopausal Hormone Replacement 
Therapy and Risk of Ovarian Cancer." JAMA 288(3): 334-341. 
Lassus, H., H. Sihto, A. Leminen, H. Joensuu, J. Isola, N. N. Nupponen and R. 
Butzow (2006). "Gene amplification, mutation, and protein expression of 




Lau, K. M., S. C. Mok and S. M. Ho (1999). "Expression of human estrogen 
receptor-alpha and -beta, progesterone receptor, and androgen receptor 
mRNA in normal and malignant ovarian epithelial cells." Proc Natl Acad Sci 
U S A 96(10): 5722-7. 
Lee, P., D. G. Rosen, C. Zhu, E. G. Silva and J. Liu (2005). "Expression of 
progesterone receptor is a favorable prognostic marker in ovarian cancer." 
Gynecologic Oncology 96(3): 671-677. 
Lee, Y., A. Miron, R. Drapkin, M. R. Nucci, F. Medeiros, A. Saleemuddin, J. 
Garber, C. Birch, H. Mou, R. W. Gordon, D. W. Cramer, F. D. McKeon and 
C. P. Crum (2007). "A candidate precursor to serous carcinoma that 
originates in the distal fallopian tube." J Pathol 211(1): 26-35. 
Levine, A. J. (1997). "p53, the cellular gatekeeper for growth and division." Cell 
88(3): 323-31. 
Li, J., C. Yen, D. Liaw, K. Podsypanina, S. Bose, S. I. Wang, J. Puc, C. Miliaresis, L. 
Rodgers, R. McCombie, S. H. Bigner, B. C. Giovanella, M. Ittmann, B. 
Tycko, H. Hibshoosh, M. H. Wigler and R. Parsons (1997). "PTEN, a 
Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, 
Breast, and Prostate Cancer." Science 275(5308): 1943-1947. 
Li, W., L. Gao, Y. Wang, T. Duan, L. Myatt and K. Sun (2006). "Enhancement of 
Cortisol-Induced 11{beta}-Hydroxysteroid dehydrogenase Type 1 
Expression by Interleukin 1{beta} in Cultured Human Chorionic Trophoblast 
Cells." Endocrinology 147(5): 2490-2495. 
Liotta, L. A. and E. Kohn (2004). "Anoikis: cancer and the homeless cell." Nature 
430(7003): 973-4. 
Liu, Y., J. M. Cousin, J. Hughes, J. Van Damme, J. R. Seckl, C. Haslett, I. 
Dransfield, J. Savill and A. G. Rossi (1999). "Glucocorticoids Promote 
Nonphlogistic Phagocytosis of Apoptotic Leukocytes." J Immunol 162(6): 
3639-3646. 
Lodge, A. P., M. R. Howard, C. J. McNamee and D. J. Moss (2000). "Co-
localisation, heterophilic interactions and regulated expression of IgLON 
family proteins in the chick nervous system." Brain Res Mol Brain Res 82(1-
2): 84-94. 
Maines-Bandiera, S. L. and N. Auersperg (1997). "Increased E-cadherin expression 
in ovarian surface epithelium: an early step in metaplasia and dysplasia?" Int 
J Gynecol Pathol 16(3): 250-5. 
Matsuzaki, S., T. Fukaya, S. Uehara, T. Murakami, H. Sasano and A. Yajima (2000). 
"Characterization of messenger RNA expression of estrogen receptor-alpha 
and -beta in patients with ovarian endometriosis." Fertil Steril 73(6): 1219-25. 
Mayr, D., A. Hirschmann, U. Lohrs and J. Diebold (2006). "KRAS and BRAF 
mutations in ovarian tumors: A comprehensive study of invasive carcinomas, 




McDonald, S. E., T. A. Henderson, C. E. Gomez-Sanchez, H. O. D. Critchley and J. 
I. Mason (2006). "11[beta]-Hydroxysteroid dehydrogenases in human 
endometrium." Molecular and Cellular Endocrinology 248(1-2): 72. 
McLaren, J., A. Prentice, D. S. Charnock-Jones, S. A. Millican, K. H. Muller, A. M. 
Sharkey and S. K. Smith (1996). "Vascular endothelial growth factor is 
produced by peritoneal fluid macrophages in endometriosis and is regulated 
by ovarian steroids." J Clin Invest 98(2): 482-9. 
McNamee, C. J., J. E. Reed, M. R. Howard, A. P. Lodge and D. J. Moss (2002). 
"Promotion of neuronal cell adhesion by members of the IgLON family 
occurs in the absence of either support or modification of neurite outgrowth." 
J Neurochem 80(6): 941-8. 
Melichar, B., D. Solichova and R. S. Freedman (2006). "Neopterin as an indicator of 
immune activation and prognosis in patients with gynecological 
malignancies." International Journal of Gynecological Cancer 16(1): 240-
252. 
Metzger, D. A., D. L. Olive and A. F. Haney (1988). "Limited hormonal 
responsiveness of ectopic endometrium: Histologic correlation with 
intrauterine endometrium." Human Pathology 19(12): 1417-1424. 
Michael, A. E., M. Evagelatou, et al. (1997). "Isoforms of 11beta-hydroxysteroid 
dehydrogenase in human granulosa-lutein cells." Mol Cell Endocrinol 132(1-
2): 43-52. 
Michailova, K. N. and K. G. Usunoff (2006). "Serosal membranes (pleura, 
pericardium, peritoneum). Normal structure, development and experimental 
pathology." Adv Anat Embryol Cell Biol 183: i-vii, 1-144, back cover. 
Miki, Y., J. Swensen, D. Shattuck-Eidens, P. A. Futreal, K. Harshman, S. Tavtigian, 
Q. Liu, C. Cochran, L. M. Bennett, W. Ding and et al. (1994). "A strong 
candidate for the breast and ovarian cancer susceptibility gene BRCA1." 
Science 266(5182): 66-71. 
Mittal, K. R., A. Zeleniuch-Jacquotte, J. L. Cooper and R. I. Demopoulos (1993). 
"Contralateral ovary in unilateral ovarian carcinoma: a search for 
preneoplastic lesions." Int J Gynecol Pathol 12(1): 59-63. 
Miyata, S., N. Matsumoto and S. Maekawa (2003). "Polarized targeting of IgLON 
cell adhesion molecule OBCAM to dendrites in cultured neurons." Brain Res 
979(1-2): 129-36. 
Modesitt, S. C., E. J. Pavlik, F. R. Ueland, P. D. DePriest, R. J. Kryscio and J. R. van 
Nagell, Jr. (2003). "Risk of malignancy in unilocular ovarian cystic tumors 
less than 10 centimeters in diameter." Obstet Gynecol 102(3): 594-9. 
Modugno, F., R. B. Ness and J. E. Wheeler (2001). "Reproductive risk factors for 
epithelial ovarian cancer according to histologic type and invasiveness." Ann 
Epidemiol 11(8): 568-74. 
Moen, M. H. and K. M. Muus (1991). "Endometriosis in pregnant and non-pregnant 
women at tubal sterilization." Hum. Reprod. 6(5): 699-702. 
 
 253
Moen, M. H. and T. Stokstad (2002). "A long-term follow-up study of women with 
asymptomatic endometriosis diagnosed incidentally at sterilization." Fertility 
and Sterility 78(4): 773-776. 
Moradi, M. M., L. F. Carson, B. Weinberg, A. F. Haney, L. B. Twiggs and S. 
Ramakrishnan (1993). "Serum and ascitic fluid levels of interleukin-1, 
interleukin-6, and tumor necrosis factor-alpha in patients with ovarian 
epithelial cancer." Cancer 72(8): 2433-40. 
Mukherjee, K., V. Syed and S.-M. Ho (2005). "Estrogen-induced loss of 
progesterone receptor expression in normal and malignant ovarian surface 
epithelial cells." Oncogene 24(27): 4388-4400. 
Murdoch, W. J. and J. F. Martinchick (2004). "Oxidative damage to DNA of ovarian 
surface epithelial cells affected by ovulation: carcinogenic implication and 
chemoprevention." Exp Biol Med (Maywood) 229(6): 546-52. 
Murdoch, W. J. and A. C. McDonnel (2002). "Roles of the ovarian surface 
epithelium in ovulation and carcinogenesis." Reproduction 123(6): 743-50. 
Mutsaers, S. E. (2002). "Mesothelial cells: Their structure, function and role in 
serosal repair." Respirology 7(3): 171-191. 
Mutsaers, S. E., D. Whitaker and J. M. Papadimitriou (2002). "Stimulation of 
Mesothelial Cell Proliferation by Exudate Macrophages Enhances Serosal 
Wound Healing in a Murine Model." Am J Pathol 160(2): 681-692. 
Nelson-Rees, W. A., D. W. Daniels and R. R. Flandermeyer (1981). "Cross-
contamination of cells in culture." Science 212(4493): 446-52. 
Ness, R. B. (2003). "Endometriosis and ovarian cancer: thoughts on shared 
pathophysiology." Am J Obstet Gynecol 189(1): 280-94. 
Ness, R. B. and C. Cottreau (1999). "Possible role of ovarian epithelial inflammation 
in ovarian cancer." J Natl Cancer Inst 91(17): 1459-67. 
Ness, R. B., J. A. Grisso, C. Cottreau, J. Klapper, R. Vergona, J. E. Wheeler, M. 
Morgan and J. J. Schlesselman (2000). "Factors related to inflammation of 
the ovarian epithelium and risk of ovarian cancer." Epidemiology 11(2): 111-
7. 
Ness, R. B., J. A. Grisso, R. Vergona, J. Klapper, M. Morgan and J. E. Wheeler 
(2001). "Oral contraceptives, other methods of contraception, and risk 
reduction for ovarian cancer." Epidemiology 12(3): 307-12. 
Newton, T., P. PG, D. J. Lincoln, M. C. Cummings, D. K. Wyld, P. M. Webb, A. C. 
Green and G. M. Boyle (2006). "Expression profiling correlates with 
treatment response in women with advanced serous epithelial ovarian 
cancer." International Journal of Cancer 119(4): 875-883. 
Ntougkos, E., R. Rush, D. Scott, T. Frankenberg, H. Gabra, J. F. Smyth and G. C. 
Sellar (2005). "The IgLON family in epithelial ovarian cancer: expression 
profiles and clinicopathologic correlates." Clin Cancer Res 11(16): 5764-8. 
Obata, K., S. J. Morland, R. H. Watson, A. Hitchcock, G. Chenevix-Trench, E. J. 
Thomas and I. G. Campbell (1998). "Frequent PTEN/MMAC mutations in 
 
 254
endometrioid but not serous or mucinous epithelial ovarian tumors." Cancer 
Res 58(10): 2095-7. 
Odukoya, O. A., R. Ajjan, K. Lim, P. F. Watson, A. P. Weetman and I. D. Cooke 
(1997). "The pattern of cytokine mRNA expression in ovarian 
endometriomata." Mol. Hum. Reprod. 3(5): 393-397. 
Ogawa, S., T. Kaku, S. Amada, H. Kobayashi, T. Hirakawa, K. Ariyoshi, T. Kamura 
and H. Nakano (2000). "Ovarian endometriosis associated with ovarian 
carcinoma: a clinicopathological and immunohistochemical study." Gynecol 
Oncol 77(2): 298-304. 
Okamura, H. and H. Katabuchi (2001). "Detailed morphology of human ovarian 
surface epithelium focusing on its metaplastic and neoplastic capability." Ital 
J Anat Embryol 106(2 Suppl 2): 263-76. 
Omura, G. A., M. F. Brady, H. D. Homesley, E. Yordan, F. J. Major, H. J. 
Buchsbaum and R. C. Park (1991). "Long-term follow-up and prognostic 
factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology 
Group experience." J Clin Oncol 9(7): 1138-50. 
Oral, E., S. Ilvan, E. Tustas, B. Korbeyli, T. Bese, F. Demirkiran, M. Arvas and D. 
Kosebay (2003). "Prevalence of endometriosis in malignant epithelial ovary 
tumours." Eur J Obstet Gynecol Reprod Biol 109(1): 97-101. 
Paley, P. J., E. M. Swisher, R. L. Garcia, S. N. Agoff, B. E. Greer, K. L. Peters and 
B. A. Goff (2001). "Occult Cancer of the Fallopian Tube in BRCA-1 
Germline Mutation Carriers at Prophylactic Oophorectomy: A Case for 
Recommending Hysterectomy at Surgical Prophylaxis." Gynecologic 
Oncology 80(2): 176-180. 
Papacleovoulou, G., R. J. Edmondson, H. O. Critchley, S. G. Hillier and J. I. Mason 
(2008). "3beta-Hydroxysteroid dehydrogenases and pre-receptor steroid 
metabolism in the human ovarian surface epithelium." Mol Cell Endocrinol. 
Piek, J. M., P. Kenemans and R. H. Verheijen (2004). "Intraperitoneal serous 
adenocarcinoma: a critical appraisal of three hypotheses on its cause." Am J 
Obstet Gynecol 191(3): 718-32. 
Piek, J. M., P. J. van Diest and R. H. Verheijen (2008). "Ovarian carcinogenesis: an 
alternative hypothesis." Adv Exp Med Biol 622: 79-87. 
Pimenta, A. F., I. Fischer and P. Levitt (1996). "cDNA cloning and structural 
analysis of the human limbic-system-associated membrane protein (LAMP)." 
Gene 170(2): 189-195. 
Pimenta, A. F., V. Zhukareva, M. F. Barbe, B. S. Reinoso, C. Grimley, W. Henzel, I. 
Fischer and P. Levitt (1995). "The limbic system-associated membrane 
protein is an Ig superfamily member that mediates selective neuronal growth 
and axon targeting." Neuron 15(2): 287-297. 
Prat, J. and M. De Nictolis (2002). "Serous borderline tumors of the ovary: a long-
term follow-up study of 137 cases, including 18 with a micropapillary pattern 
and 20 with microinvasion." Am J Surg Pathol 26(9): 1111-28. 
 
 255
Pronk, A., P. Leguit, A. A. Hoynck van Papendrecht, E. Hagelen, T. J. van 
Vroonhoven and H. A. Verbrugh (1993). "A cobblestone cell isolated from 
the human omentum: the mesothelial cell; isolation, identification, and 
growth characteristics." In Vitro Cell Dev Biol 29A(2): 127-34. 
Purdie, D. M., C. J. Bain, V. Siskind, P. Russell, N. F. Hacker, B. G. Ward, M. A. 
Quinn and A. C. Green (1999). "Hormone replacement therapy and risk of 
epithelial ovarian cancer." Br J Cancer 81(3): 559-63. 
Purdie, D. M., C. J. Bain, V. Siskind, P. M. Webb and A. C. Green (2003). 
"Ovulation and risk of epithelial ovarian cancer." Int J Cancer 104(2): 228-
32. 
Purdie, D. M., P. M. Webb, V. Siskind, C. J. Bain and A. C. Green (2003). "The 
different etiologies of mucinous and nonmucinous epithelial ovarian 
cancers." Gynecol Oncol 88(1 Pt 2): S145-8. 
Rabbitt, E. H., N. J. Gittoes, P. M. Stewart and M. Hewison (2003). "11beta-
hydroxysteroid dehydrogenases, cell proliferation and malignancy." J Steroid 
Biochem Mol Biol 85(2-5): 415-21. 
Rabbitt, E. H., G. G. Lavery, E. A. Walker, M. S. Cooper, P. M. Stewart and M. 
Hewison (2002). "Prereceptor regulation of glucocorticoid action by 11beta-
hydroxysteroid dehydrogenase: a novel determinant of cell proliferation." 
Faseb J 16(1): 36-44. 
Radisavljevic, S. V. (1977). "The pathogenesis of ovarian inclusion cysts and 
cystomas." Obstet Gynecol 49(4): 424-9. 
Rae, M. T., D. Niven, H. O. Critchley, C. R. Harlow and S. G. Hillier (2004). 
"Antiinflammatory steroid action in human ovarian surface epithelial cells." J 
Clin Endocrinol Metab 89(9): 4538-44. 
Rae, M. T., D. Niven, A. Ross, T. Forster, R. Lathe, H. O. Critchley, P. Ghazal and 
S. G. Hillier (2004). "Steroid signalling in human ovarian surface epithelial 
cells: the response to interleukin-1alpha determined by microarray analysis." 
J Endocrinol 183(1): 19-28. 
Rae, M. T., D. Price, C. R. Harlow, H. O. Critchley and S. G. Hillier (2008). 
"Glucocorticoid receptor-mediated regulation of MMP9 gene expression in 
human ovarian surface epithelial cells." Fertil Steril. 
Redwine, D. B. (2002). "Was Sampson wrong?" Fertility and Sterility 78(4): 686-
693. 
Reed, J., C. McNamee, S. Rackstraw, J. Jenkins and D. Moss (2004). "Diglons are 
heterodimeric proteins composed of IgLON subunits, and Diglon-CO inhibits 
neurite outgrowth from cerebellar granule cells." J Cell Sci 117(Pt 17): 3961-
73. 
Riman, T., P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, 
E. Weiderpass and I. R. Persson (2002). "Hormone replacement therapy and 
the risk of invasive epithelial ovarian cancer in Swedish women." J Natl 
Cancer Inst 94(7): 497-504. 
 
 256
Risch, H. A., J. R. McLaughlin, D. E. C. Cole, B. Rosen, L. Bradley, E. Kwan, E. 
Jack, D. J. Vesprini, G. Kuperstein, J. L. A. Abrahamson, I. Fan, B. Wong 
and S. A. Narod (2001). "Prevalence and penetrance of germline BRCA1 and 
BRCA2 mutations in a population series of 649 women with ovarian cancer." 
American Journal of Human Genetics 68(3): 700-710. 
Robson, R. L., R. M. McLoughlin, J. Witowski, P. Loetscher, T. S. Wilkinson, S. A. 
Jones and N. Topley (2001). "Differential regulation of chemokine 
production in human peritoneal mesothelial cells: IFN-gamma controls 
neutrophil migration across the mesothelium in vitro and in vivo." J Immunol 
167(2): 1028-38. 
Rodriguez, C., A. V. Patel, E. E. Calle, E. J. Jacob and M. J. Thun (2001). "Estrogen 
replacement therapy and ovarian cancer mortality in a large prospective study 
of US women." Jama 285(11): 1460-5. 
Rodriguez, G. C., N. P. Nagarsheth, K. L. Lee, R. C. Bentley, D. K. Walmer, M. 
Cline, R. S. Whitaker, P. Isner, A. Berchuck, R. K. Dodge and C. L. Hughes 
(2002). "Progestin-Induced Apoptosis in the Macaque Ovarian Epithelium: 
Differential Regulation of Transforming Growth Factor-{beta}." J. Natl. 
Cancer Inst. 94(1): 50-60. 
Rosenblatt, K. A. and D. B. Thomas (1996). "Reduced risk of ovarian cancer in 
women with a tubal ligation or hysterectomy. The World Health Organization 
Collaborative Study of Neoplasia and Steroid Contraceptives." Cancer 
Epidemiol Biomarkers Prev 5(11): 933-5. 
Roy, K. K., P. Hegde, K. Banerjee, N. Malhotra, B. Nayyar, D. Deka and S. Kumar 
(2005). "Fimbrio-ovarian relationship in unexplained infertility." Gynecol 
Obstet Invest 60(3): 128-32. 
Roy, S., Y. X. Zhu, N. M. Lee and H. H. Loh (1988). "Different molecular weight 
forms of opioid receptors revealed by polyclonal antibodies." Biochemical 
and Biophysical Research Communications 150(1): 237-244. 
Rubin, S. C., I. Benjamin, K. Behbakht, H. Takahashi, M. A. Morgan, V. A. LiVolsi, 
A. Berchuck, M. G. Muto, J. E. Garber, B. L. Weber, H. T. Lynch and J. 
Boyd (1996). "Clinical and pathological features of ovarian cancer in women 
with germ-line mutations of BRCA1." N Engl J Med 335(19): 1413-6. 
Ryan, I. P., J. F. Tseng, E. D. Schriock, O. Khorram, D. V. Landers and R. N. Taylor 
(1995). "Interleukin-8 concentrations are elevated in peritoneal fluid of 
women with endometriosis." Fertil Steril 63(4): 929-32. 
Saga, Y., H. Mizukami, M. Suzuki, M. Urabe, A. Kume, T. Nakamura, I. Sato and K. 
Ozawa (2001). "Expression of HGF/NK4 in ovarian cancer cells suppresses 
intraperitoneal dissemination and extends host survival." Gene Ther 8(19): 
1450-5. 
Sainz de la Cuesta, R., J. H. Eichhorn, L. W. Rice, J. A. F. Fuller, N. Nikrui and B. 
A. Goff (1996). "Histologic Transformation of Benign Endometriosis to 
Early Epithelial Ovarian Cancer." Gynecologic Oncology 60(2): 238-244. 
 
 257
Salamanca, C. M., S. L. Maines-Bandiera, P. C. Leung, Y. L. Hu and N. Auersperg 
(2004). "Effects of epidermal growth factor/hydrocortisone on the growth and 
differentiation of human ovarian surface epithelium." J Soc Gynecol Investig 
11(4): 241-51. 
Sampson, J. (1927). "Peritoneal endometriosis due to the menstrual dissemination of 
endometrial tissue into the peritoneal cavity." Am J Obstet Gynecol 14: 422–
469. 
Sawada, K., A. R. Radjabi, N. Shinomiya, E. Kistner, H. Kenny, A. R. Becker, M. A. 
Turkyilmaz, R. Salgia, S. D. Yamada, G. F. Vande Woude, M. S. Tretiakova 
and E. Lengyel (2007). "c-Met Overexpression Is a Prognostic Factor in 
Ovarian Cancer and an Effective Target for Inhibition of Peritoneal 
Dissemination and Invasion." Cancer Res 67(4): 1670-1679. 
Schaner, M. E., D. T. Ross, G. Ciaravino, T. Sorlie, O. Troyanskaya, M. Diehn, Y. 
C. Wang, G. E. Duran, T. L. Sikic, S. Caldeira, H. Skomedal, I. P. Tu, T. 
Hernandez-Boussard, S. W. Johnson, P. J. O'Dwyer, M. J. Fero, G. B. 
Kristensen, A. L. Borresen-Dale, T. Hastie, R. Tibshirani, M. van de Rijn, N. 
N. Teng, T. A. Longacre, D. Botstein, P. O. Brown and B. I. Sikic (2003). 
"Gene expression patterns in ovarian carcinomas." Mol Biol Cell 14(11): 
4376-86. 
Schildkraut, J. M., E. Bastos and A. Berchuck (1997). "Relationship between lifetime 
ovulatory cycles and overexpression of mutant p53 in epithelial ovarian 
cancer." J Natl Cancer Inst 89(13): 932-8. 
Schildkraut, J. M., B. Calingaert, P. A. Marchbanks, P. G. Moorman and G. C. 
Rodriguez (2002). "Impact of progestin and estrogen potency in oral 
contraceptives on ovarian cancer risk." J Natl Cancer Inst 94(1): 32-8. 
Scully, R. E. (1995). "Pathology of ovarian cancer precursors." J Cell Biochem Suppl 
23: 208-18. 
Seidman, J. D., A. M. Elsayed, L. H. Sobin and F. A. Tavassoli (1993). "Association 
of mucinous tumors of the ovary and appendix. A clinicopathologic study of 
25 cases." Am J Surg Pathol 17(1): 22-34. 
Sellar, G. C., K. P. Watt, G. J. Rabiasz, E. A. Stronach, L. Li, E. P. Miller, C. E. 
Massie, J. Miller, B. Contreras-Moreira, D. Scott, I. Brown, A. R. Williams, 
P. A. Bates, J. F. Smyth and H. Gabra (2003). "OPCML at 11q25 is 
epigenetically inactivated and has tumor-suppressor function in epithelial 
ovarian cancer." Nat Genet 34(3): 337-43. 
Serrano-Olvera, A., A. Duenas-Gonzalez, D. Gallardo-Rincon, M. Candelaria and J. 
De la Garza-Salazar (2006). "Prognostic, predictive and therapeutic 
implications of HER2 in invasive epithelial ovarian cancer." Cancer 
Treatment Reviews 32(3): 180-190. 
Sevelda, P., U. Denison, M. Schemper, J. Spona, N. Vavra and H. Salzer (1990). 
"Oestrogen and progesterone receptor content as a prognostic factor in 
advanced epithelial ovarian carcinoma." Br J Obstet Gynaecol 97(8): 706-12. 
 
 258
Shark, K. B. and N. M. Lee (1995). "Cloning, sequencing and localization to 
chromosome 11 of a cDNA encoding a human opioid-binding cell adhesion 
molecule (OBCAM)." Gene 155(2): 213-7. 
Shen, L., J. V. Fahey, S. B. Hussey, S. N. Asin, C. R. Wira and M. W. Fanger 
(2004). "Synergy between IL-8 and GM-CSF in reproductive tract epithelial 
cell secretions promotes enhanced neutrophil chemotaxis." Cell Immunol 
230(1): 23-32. 
Shih Ie, M. and R. J. Kurman (2004). "Ovarian tumorigenesis: a proposed model 
based on morphological and molecular genetic analysis." Am J Pathol 164(5): 
1511-8. 
Sieben, N. L., G. M. Roemen, J. Oosting, G. J. Fleuren, M. van Engeland and J. Prat 
(2006). "Clonal analysis favours a monoclonal origin for serous borderline 
tumours with peritoneal implants." J Pathol 210(4): 405-11. 
Sieben, N. L. G., J. Oosting, A. M. Flanagan, J. Prat, G. M. J. M. Roemen, S. M. 
Kolkman-Uljee, R. van Eijk, C. J. Cornelisse, G. J. Fleuren and M. van 
Engeland (2005). "Differential Gene Expression in Ovarian Tumors Reveals 
Dusp 4 and Serpina 5 As Key Regulators for Benign Behavior of Serous 
Borderline Tumors." J Clin Oncol 23(29): 7257-7264. 
Silver, D. P., S. D. Dimitrov, J. Feunteun, R. Gelman, R. Drapkin, S. D. Lu, E. 
Shestakova, S. Velmurugan, N. DeNunzio, S. Dragomir, J. Mar, X. Liu, S. 
Rottenberg, J. Jonkers, S. Ganesan and D. M. Livingston (2007). "Further 
Evidence for BRCA1 Communication with the Inactive X Chromosome." 
Cell 128(5): 991-1002. 
Simon, C., A. Frances, G. Piquette and M. L. Polan (1994). "Immunohistochemical 
localization of the interleukin-1 system in the mouse ovary during follicular 
growth, ovulation, and luteinization." Biol Reprod 50(2): 449-57. 
Siskind, V., A. Green, C. Bain and D. Purdie (2000). "Beyond ovulation: Oral 
contraceptives and epithelial ovarian cancer." Epidemiology 11(2): 106-110. 
Sit, A. S., F. Modugno, J. L. Weissfeld, S. L. Berga and R. B. Ness (2002). 
"Hormone replacement therapy formulations and risk of epithelial ovarian 
carcinoma." Gynecol Oncol 86(2): 118-23. 
Skaane, P., T. Sauer and F. Jerve (1986). "Mucinous adenocarcinoma of the 
appendix presenting as an ovarian cystadenocarcinoma: case report and 
review of appendiceal neoplasms with ovarian metastases." Eur J Surg Oncol 
12(4): 379-84. 
Smyth, J. F., C. Gourley, G. Walker, M. J. MacKean, A. Stevenson, A. R. W. 
Williams, A. A. Nafussi, T. Rye, R. Rye, M. Stewart, J. McCurdy, M. Mano, 
N. Reed, T. McMahon, P. Vasey, H. Gabra and S. P. Langdon (2007). 
"Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use 




Sowter, H. M., A. N. Corps and S. K. Smith (1999). "Hepatocyte growth factor 
(HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian 
carcinoma cells." Int J Cancer 83(4): 476-80. 
Spaltmann, F. and T. Brummendorf (1996). "CEPU-1, a novel immunoglobulin 
superfamily molecule, is expressed by developing cerebellar Purkinje cells." J 
Neurosci 16(5): 1770-9. 
Spears, N., M. D. Molinek, L. L. Robinson, N. Fulton, H. Cameron, K. Shimoda, E. 
E. Telfer, R. A. Anderson and D. J. Price (2003). "The role of neurotrophin 
receptors in female germ-cell survival in mouse and human." Development 
130(22): 5481-91. 
Stadlmann, S., A. Amberger, J. Pollheimer, G. Gastl, F. A. Offner, R. Margreiter and 
A. G. Zeimet (2005). "Ovarian carcinoma cells and IL-1[beta]-activated 
human peritoneal mesothelial cells are possible sources of vascular 
endothelial growth factor in inflammatory and malignant peritoneal 
effusions." Gynecologic Oncology 97(3): 784-789. 
Steffensen K.D. , M. W. U. J. E. J. I. B. A. J. (2007). "The prognostic importance of 
cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer." 
International Journal of Gynecological Cancer 17(4): 798-807. 
Struyk, A. F., P. D. Canoll, M. J. Wolfgang, C. L. Rosen, P. D'Eustachio and J. L. 
Salzer (1995). "Cloning of neurotrimin defines a new subfamily of 
differentially expressed neural cell adhesion molecules." J Neurosci 15(3 Pt 
2): 2141-56. 
Stylianou, E., L. A. Jenner, M. Davies, G. A. Coles and J. D. Williams (1990). 
"Isolation, culture and characterization of human peritoneal mesothelial 
cells." Kidney Int 37(6): 1563-70. 
Sulaiman, H., G. Gabella, M. C. Davis, S. E. Mutsaers, P. Boulos, G. J. Laurent and 
S. E. Herrick (2001). "Presence and distribution of sensory nerve fibers in 
human peritoneal adhesions." Ann Surg 234(2): 256-61. 
Sumithran, E. and B. J. Susil (1992). "Concomitant mucinous tumors of appendix 
and ovary. Result of a neoplastic field change?" Cancer 70(12): 2980-3. 
Sun, K. and L. Myatt (2003). "Enhancement of glucocorticoid-induced 11beta-
hydroxysteroid dehydrogenase type 1 expression by proinflammatory 
cytokines in cultured human amnion fibroblasts." Endocrinology 144(12): 
5568-77. 
Sundfeldt, K., Y. Piontkewitz, K. Ivarsson, O. Nilsson, P. Hellberg, M. Brannstrom, 
P. O. Janson, S. Enerback and L. Hedin (1997). "E-cadherin expression in 
human epithelial ovarian cancer and normal ovary." Int J Cancer 74(3): 275-
80. 
Syed, V. and S. M. Ho (2003). "Progesterone-induced apoptosis in immortalized 
normal and malignant human ovarian surface epithelial cells involves 
enhanced expression of FasL." Oncogene 22(44): 6883-90. 
Syed, V., G. Ulinski, S. C. Mok, G. K. Yiu and S. M. Ho (2001). "Expression of 
gonadotropin receptor and growth responses to key reproductive hormones in 
 
 260
normal and malignant human ovarian surface epithelial cells." Cancer Res 
61(18): 6768-76. 
Szlosarek, P. W., M. J. Grimshaw, H. Kulbe, J. L. Wilson, G. D. Wilbanks, F. Burke 
and F. R. Balkwill (2006). "Expression and regulation of tumor necrosis 
factor alpha in normal and malignant ovarian epithelium." Mol Cancer Ther 
5(2): 382-90. 
Takahashi, K., H. Sasano, K. Fukushima, G. Hirasawa, H. Miura, I. Sasaki, S. 
Matsuno, Z. S. Krozowski and H. Nagura (1998). "11 beta-hydroxysteroid 
dehydrogenase type II in human colon: a new marker of fetal development 
and differentiation in neoplasms." Anticancer Res 18(5A): 3381-8. 
Taketani, Y., T. M. Kuo and M. Mizuno (1992). "Comparison of cytokine levels and 
embryo toxicity in peritoneal fluid in infertile women with untreated or 
treated endometriosis." Am J Obstet Gynecol 167(1): 265-70. 
Tan, O. L., P. R. Hurst and J. S. Fleming (2005). "Location of inclusion cysts in 
mouse ovaries in relation to age, pregnancy, and total ovulation number: 
implications for ovarian cancer?" J Pathol 205(4): 483-90. 
Tanaka, K., C. R. Boice and J. R. Testa (1989). "Chromosome aberrations in nine 
patients with ovarian cancer." Cancer Genetics and Cytogenetics 43(1): 1-14. 
Temkin, S., V. L. Nacharaju, M. Hellman, Y. C. Lee and O. Abulafia (2006). "Type 
2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer." 
Steroids 71(11-12): 1019-23. 
Tetsuka, M., L. C. Haines, M. Milne, G. E. Simpson and S. G. Hillier (1999). 
"Regulation of 11beta-hydroxysteroid dehydrogenase type 1 gene expression 
by LH and interleukin-1beta in cultured rat granulosa cells." J Endocrinol 
163(3): 417-23. 
Tetsuka, M., M. Milne, G. E. Simpson and S. G. Hillier (1999). "Expression of 
11beta-hydroxysteroid dehydrogenase, glucocorticoid receptor, and 
mineralocorticoid receptor genes in rat ovary." Biol Reprod 60(2): 330-5. 
Tetsuka, M., F. J. Thomas, M. J. Thomas, R. A. Anderson, J. I. Mason and S. G. 
Hillier (1997). "Differential expression of messenger ribonucleic acids 
encoding 11beta-hydroxysteroid dehydrogenase types 1 and 2 in human 
granulosa cells." J Clin Endocrinol Metab 82(6): 2006-9. 
Thornton, J. W. (2001). "Evolution of vertebrate steroid receptors from an ancestral 
estrogen receptor by ligand exploitation and serial genome expansions." 
PNAS 98(10): 5671-5676. 
Thorsen, P., H. Dybdahl, H. Sogaard and B. R. Moller (1991). "Ovarian tumors 
caused by metastatic tumors of the appendix; two case reports." Eur J Obstet 
Gynecol Reprod Biol 40(1): 67-71. 
Tomlinson, J. W., J. Moore, M. S. Cooper, I. Bujalska, M. Shahmanesh, C. Burt, A. 
Strain, M. Hewison and P. M. Stewart (2001). "Regulation of expression of 
11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific 
induction by cytokines." Endocrinology 142(5): 1982-9. 
 
 261
Topley, N., M. M. Petersen, R. Mackenzie, A. Neubauer, E. Stylianou, V. Kaever, 
M. Davies, G. A. Coles, A. Jorres and J. D. Williams (1994). "Human 
peritoneal mesothelial cell prostaglandin synthesis: induction of 
cyclooxygenase mRNA by peritoneal macrophage-derived cytokines." 
Kidney Int 46(3): 900-9. 
Ushijima, T., T. Nakajima and T. Maekita (2006). "DNA methylation as a marker for 
the past and future." J Gastroenterol 41(5): 401-7. 
Valentin, L., L. Skoog and E. Epstein (2003). "Frequency and type of adnexal lesions 
in autopsy material from postmenopausal women: ultrasound study with 
histological correlation." Ultrasound Obstet Gynecol 22(3): 284-9. 
van Bokhoven, A., M. Varella-Garcia, C. Korch, D. Hessels and G. J. Miller (2001). 
"Widely used prostate carcinoma cell lines share common origins." Prostate 
47(1): 36-51. 
Van der Hoek, K. H., S. Maddocks, C. M. Woodhouse, N. van Rooijen, S. A. 
Robertson and R. J. Norman (2000). "Intrabursal Injection of Clodronate 
Liposomes Causes Macrophage Depletion and Inhibits Ovulation in the 
Mouse Ovary." Biol Reprod 62(4): 1059-1066. 
Vasey, P. A., L. N. Shulman, S. Campos, J. Davis, M. Gore, S. Johnston, D. H. Kirn, 
V. O'Neill, N. Siddiqui, M. V. Seiden and S. B. Kaye (2002). "Phase I Trial 
of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus 
ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients 
With Recurrent/Refractory Epithelial Ovarian Cancer." J Clin Oncol 20(6): 
1562-1569. 
Venkitaraman, A. R. (2002). "Cancer Susceptibility and the Functions of BRCA1 
and BRCA2." Cell 108(2): 171-182. 
Vercellini, P., F. Parazzini, G. Bolis, S. Carinelli, M. Dindelli, N. Vendola, L. 
Luchini and P. G. Crosignani (1993). "Endometriosis and ovarian cancer." 
Am J Obstet Gynecol 169(1): 181-2. 
Vercellini, P., G. Scarfone, G. Bolis, G. Stellato, S. Carinelli and P. G. Crosignani 
(2000). "Site of origin of epithelial ovarian cancer: the endometriosis 
connection." Bjog 107(9): 1155-7. 
Verri, E., P. Guglielmini, M. Puntoni, L. Perdelli, A. Papadia, P. Lorenzi, A. 
Rubagotti, N. Ragni and F. Boccardo (2005). "HER2/neu oncoprotein 
overexpression in epithelial ovarian cancer: evaluation of its prevalence and 
prognostic significance. Clinical study." Oncology 68(2-3): 154-61. 
Vigano, P., E. Somigliana, et al. (2007). "Bias versus causality: interpreting recent 
evidence of association between endometriosis and ovarian cancer." Fertil 
Steril 88(3): 588-93. 
Vincenti, M. P. and C. E. Brinckerhoff (2001). "Early response genes induced in 
chondrocytes stimulated with the inflammatory cytokine interleukin-1beta." 
Arthritis Res 3(6): 381-8. 
Wamunyokoli, F. W., T. Bonome, J.-Y. Lee, C. M. Feltmate, W. R. Welch, M. 
Radonovich, C. Pise-Masison, J. Brady, K. Hao, R. S. Berkowitz, S. Mok and 
 
 262
M. J. Birrer (2006). "Expression Profiling of Mucinous Tumors of the Ovary 
Identifies Genes of Clinicopathologic Importance." Clin Cancer Res 12(3): 
690-700. 
Wang, V., C. Li, M. Lin, W. Welch, D. Bell, Y. F. Wong, R. Berkowitz, S. C. Mok 
and C. A. Bandera (2005). "Ovarian cancer is a heterogeneous disease." 
Cancer Genet Cytogenet 161(2): 170-3. 
Welsh, J. B., P. P. Zarrinkar, L. M. Sapinoso, S. G. Kern, C. A. Behling, B. J. Monk, 
D. J. Lockhart, R. A. Burger and G. M. Hampton (2001). "Analysis of gene 
expression profiles in normal and neoplastic ovarian tissue samples identifies 
candidate molecular markers of epithelial ovarian cancer." PNAS 98(3): 
1176-1181. 
Werness, B. A., A. M. Afify, K. L. Bielat, G. H. Eltabbakh, M. S. Piver and J. M. 
Paterson (1999). "Altered surface and cyst epithelium of ovaries removed 
prophylactically from women with a family history of ovarian cancer." Hum 
Pathol 30(2): 151-7. 
Whiteman, D. C., M. F. G. Murphy, L. S. Cook, D. W. Cramer, P. Hartge, P. A. 
Marchbanks, P. C. Nasca, R. B. Ness, D. M. Purdie and H. A. Risch (2000). 
"Multiple Births and Risk of Epithelial Ovarian Cancer." J. Natl. Cancer Inst. 
92(14): 1172-1177. 
Widschwendter, M., G. Jiang, C. Woods, H. M. Muller, H. Fiegl, G. Goebel, C. 
Marth, E. Muller-Holzner, A. G. Zeimet, P. W. Laird and M. Ehrlich (2004). 
"DNA Hypomethylation and Ovarian Cancer Biology." Cancer Res 64(13): 
4472-4480. 
Wilson, A. P. (2004). The Development of Human Ovarian Tumor Cell Lines from 
Solid Tumors and Ascites. Culture of Human Tumor Cells. R. F. Pfragner, 
R.I., Wiley-Liss Inc.: 145-178. 
Wilson, D. J., D. S. Kim, G. A. Clarke, S. Marshall-Clarke and D. J. Moss (1996). 
"A family of glycoproteins (GP55), which inhibit neurite outgrowth, are 
members of the Ig superfamily and are related to OBCAM, neurotrimin, 
LAMP and CEPU-1." J Cell Sci 109 ( Pt 13): 3129-38. 
Wilson J and Jungner G (1968). Principles and Practice of Screening for Disease. 
Geneva, WHO. 
Witz, C. A., K. T. Allsup, I. A. Montoya-Rodriguez, S. L. Vaughn, V. E. Centonze 
and R. S. Schenken (2002). "Culture of menstrual endometrium with 
peritoneal explants and mesothelial monolayers confirms attachment to intact 
mesothelial cells." Hum Reprod 17(11): 2832-8. 
Witz, C. A., M. R. Thomas, I. A. Montoya-Rodriguez, A. S. Nair, V. E. Centonze 
and R. S. Schenken (2001). "Short-term culture of peritoneum explants 
confirms attachment of endometrium to intact peritoneal mesothelium." Fertil 
Steril 75(2): 385-90. 
Wong, A. S. T., C. D. Roskelley, S. Pelech, D. Miller, P. C. K. Leung and N. 
Auersperg (2004). "Progressive changes in Met-dependent signaling in a 
 
 263
human ovarian surface epithelial model of malignant transformation." 
Experimental Cell Research 299(1): 248-256. 
Wooster, R., G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, N. Collins, S. 
Gregory, C. Gumbs and G. Micklem (1995). "Identification of the breast 
cancer susceptibility gene BRCA2." Nature 378(6559): 789-92. 
Wu, R., K. H. Van der Hoek, N. K. Ryan, R. J. Norman and R. L. Robker (2004). 
"Macrophage contributions to ovarian function." Hum Reprod Update 10(2): 
119-33. 
Xiao, C., J. A. Sharp, M. Kawahara, A. R. Davalos, M. J. Difilippantonio, Y. Hu, W. 
Li, L. Cao, K. Buetow, T. Ried, B. P. Chadwick, C.-X. Deng and B. Panning 
(2007). "The XIST Noncoding RNA Functions Independently of BRCA1 in 
X Inactivation." Cell 128(5): 977-989. 
Yong, P. Y., C. Harlow, K. J. Thong and S. G. Hillier (2002). "Regulation of 11beta-
hydroxysteroid dehydrogenase type 1 gene expression in human ovarian 
surface epithelial cells by interleukin-1." Hum Reprod 17(9): 2300-6. 
Young, R. H., C. B. Gilks and R. E. Scully (1991). "Mucinous tumors of the 
appendix associated with mucinous tumors of the ovary and pseudomyxoma 
peritonei. A clinicopathological analysis of 22 cases supporting an origin in 
the appendix." Am J Surg Pathol 15(5): 415-29. 
Zebrowski, B. K., W. Liu, K. Ramirez, Y. Akagi, G. B. Mills and L. M. Ellis (1999). 
"Markedly elevated levels of vascular endothelial growth factor in malignant 
ascites." Ann Surg Oncol 6(4): 373-378. 
Zeimet, A. G., M. Widschwendter, C. Knabbe, D. Fuchs, M. Herold, E. Muller-
Holzner, G. Daxenbichler, F. A. Offner, O. Dapunt and C. Marth (1998). 
"Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer." 
J Clin Oncol 16(5): 1861-8. 
Zha, S., V. Yegnasubramanian, W. G. Nelson, W. B. Isaacs and A. M. De Marzo 
(2004). "Cyclooxygenases in cancer: progress and perspective." Cancer 
Letters 215(1): 1-20. 
Zhang, X. Y., R. Pettengell, N. Nasiri, V. Kalia, A. G. Dalgleish and D. P. Barton 
(1999). "Characteristics and growth patterns of human peritoneal mesothelial 
cells: comparison between advanced epithelial ovarian cancer and non-
ovarian cancer sources." J Soc Gynecol Investig 6(6): 333-40. 
Zheng, J., W. F. Benedict, H.-J. Xu, S.-X. Hu, T. M. Kim, M. Velicescu, M. Wan, K. 
F. Cofer and L. Dubeau (1995). "Genetic Disparity Between Morphologically 
Benign Cysts Contiguous to Ovarian Carcinomas and Solitary 
Cystadenomas." J. Natl. Cancer Inst. 87(15): 1146-1153. 
Ziegler, C., M. Torchia, G. R. Grahame and I. A. Ferguson (1989). "Peritoneal 
surface-active material in continuous ambulatory peritoneal dialysis (CAPD) 
patients." Perit Dial Int 9(1): 47-9. 
Ziltener, H. J., S. Maines-Bandiera, J. W. Schrader and N. Auersperg (1993). 
"Secretion of bioactive interleukin-1, interleukin-6, and colony-stimulating 
factors by human ovarian surface epithelium." Biol Reprod 49(3): 635-41. 
 
 264
Zipper, H., H. Brunner, J. Bernhagen and F. Vitzthum (2004). "Investigations on 
DNA intercalation and surface binding by SYBR Green I, its structure 
determination and methodological implications." Nucleic Acids Res 32(12): 
e103. 
Zorn, K. K., A. A. Jazaeri, C. S. Awtrey, G. J. Gardner, S. C. Mok, J. Boyd and M. J. 
Birrer (2003). "Choice of Normal Ovarian Control Influences Determination 
of Differentially Expressed Genes in Ovarian Cancer Expression Profiling 














Ovulation, Inflammation and The Normal Ovarian Surface Epithelium 
 
Chief Investigator – Dr Scott Fegan  
Research Nurses – Catherine Murray, Sharon McPherson 
Centre for Reproductive Biology, The Queen’s Medical Research Institute, 47 Little 
France Crescent, Edinburgh EH16 4TJ 
Telephone – 0131 242 2483 
 
You are being invited to take part in a research study.  Before you decide to take part it is 
important for you to understand why the research is being done and what it will involve.  
Please read the following information carefully and ask us if there is anything that is not 




There is now evidence that the ovarian surface (OSE) may play an important role in the 
release of an egg from the ovary – a process known as ovulation.  Ovulation is a complicated 
event which we are only beginning to understand.  Our research involves the investigation of 
how ovulation affects the OSE.  This will help us understand not only ovulation but also how 
more serious conditions affecting the ovary might arise.  We want to start off by looking at 




We are asking for your permission to take a sample of your OSE cells during your operation. 
The OSE cells are very loosely attached to the outside of the ovary and can be easily 
collected at the time of operation by gentle scraping of the ovary, rather like when a 
cervical smear is performed.  We are interested in finding out if the OSE cells are related 
to the cells lining the rest of the abdominal cavity (peritoneum) and may also wish to collect 
a further sample of these peritoneal cells, again by gentle scraping.  The sample collection 
takes only a few seconds and will not delay your operation or cause any side effects.  It will 
not cause any damage to the ovaries or underlying tissues.  There will be no increased pain or 
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discomfort as a result of your participation and your recovery from the operation will not be 
affected.   
 
Once the cells are collected they will be taken to the laboratory until enough cells have 
grown (possibly up to 6-8 weeks).  At this stage the effect of hormones involved with 
ovulation on the cells will be studied.  In most cases the cells will not survive beyond this 
time.  However in a few cases we may wish to keep the cells alive for longer by introducing a 
survival gene called hTERT which prevents the cells from ageing.  This means the cells could 
be used for related experiments in the future.  All laboratory work will be carried out at the 
University of Edinburgh.  
 
What to do if you wish to participate. 
 
If you wish to participate we will ask you a few questions about your health.  All information 
about you will be kept confidential.  Your name or address will not appear on any sample 
container. It is up to you to decide whether you take part.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form.  If you 
decide to take part you are still free to withdraw at any time and without giving a reason.  A 
decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive.  We will seek your permission to contact your GP and let them know of 
your participation. 
 
You will not benefit directly by participating but your involvement in this study will add to 
our knowledge of ovarian biology.  Your gynaecologist is independent of this study and will 
not benefit from your involvement.  You will not be able to find out the results of 
experiments on your own sample but we hope to publish the results of the project in 
scientific journals at a later date.  Posters that have been presented at scientific meetings 
may be available for viewing at the Simpson Centre for Reproductive Health. 
 
Cover for negligence is in place by virtue of the code of employment for approved patient 
research.  No special arrangements will be made to cover non-negligent actions but normal 
channels for dealing with complaints are in place.   
 
This study has been approved by the local ethics committee. 
 
If you wish further information from a doctor who is not involved in this study in any way 
you can contact Dr C P West, Simpson Centre for Reproductive Health, Royal Infirmary of 
Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA. Tel 0131 242 2525. 
 
Thank you for reading this information sheet. 
 
 
Study Number: LREC 04/S1103/36 
Patient Identification Number for this trial: 
 
 
CONSENT FORM  
Version 3 – 7th July 2005    
Department of Obstetrics and Gynaecology 
Study Title Ovulation, Inflammation and the Normal Ovarian Surface 
Epithelium 
 
Name of Researcher: 
 
Dr K S Fegan 
University of Edinburgh Cancer Research Unit 
Western General Hospital  
Crewe Road South 
Edinburgh 
EH4 2XR  
Tel: 0131 777 3500 
Or : 0131 242 2483 (Research Nurses) 
 
1. I confirm that I have read and understand the information sheet for the above study and 
have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
 without giving any reason, and without my medical care or legal rights being affected. 
3. I agree to a letter being sent to my General Practitioner about my participation in this 
study. 
4. I agree to the provision of any clinically significant information to my General Practitioner. 
5 I understand that my medical notes may be looked at by the researchers involved in the 
study or from regulatory authorities where it is relevant to my taking part in research. 
 I give permission for these individuals to have access to my records. 
6. I agree that the sample I have given and the information gathered from me may be stored 
by Dr K S Fegan and Professor S G Hillier at the Centre for Reproductive Biology and 
Cancer Research Unit, University of Edinburgh for possible use in future projects, as 
described in the attached information sheet.  I understand that some of these projects 
may be carried out by researchers other than Dr Fegan who ran the first project. 
7. I understand that this is non-therapeutic research from which I cannot expect to derive any 
benefit. 
8.  I agree to take part in the above study. 
 
 
________________________ _______________ ________________ 
Name of Patient Date Signature 
 
_________________________ ________________     ________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ ________________ ________________ 
Researcher Date Signature 
 
 
1 for patient;  1 for researcher;  1 to be kept with hospital notes 
 
Ref.          
 
  Reproductive & Developmental Sciences 
(Obstetrics & Gynaecology) 
The University of Edinburgh 
Centre For Reproductive Biology 
The Queen’s Medical Research Institute 















Your patient has agreed we may contact you to inform you that she has consented to 
taking part in a research study entitled “Ovulation, Inflammation and the Normal 
Ovarian Surface Epithelium”.  Ethical approval has been granted by the local ethics 
committee.  The study involved obtaining a sample of ovarian surface epithelial 
(OSE) cells at the time of her scheduled hysterectomy / laparoscopy  
on  / / . 
 
The ovarian surface epithelium, or OSE is intimately involved in ovulation, which can 
be considered a naturally occurring inflammatory process.  However, inflammation 
itself can cause cell damage and damage to DNA, which may predispose to cancer.  
The aim of this study is to investigate the role of inflammation in the development of 
ovarian cancer. 
 
Please contact me if you would like any further information. 
 








Dr K Scott Fegan MRCOG 
Cancer Research UK Clinical Research Fellow 
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Patient information sheet 
                        
 
                         Department of Obstetrics and 
Gynaecology 
 
Inflammation In The Normal And Diseased Ovary 
 
Chief Investigator – Dr Scott Fegan  
Research Nurses – Catherine Murray, Sharon McPherson 
Centre for Reproductive Biology, Chancellor’s Building, 49 Little France Crescent, 
Edinburgh, EH16 4SB 
Telephone – 0131 242 2483 (Research Nurses) 0131 777 3500 (Dr Fegan) 
 
You are being invited to take part in a research study.  Before you decide to take part it is 
important for you to understand why the research is being done and what it will involve.  
Please read the following information carefully and ask us if there is anything that is not 
clear, or if you would like more information. 
 
What is the Research About? 
 
You are undergoing an operation because your doctor has discovered a problem with one or 
both of your ovaries.  It is uncertain how ovarian disease arises but by examining the ovaries 
after your operation we hope to identify some clues as to how it occurs.  We are hoping to 
grow some of the cells from the ovary and the fluid.  Then we can look at the genetic 
material (DNA) in the ovary and fluid and compare it with that in your blood. This may help 
us in the future to identify women with ovarian disease before it becomes serious and help 
to find ways of preventing it. 
 
What will I be asked to give? 
 
Firstly, we are asking for your permission to take an extra sample of blood when you are in 
hospital.  This will be a similar amount to that taken for routine tests before your operation 
(about an egg-cupful).  Your surgeon will carry out your operation as planned.  In addition to 
removal of the diseased tissue, the surgeon will take samples of fluid from your pelvis to 
check for the presence of abnormal cells.  This fluid and tissue is sent to the pathologist for 
detailed examination.  
 We are asking for your permission to take samples from : 
1. the cells covering both the normal and diseased ovaries by gently scraping the ovaries 
at the beginning of the operation 
2. the fluid from inside your tummy 
3. the normal and diseased ovaries 
4. the fatty tissue inside the tummy  
These will be used for research in our laboratory.  This will not affect the length of your 
operation or delay your recovery and will not affect the quality of the samples received by 
the pathologist.    Participating carries no additional risk to your health.  We are also asking 
for your permission to keep and store any samples you donate for related experiments in the 
future.  All work will be done at the University of Edinburgh. 
 
How Can I Take Part? 
 
If you wish to take part we will speak to you when you come into hospital and ask you a few 
questions about your health.  All information about you will be kept confidential.  Your name 
or address will not appear on any sample container. It is up to you to decide whether you 
take part.  If you do decide to take part you will be given this information sheet to keep and 
be asked to sign a consent form.  We will seek your permission to contact your GP and let 
them know of your participation. 
 
Can I Change My Mind? 
 
If you decide to take part you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive.   
 
You will not benefit directly by participating but your involvement in this study may help 
women with diseases of the ovary in the future.  Your gynaecologist is not involved in this 
study and   will not benefit if you take part.  You will not be able to find out the results of 
experiments on your own sample, but we hope to publish the results of the project in 
scientific journals at a later date.   
 
Normal channels for dealing with complaints are in place and your legal rights will not be 
affected by your participation. 
This study has been approved by the local ethics committee. 
If you wish further information from a doctor who is not involved in this study in any way 
you can contact Dr C P West, Simpson Centre for Reproductive Health, Royal Infirmary of 
Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA. Tel 0131 242 2698. 
 
Thank you for reading this information sheet. 
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Study Number:  
Patient Identification Number for this trial: 
 
 
CONSENT FORM   
 
Department of Obstetrics and Gynaecology 
Study Title :  Inflammation in the Normal and Diseased Ovary  
 
Name of Researcher: 
Dr K Scott Fegan 
University of Edinburgh Cancer Research Unit 
Western General Hospital  
Crewe Road South 
Edinburgh 
EH4 2XR  
Tel: 0131 777 3500 Or : 0131 242 2483 (Research Nurses) 
 
1. I confirm that I have read and understand the information sheet for the above study and have had the 
opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any 
reason, and without my medical care or legal rights being affected. 
 
3. I agree to a letter being sent to my General Practitioner about my participation in this study. 
 
4. I agree to the provision of any clinically significant information to my General Practitioner. 
 
5 I understand that my medical notes may be looked at by the researchers involved in the study or from 
regulatory authorities where it is relevant to my taking part in research. 
 I give permission for these individuals to have access to my records. 
 
6. I agree that the samples I have given and the information gathered from me may be stored at the Centre for 
Reproductive Biology and Cancer Research Centre, University of Edinburgh for possible use in future projects, 
as described in the attached information sheet.  I understand that some of these projects may be carried out by 
researchers other than Dr Fegan who ran the first project. 
 
7. I understand that this is non-therapeutic research from which I cannot expect to derive any benefit. 
 
8. I understand that the research may include genetic research aimed at understanding the genetic background 
of ovarian disease but that these investigations are unlikely to have any implications for me personally.   
9.  I agree to take part in the above study. 
 
________________________ ________________ ________________ 
Name of Patient Date Signature 
 
 
_________________________ ________________ ________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ ________________ ________________ 
Researcher Date Signature 
 
1 for patient;  1 for researcher;  1 to be kept with hospital notes 
Thank you for agreeing to participate in this research. 
          
 
  Reproductive & Developmental Sciences 
(Obstetrics & Gynaecology) 
The University of Edinburgh 
Centre For Reproductive Biology 
The Queen’s Medical Research Institute 










Your patient has agreed we may contact you to inform you that she has consented to 
taking part in a research study entitled “Inflammation in the Normal and Diseased 
Ovary”.  Ethical approval has been granted by the local ethics committee.  The study 
involves obtaining a pre-operative blood sample and samples of ovarian tissue and 
peritoneal fluid at the time of her scheduled laparotomy on  / / .  
Follow-up for research purposes will not be required. 
 
While it appears that the ovarian surface epithelium is the likely origin of ovarian 
cancer the factors involved in oncogenesis are unexplained.  We wish to compare 
the expression of inflammatory mediators and tumour suppressor genes in benign, 
borderline and malignant ovarian tumours.  
 
Please contact me if you would like any further information. 
 









Dr K Scott Fegan MRCOG 
Clinical Research Fellow 
Cancer Research UK 
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Abstract
.Peritoneal surface epithelial (PSE) cells participate in adhesion
formation following inflammatory injury yet adjacent ovarian
RT-PCR. IL-1a (0 5 ng/ml) stimulated 11bHSD1 and
COX-2 mRNA levels in PSE cells but 11bHSD2 wasSE (OSE) cells regenerate without scarification after ovulation.
OSE cells show inflammation-associated expression of 11b
unaffected. Cortisol (1 mM), not progesterone (1 mM),
increased 11bHSD1 mRNA and synergistically enhancedhydroxysteroid dehydrogenase type 1 (11bHSD1) enzyme, IL-1a action. Cortisol suppressed IL-1a-stimulated COX-2
enabling intracrine generation of anti-inflammatory cortisol to
minimise tissue damage. We asked if human PSE cells show an
11bHSD1 response to pro-/anti-inflammatory stimulation and
if so, how the 11-oxoreductase activity generated compareswith
OSE. PSE collected from premenopausal women undergoing
surgery for benign gynaecological conditions were used to
establish primary PSE cell cultures that were treated for 48 h
with interleukin-1a (IL-1a) with/without anti-inflammatory
steroid (cortisol or progesterone). mRNA levels corres-
ponding to the genes of interest (11bHSD1, 11bHSD2,
cyclooxygenase-2, COX-2) were measured by quantitative
Introductionmatory stimuli regulate genes that localise and limit potentially
damaging cellular responses. When this machinery fails,
eatmore effectively than progesterone. PSE cells had a
significantly lower basal 11-oxoreductase enzyme activity
than OSE cells; IL-1a did not significantly increase the
11-oxoreductase activity in PSE cells but did so in OSE cells.
We conclude that PSE cells respond to IL-1a and anti-
inflammatory steroids in qualitatively similar ways as OSE.
However, the enzymatic activity of 11bHSD1 is lower in
PSE and less responsive to IL-1a. This could help explain
why peritoneal healing often leads to adhesion formation,
whereas postovulatory ovarian healing is scar-free.
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tumour necrosis factor a directly stimulate 11bHSD1 and
suppress 11bHSD2 activities in vitro (Escher et al. 1997). This isAn emerging theme in inflammation research is that inflam- now known to hold for several other cell types that naturallyrespond to inflammatory signals, including ovarian granulosa
(Tetsuka et al. 1999) and surface epithelial cells (Yong et al. 2002),pathological sequelae ensue. One such ‘anti-inflammatory’
gene isHSD11B1, encoding 11bhydroxysteroid dehydrogenase
type 1 (11bHSD1), a steroidogenic enzyme that metabolises
cortisone to cortisol through its 11-oxoreductase enzymatic
activity. The activity of 11bHSD1 is offset by 11bHSD2, the
encoded product of HSD11B2 that back converts cortisol to
cortisone. Since cortisol – but not cortisone – binds
glucocorticoid receptor (GR) and activates downstream anti-
inflammatory signalling, relative levels of 11bHSD1 and
11bHSD2 potentially set local inflammatory tone (Draper &
Stewart 2005). Differentially expressed 11bHSD1 and
11bHSD2 in a naturally inflamed tissue was first observed in
human ovary approaching ovulation. Ovulation bears vascular,
haemodynamic and biochemical hallmarks of inflammation,
and granulosa cells from periovulatory follicles selectively
express 11bHSD1 mRNA over 11bHSD2 mRNA (Tetsuka
et al. 1997). Fromwork on renal mesangeal cells it emerged that
inflammatory cytokines such as interleukin-1a (IL-1a) and
Journal of Endocrinology (2008) 196, 369–376
0022–0795/08/0196–369 q 2008 Society for Endocrinology Printed in Grbronchial epithelial cells (Feinstein & Schleimer 1999),
preadipocytes (Tomlinson et al. 2001), osteoblasts (Cooper
et al. 2001), aortic smooth muscle cells (Cai et al. 2001),
peritoneal macrophages (Gilmour et al. 2006), trophoblast (Li et
al. 2006) and fetal membranes (Sun & Myatt 2003).
At the ovarian level, cortisol generated through intracrine
11bHSD signalling potentially contributes to the natural injury-
repair process associated with ovulation. In particular, the
ovarian surface epithelium (OSE), which is contiguouswith the
peritoneal SE (PSE), undergoes serial inflammation-associated
injury and repair with each follicular rupture (Rae & Hillier
2005). We have previously shown that OSE cells express
11bHSD1 mRNA and 11-oxoreductase enzyme activity
catalysed by the encoded 11bHSD1 protein (Yong et al.
2002). We have also shown that IL-1a-induced experimental
‘inflammation’ ofOSE cellsmeasured as an increased expression
of cyclooxygenase-2 (COX-2) is suppressed by cortisol and to a
lesser extent progesterone (Rae et al. 2004). Both cortisol and
DOI: 10.1677/JOE-07-0419
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progesterone are anti-inflammatory steroids that act via nuclear
GR and progesterone (PR) receptors in target cells to repress
pro-inflammatory transcription factors such as nuclear factor k
B and activating protein-1 (van der Burg & van der Saag 1996,
Rhen & Cidlowski 2005). Since micromolar concentrations of
Materials and Methods
Patients
Samples of PSE were obtained at the time of surgery from
mediumwasMedium199:MCDB105 (1:1, v/v) supplemented
face
Su
K S FEGAN and others . Immunoendocrine peritoneum370cortisol and progesterone accumulate in follicular fluid at
ovulation (Andersen 1991, Andersen & Hornnes 1994), either
or both might participate in postovulatory ovarian healing and
act on adjacent PSE.
The mesothelial cells lining the peritoneal surface are also
potential glucocorticoid and progesterone targets and are
inevitably exposed to high concentrations of follicular steroids
following follicular rupture. Interestingly, when postovula-
tory OSE repairs it does so rapidly without scarification or
involving i.p. adhesions. On the other hand, inflammatory
injury to the PSE frequently leads to adhesion formation with
adverse clinical sequelae including pain, bowel obstruction
and, in the female, infertility. Thus, despite their common
embryological origin, the anti-inflammatory machineries of
PSE and OSE cells likely differ. Here, we describe a simple
method to collect and culture human PSE cells, based on the
one we have previously used to study human OSE cells
(Hillier et al. 1998, Auersperg et al. 2001). Using this culture
system, we define interactions between an inflammatory
cytokine (IL-1a) and two anti-inflammatory steroids (cortisol
and progesterone) on 11bHSD1, 11bHSD2 and COX-2
mRNA expression in PSE cells in vitro. We also compare basal
and cytokine-responsive 11-oxoreductase activities of PSE
and OSE cells. Our results define properties of PSE cells that
differ from OSE, which could bear on the particular way in
which the peritoneum responds to inflammation and
becomes involved in gynaecological disease states in vivo.
Table 1 Relevant clinical details of patients donating peritoneal sur
measurements obtained
Parity Contraception Day of cycleAge (year)
38 1C2 DMPA NA La
40 3C0 Fem Ster 2 TA
42 0C1 None ? TA
50 2C0 None 11 TA
33 0C0 None 19 D
25 0C1 None ? D
31 0C0 COCP NA D
39 1C0 None 5 TA
34 2C0 Fem Ster 27 LA
47 2C0 LNG-IUS NA TA
48 3C0 Fem Ster 2 TA
43 2C0 Barrier ? La
29 3C0 None 13 D
22 1C0 DMPA NA La
28 0C0 COCP NA D
Parity is defined in xCy format indicating number of pregnancies over 24 weeks
NA, not applicable; ?, uncertain; DMPA, depo-medroxyprogesterone acetate; Fem
levonorgestrel intra-uterine system; Lap Ster, laparoscopic sterilisation; TAH, tota
diagnostic laparoscopy; HMB, heavy menstrual bleeding; dysmen, dysmenorrhoe
Journal of Endocrinology (2008) 196, 369–376premenopausal women undergoing surgery for benign
gynaecological conditions. OSE cells for comparative
purposes were also obtained from a subset of patients. All
participants gave informed consent and the Local Research
Ethics Committee approved the study. Relevant clinical
details of the patients who donated cells are shown in Table 1.
Patients with endometriosis or overt signs of peritoneal
pathology were excluded from study.
Collection and culture of PSE cells
The method for PSE collection and culture was similar to that
previously described for OSE (Hillier et al. 1998). The culturewith fetal calf serum (15% v/v), penicillin (50 IU/ml),
streptomycin (50 mg/ml) and L-glutamine (2 mmol/l), all from
Sigma–Aldrich Company Ltd. Briefly, the peritoneum was
gently brushed using a sterile Aylesbury spatula or cytobrush
(Cook Ireland Ltd, Limerick, Ireland) and then rinsed into
prewarmed culture medium. Two sites were chosen for
sampling PSE cells: the anterior abdominal wall, which has no
contact with the OSE or pelvic organs, and the uterine fundus.
The purpose of using these two sites was to determine whether
the Müllerian source of PSE behaves in a manner similar to
cells sourced from the non-Müllerian abdominal wall. The
medium used to collect cells was transferred to 75 cm2 plastic
tissue culture flasks (Corning BV Life Sciences, Schiphol-Rijk,
epithelial (PSE) cells from which cultures were established and
rgery Indication for surgery Measurementp Ster Unwanted fertility mRNA
H HMB mRNA
H HMB, dysmen mRNA
H&BSO HMB, fibroids mRNA
iag Lap Pelvic pain, dyspareunia mRNA
iag Lap Pelvic pain mRNA
iag Lap Pelvic pain, dyspareunia mRNA
H HMB, dysmen mRNA
VH HMB, dysmen mRNA
H&BSO Irreg bleeding, fibroids mRNA
H HMB, fibroids mRNA
p Ster Unwanted fertility 11-oxo-reductase
iag Lap Dyspareunia 11-oxo-reductase
p ovarian
cystectomy
Benign ovarian cyst 11-oxo-reductase
iag Lap Pelvic pain, dyspareunia 11-oxo-reductase
(x)Cnumber of pregnancies failing to reach 24 weeks (y).
Ster, female sterilisation; COCP, combined oral contraceptive pill; LNG-IUS,
l abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; Diag Lap,
a.
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The Netherlands) precoated with donor calf serum. Each flask
was examined by phase-contrast microscopy to verify that
sufficient cellular material had been obtained. Cultures were
then established by incubating the flasks at 37 8C in a humidified
atmosphere of 5%CO and 95% air for up to 42 days. The flasks
RNA extraction and quality analysis
Total RNA was extracted using RNEasy Minispin columns
(Qiagen) as per the manufacturer’s instructions. RNA was
quantified and quality assessed by microfluidic analysis (Agilent
Immunoendocrine peritoneum . K S FEGAN and others 3712
were inspected regularly, with medium renewal every 7 days.
Experimental treatment of PSE cultures
Confluent cell monolayerswerewashed twicewith PBS prior to
incubation in 1!Trypsin/EDTAsolution (Invitrogen) for 5 min
at 37 8C.Dissociated cellswere then aspirated and sedimented by Warrington, Cheshire, UK) and 2 ml resultant cDNA was
as described previously (5). Briefly, each culture well receivedcentrifugation for 5 min at 800 g. The resulting cell pellet was
resuspended in 2 ml culture medium. Cell number and viability
were estimated using a haemocytometer and vital staining with
Trypan Blue (Sigma–Aldrich). To provide cell monolayers for
immunohistochemical assessment (see below), PSE cells were
seeded into eight-well chamber slides (VWR, Batavia, IL, USA)
at a density of 5–10!104 cells/0.5 ml medium and incubated at
37 8Covernight. For experiments involving hormone treatment
and subsequent analysis of effect, cells were distributed into
six-well plates (Corning) at a density of 4–5!105 cells/0.5 ml
medium (for mRNA analysis) or 12-well plates at a density of
2!105 cells/0.5 mlmedium (for 11-oxoreductase analysis). The
mediumwas then aspirated and replacedwith serum-free culture
medium, containing 0.01%BSA (Sigma–Aldrich). IL-1a (R&D
Systems Europe Ltd, Abingdon, Oxon, UK) was diluted in
serum-free medium to a final concentration of 0.5 ng/ml, this
concentration having been previously shown to be maximally
effective in inducing 11bHSD1 mRNA expression and activity
inOSE cells cultured in the sameway (Yong et al. 2002). Cortisol
and progesterone (stored as 100 mM stock solutions in ethanol)
were added to culture medium at a final concentration of 1 mM.
Control culture medium received a similar dilution (1% v/v) of
ethanol alone. The incubation was done for 48 h at 37 8C,
whereupon media were aspirated and the cell monolayers
processed as described below.
Immunohistochemistry
Following methanol fixation and triplicate 3-min washes in
PBS, cell monolayers were sequentially blocked with avidin(Vector, Peterborough, UK), biotin (Vector) and non-immune
from multiple patients (see figure legends) were grouped andserum (horse, Vector). Primary monoclonal antibodies for
human GR (Santa Cruz Biotechnology Inc., Heidelberg,
Germany), cytokeratin or PR (Dako Corp., Glostrup, Den-
mark), diluted 1/100, 1/1000 and 1/50 respectively were
applied for 1 h at 37 8C. After three washes with PBSC0.01%
Tween 20 (Sigma–Aldrich; 3 min each), secondary antibody
(horse-antimouse) diluted in non-immune horse serum was
applied for 1 h at room temperature. Sequential washes with
PBSC0.01% Tween 20 (3!3 min) were then performed
before incubating with Vector-ABC Elite reagents and
visualisation via chromagen (diaminobenzidine) staining.
Negative controls consisted of non-immune mouse IgG2
substituted for primary antiserum.
www.endocrinology-journals.org2100 bioanalyser, Agilent technologies, Cheshire, UK).
Quantitative RT-PCR analysis
DNAseI-treated total RNA (200 ng) was reverse-transcribed
to cDNA (random hexamer kit, Applied Biosystems,analysed per reaction. The reaction mixture (25 ml) consisted
of 200 nmol/l probe and 300 nmol/l primers and was
analysed using the ABI Prism 7900 real-time PCR system
(Applied Biosystems). Primer and probe sequences have been
reported previously (Rae et al. 2004). Target mRNA was
quantified in relation to the abundance of 18S rRNA in each
sample. Controls included human liver, RT negative (RNA
template but lacking reverse transcriptase), RT no template
control (water instead of RNA template) and a Taqman step
negative control (water instead of cDNA).
11-Oxoreductase assay
11-Oxoreductase activity was determined by measuring the
conversion of [1,2,6,7-3H]cortisone to [1,2,6,7-3H]cortisol,0.5 ml serum-free culture medium containing 0.1 mCi
[1,2,6,7-3H]cortisone and 50 pmol carrier cortisone (total
substrate concentration 0.1 mM). Incubation was for 8 h at
37 8C. The medium was then aspirated and vortexed with
5 ml dichloromethane to extract steroids. The organic phase
was then collected and evaporated to dryness under a stream
of nitrogen. Dry steroid extracts were reconstituted in fresh
dichloromethane and spotted onto silica gel precoated
aluminium sheets (Sigma–Aldrich) for the separation of
cortisone and cortisol by thin layer chromatography, using
chloroform:ethanol (92:8 v/v) as the solvent system. Radio-
labelled steroids on the chromatogram were located and
quantified using a Bioscan 200 imaging detector (Lablogic
Systems, Sheffield, UK).
Statistical analysis
Quantitative RT-PCR measurements were normalised to the
control (no treatment) value for each mRNA measured. Dataexpressed as meanGS.E.M. Statistical differences due to
treatment were determined by repeated measures ANOVA
of raw data reflecting the mean CT difference between 18S
rRNA and target mRNA. The mean 11-oxoreductase
enzymatic activity expressed as pmol/culture per h was
compared between treated and untreated samples of the same
cell type using paired Student’s t-tests, and between OSE and
Journal of Endocrinology (2008) 196, 369–376
PSE samples using unpaired Student’s t-tests. Treatment
effects were considered significant at P!0.05.
(data not shown). Immunostaining with antisera to GR (Fig. 1c)
or PR (Fig. 1d) revealed the presence of both the steroid receptor
proteins in PSE cells, with a predominantly nuclear location.
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PSE cell morphologyThe morphology of PSE cells in culture and their responses to
11bHSD2 and COX-2 mRNA levels, reasoning that theexperimental treatment in vitrowere unaffected by the sitewithin
the abdominal cavity from which they had been obtained (data
not shown). Sheets of PSE cells collected into culture medium
usually attached to the serum-coated flask surface within 48 h.
Further incubation allowed multiple epithelial cell colonies to
becomeestablished, eventually producingconfluentmonolayers.
The ‘cobblestone’ morphology (Fig. 1a) and the mode of
cytokeratin expression (Fig. 1b) shown by cultured PSE cells was
similar to that previously described for OSE cells cultured in the
same way (Hillier et al. 1998). Flasks that became contaminated
by cells showing a fibroblastic phenotype were excluded from
experimentation. Overall, out of the 29 patient PSE specimens
collected, 21 (72.4%) produced cultures suitable for further study.
PSE cell steroid receptor status
PSEcellmonolayers containedGRandPRmRNAlevels similar
to those present in OSE cells cultured under identical conditionsFigure 1 Morphology and immunohistochemical prope
microscopy of PSE cell monolayer on day 12 of culture
immunohistochemistry using antiserum against a panel
phenotype of cultured PSE cells and purity of cell cultu
(D) progesterone receptor (PR) immunohistochemistry d
in B–D show matched non-immune control staining. Ba
Journal of Endocrinology (2008) 196, 369–376PSE cell responses to IL-1a and cortisol
Todetermine influences of IL-1a and cortisol on inflammation-
associated gene expression in PSE cells, we assessed 11bHSD1,11bHSD isoform expression profile defines the potential for
intracrine generation of anti-inflammatory cortisol, while
COX-2 provides a referent inflammatory readout.
The treatment of PSE cell cultures from five patients
with IL-1a significantly increased the expression of 11bHSD1
mRNA relative to non-treated control values (mean fold
induction, 9.75, P!0.01; Fig. 2a). PSE cells sampled from the
anterior abdominal wall and the uterine serosal surface
responded similarly to IL-1a (average fold induction, 10.4 and
9.0 respectively). Cortisol alone also up-regulated 11bHSD1
mRNA expression 12.6-fold (P!0.001). In combination,
cortisol and IL-1a synergised to increase 11bHSD1 expression
67.9-fold relative to the control (P!0.001).
Neither IL-1a nor cortisol, alone or in combination,
significantly affected 11bHSD2 mRNA expression (Fig. 2b).
The exposure to IL-1a stimulated COX-2 mRNA
expression on average was 10.6-fold (P!0.001; Fig. 2c).rties of cultured human PSE cells. (A) Phase-contrast
following collection. (B) Cytokeratin
of low MW cytokeratins confirms epithelial
re. (C) Glucocorticoid receptor (GR) and
etect each receptor protein in PSE cell nuclei. Insets
rs represent 100 mm.
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Again, there was no significant difference in the magnitude of
response in relation to the site of cell sampling from within the
same patient (data not shown). Cortisol alone had no significant
effect onCOX-2mRNAexpression.However, in combination
with IL-1a, cortisol significantly suppressed the IL-1a-induced
11bHSD2 mRNA expression was unaffected by any of the
treatments applied (Fig. 3b).
Figure 2 Interaction between interleukin-1a (IL-1a) and cortisol (F) on
inflammation-associated gene expression in PSE cells. Quantitative
RT-PCR analysis of mRNA for (A) 11bHSD1, (B) 11bHSD2 and
(C) COX-2 following treatment with IL-1a (0.5 ng/ml) and/or F (1 mM).
Bars representmean (CS.E.M.) values relative tountreatedcontrol forPSE
cell cultures from five individual patients. Values with no superscript
letter in common are statistically different from each other (P!0.01).
Figure 3 Comparison of the effects of cortisol (F) and progesterone
(P) on inflammation-associated gene expression in PSE cells.
Quantitative RT-PCR analysis of mRNA for (A) 11bHSD1,
(B) 11bHSD2 and (C) COX-2 following treatment with F (1 mM) or P
(1 mM) in the presence and absence of interleukin-1a (IL-1a;
0.5 ng/ml). Bars represent mean (CS.E.M.) values relative to
untreated control for PSE cell cultures from six individual patients.
Values with no superscript letter in common are statistically
different from each other (P!0.01).
Immunoendocrine peritoneum . K S FEGAN and others 373rise in COX-2 mRNA to near control levels (P!0.001).
Anti-inflammatory actions of cortisol and progesterone compared
PSE cell cultures from a further six patients were used to test
the relative anti-inflammatory effects of cortisol andprogesterone on inflammation-associated gene expression. Stimulation of COX-2 mRNA by IL-1a was strongly
suppressed (P!0.001) by the presence of cortisol (average fold
induction, 4.5) and to a lesser extent (PO0.05) progesterone
11-oxoreductase activity, as demonstrated previously inStimulation of 11bHSD1 mRNA by IL-1a alone (average
7.25-fold, P!0.001) was confirmed in PSE cell cultures from
this second series of patients (Fig. 3a). Cortisol alone was also
stimulatory (average 10-fold,P!0.001).However, progesterone
was inactive (Fig. 3a). Once again, cortisol augmented
IL-1a-stimulated 11bHSD1 mRNA expression (to an average
fold induction, 28.3; P!0.01). Co-treatment with
progesterone and IL-1a also consistently increased 11bHSD1
mRNA expression beyond that caused by IL-1a alone (average
11.8-fold) but this effect was not statistically significant.
www.endocrinology-journals.org(average fold induction, 12.8; Fig. 3c).
11-Oxoreductase enzymatic activity in PSE cells
The finding that IL-1a stimulates 11bHSD1 mRNA
expression in PSE cells predicts the up-regulation ofOSE cells (Yong et al. 2002). We therefore compared
Journal of Endocrinology (2008) 196, 369–376
11-oxoreductase activity between cell types using PSE
cultures from four patients (one of whom also provided an
OSE culture for the comparison) and OSE cultures from
three others. As shown in Fig. 4, the mean rate of conversion
of cortisone to cortisol was significantly less in PSE compared
peritoneum (Witz et al. 1998) and cultured with varying
success. Here, we swept up cells directly from peritoneal sites
in situ, avoiding enzymatic tissue digestion to obtain pure
mesothelial cell cultures. This atraumatic technique of PSE
collection allows single-cell-thick sheets of cells to be cultured
K S FEGAN and others . Immunoendocrine peritoneum374with OSE, under both control (0.14 picomol/culture per h
versus 0.93 picomol/culture per h, P!0.05) and IL-1a (0.33
picomol/culture per h versus 1.56 picomol/culture per h,
P!0.05) treatment conditions. Although exposure to IL-1a
consistently raised 11-oxoreductase activity in both OSE
and PSE cells, only the effect on OSE cells was statistically
significant.
DiscussionWe show that the cells lining the human peritoneum are able
to up-regulate 11bHSD1 gene expression in response to the
inflammatory cytokine IL-1a in vitro. Furthermore, cortisol –
the product of 11-oxoreductase activity catalysed by
l1bHSD1 – is anti-inflammatory in PSE cells. Basal and IL-
1a-stimulated 11-oxoreductase enzymatic activity in PSE
cells is, however, substantially weaker than that of closely
related OSE cells. Thus, we provide mechanistic insight on
anti-inflammatory signalling in human peritoneum and
establish differences between OSE and PSE cells that could
help explain the relative susceptibility of PSE to adhesion
formation following inflammation-associated injury in vivo.
Human PSE cells have previously been obtained from
resected omentum (Stylianou et al. 1990, Pronk et al. 1993) orFigure 4 Comparison of 11-oxoreductase activity in PSE and OSE
cells. 11-Oxoreductase activity in cultured cells was determined by
radiometric assay (see Materials and Methods) following a 48-h
incubation with or without interleukin-1a (IL-1a; 0.5 ng/ml). Bars
represent mean (CS.E.M.) values relative to untreated control for four
patients (cultures), one of whom provided matched PSE and OSE.
Values with no superscript letter in common are statistically
different from each other (P!0.05).
Journal of Endocrinology (2008) 196, 369–376with the low likelihood of contamination by other cell types.
Morphology of the PSE monolayer in vitro closely resembles
the classic ‘cobblestone’ appearance of OSE cultured under
similar conditions. The mesothelial origin of the PSE cultures
we studied was also confirmed by the pattern of low-
molecular weight cytokeratin expression they showed, which
is also similar to OSE (Auersperg et al. 2001) and increases
confidence that the PSE cultures were not significantly
contaminated with any other cell type.
PSE and OSE cells not only look alike but also share a
similar biochemical signature in response to inflammation.
Along with inflammation-associated COX-2 gene expression
in response to IL-1a they show up-regulation of 11bHSD1
mRNA without any change in 11bHSD2. Whether any
functional link exists between COX-2 and 11bHSD1mRNA
expression in IL-1a-stimulated PSE cells remains to be
established. However, this is suggested by the finding that
prostaglandin synthesis is required for the stimulation of
11bHSD1 enzyme activity by IL-1b in human granulosa–
lutein cell cultures (Jonas et al. 2006). PSE also has in common
with OSE the feed-forward response of 11bHSD1 when
stimulated by IL-1a in the presence of cortisol (Rae et al.
2004). This predicts the capacity to mount a compensatory
increase in intracellular levels of cortisol in response to
inflammatory stimulation in vivo.
Owing to the clinical basis of this study, insufficient patient
material was available to delineate the post-receptor signalling
mechanisms involved in the actions of IL-1a and anti-
inflammatory steroids in PSE cells. However, we did document
similar levels of mRNA for PR and GR, and clearly detected
nuclear PR and GR proteins. In other experimental systems,
nuclear GR and PR receptors transduce positive and negative
regulation of genes that impact signalling via cell-surface
receptors for pro-inflammatory cytokines (Rosen & Milner
2005) and it is reasonable to suppose that these mechanisms
operate in PSE cells too. Other caveats to our results include the
extent to which pro-/anti-inflammatory properties of PSE and
OSE cells propagated in vitromight deviate from norm in terms
of functionality in vivo. Comparisons of 11-oxoreductase
activities in PSE and OSE cell cultures from individual patients
also proved problematic owing to a variable adaptation of
individual cell biopsies to culture. However, we consistently
observed a restricted capacity of PSE cells to undertake
11-oxoreductase activity relative to OSE cells. Moreover, for
the single patient from whom both PSE and OSE cell cultures
were available for direct comparison, the result obtained
(embedded within the data set in Fig. 4) faithfully mirrored
the aggregate outcome.
The physiological significance of these results is that
cytokine-responsive 11bHSD1 could provide a mechanism
throughout the peritoneal surface to localise and limit
www.endocrinology-journals.org
inflammation-associated injury and promote rapid healing of
traumatised tissue through pre-receptor amplification of
cortisol formation. However, 11bHSD1 enzyme activity in
PSE is lower than that in OSE, indicating that the ovary is
better protected by anti-inflammatory mechanisms than the
therapeutic strategy. Progesterone has been suggested as a
potential chemopreventative agent for EOC and lack of
progesterone may have pathophysiological roles for both
endometriosis and ovarian cancer (Ho 2003, Ness 2003).
In summary, we demonstrate a simple method for the
We are grateful to Ms Deborah Price for skilled technical
support and to Ms Catherine Murray and Mrs Sharon
Donaldson for help with tissue collection. This work forms
human preovulatory follicular fluid. Human Reproduction 6 359–364.
Andersen CY & Hornnes P 1994 Intrafollicular concentrations of free cortisol
Immunoendocrine peritoneum . K S FEGAN and others 375peritoneum. The higher 11-oxoreductase tone of OSE, if
reflected in higher local cortisol levels in vivo, might be
sufficient to minimise fibrosis and thereby reduce the
likelihood of postovulatory adhesions. This is borne out by
the fact that the ovaries remain mobile and free within the
pelvis of most women. On the other hand, the peritoneum is
a more stable environment, less prone to natural injury and
with a lower 11-oxoreductase tone than the ovarian surface.
The sporadic injuries that do occur to PSE tend to be
iatrogenic – e.g. during surgery – or involve microbial
infection and are inherently more traumatic. This indicates
that downstream pro-inflammatory sequelae likely override
any compensatory anti-inflammatory benefit arising from
11bHSD1 signalling, permitting fibrosis and adhesion
formation to proceed.
Progesterone, present at high concentrations in follicular fluid
at the time of ovulation (Andersen & Hornnes 1994), is a
candidate anti-inflammatory agent throughout the pelvic cavity.
However, progesterone was considerably less potent than
cortisol as an anti-inflammatory agent in cultured PSE,
matching our previous finding for OSE (Rae et al. 2004).
Nevertheless, 1 mM progesterone reduced IL-1a-stimulated
COX-2 mRNA expression 37%, on average, in 6/6 cases
(Fig. 3). Although this effect was statistically non-significant, it
may yet be biologically important since progesterone levels in
follicular fluid can attain levels up to 30 times higher than those
tested here. Accordingly, we do not rule out the possibility that
progesterone exerts a physiologically significant action on OSE
and/or PSE cells during ovulation in vivo. The responsiveness of
PSE cells to progesterone also has broader clinical relevance.
First, it raises the possibility that the peritoneummay be affected
by menstrual fluctuations in ovarian progesterone secretion.
Secondly, it is relevant to endometriosis where withdrawal of
progesterone prior to menstruation coincides with the most
severe symptoms. Thirdly, exogenous progestin is a mainstay
treatment for endometriosis.
Finally, our results may have a bearing on the development
of epithelial ovarian cancer (EOC). The OSE is widely
regarded as the major source of most ovarian cancers (Fleming
et al. 2006) and EOC frequently involves other peritoneal
structures, hence its overall poor outcome (Freedman et al.
2004). However, the natural history of EOC is not well
defined. This is partly due to the fact that patients most
commonly present with advanced stage disease with wide-
spread peritoneal and omental involvement. This in turn
makes curative treatment difficult leading to poor survival
outcomes of 30% at 5 years. If the disease could be contained
within the ovary at FIGO (International Federation of
Gynaecology and Obstetrics) stage I, an improvement in
prognosis would be expected to follow. Therefore, manipu-
lation of the tumour–peritoneum interaction is a potential
www.endocrinology-journals.orgcollection and culture of human PSE cells. Using this culture
system, we find that PSE cells possess an anti-inflammatory
machinery similar to that previously described for OSE cells,
including a capacity to up-regulate 11bHSD1 in response to
treatment with IL-1a. However, enzymatic activity of
11-oxoreductase is lower in PSE than in OSE. Although the
cause for this difference remains unknown, our data provide a
possible explanation for the observation that peritoneal healing
is often accompanied by adhesion formation, while ovulation-
associated ovarian healing is scarless.
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